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Abstract 
The relationships between wheat dietary fibre (DF) and prebiotic effects were investigated by 
testing how various DF types in different combinations and how the structure, of the major DF 
component of wheat, arabinoxylan (AX) modulate prebiotic activity. It was hypothesised that 
DFs could act synergistically resulting in different prebiotic activities when fermented in vitro at 
different ratios. The DF, arabinogalactan-peptide (AGP) was isolated from wheat flour and 
characterised, AX and mixed-linked β-glucan were commercially bought. The three fractions 
were tested singly and in combination in in vitro fermentation studies to assess their prebiotic 
activity when used individually and in different combinations. SCFAs produced from in vitro 
fermentation were measured using HPLC; flow-FISH was used for bacterial enumeration. 
Increases in bifidobacteria and acetate were observed with combinations of AGP and AX 
fractions. There were no additive effects on prebiotic activity when AGP and AX were 
combined; the greatest increases in total SCFAs, bifidobacteria and total bacteria were observed 
when AX and β-glucan were combined at a 3:1 ratio. The importance of AX structure was 
investigated using AX isolated from transgenic wheat with an altered arabinosylation pattern 
and pre-incubation of AX fractions in a simulated gastric digest prior to in vitro colonic 
fermentation. AX isolated from flour of homozygous TaXAT1 RNAi transgenic wheat showed 
lower prebiotic activity compared to AX isolated from flour of the corresponding azygous 
control wheat. Pre-incubation of AX in an in vitro gastric digest resulted in smaller AXOS, a 
lower A:X ratio, improved bacterial composition and slower fermentation compared to the 
control. Based on these results, three soluble arabinoxylan (AX) fractions from wheat flour with 
different average molecular mass (MM) and one insoluble AX fraction were subjected to in vitro 
gastric and duodenal digestion prior to in vitro fermentation, resulting in an increase in smaller 
AXOS, decreases in MM, viscosity and A:X ratio and a reduction in bound ferulic acid. 
Differences in prebiotic activity were observed between AX samples of different MM after 
changes in structure caused by in vitro digestion. The AX fraction of 323kDa gave the greatest 
increases in SCFA production, while the insoluble AX fraction showed the smallest increases in 
SCFA production.
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1. General Introduction 
 
1.1. Human digestive system and health  
4.4.1. Gut microbiota 
The human body is colonised by a vast number of microbes, collectively known as the 
microbiota. Bacteria have co-evolved with us and colonise almost every available space within 
and on our bodies (Costello et al., 2009). It is only in more recent years that we have become 
aware of the importance of our microbiota and the relationships between them and human 
health. It is now well established that a healthy gut flora is very important for the overall health 
of the ‘host’ (Prescott et al., 1996; Aune et al., 2011). 
The largest concentration of microbiota is found in our colon. The adult human large intestine 
is about 150 cm long with a surface area of 1300 cm2. The average total colonic transit is 30.7h 
for men and 38.3h for women (Beck et al., 2014). The colon contains between 58-908 g of 
contents (Banwell et al. 1981; Cummings et al. 1990) and microbiota are a major component, 
comprising 40-45% of faecal solids in people eating a western diet (Stephen & Cummings 1980; 
Cabotaje et al. 1990). Microbiota refers to the entire population of colonizing microorganisms 
including fungi, archaea, viruses, and protozoans as well as bacteria. The vast majority of all 
microbial cells in the colon are bacteria and therefore interest has focussed on the contribution 
of bacteria to health and literature on the other microbiota is limited. 
Research is increasingly linking the importance of the gut microbiota to many aspects of human 
health, from gut physiology to depression using signalling referred to as the gut-brain axis, the 
bidirectional communication between the central and enteric nervous systems, linking the brain 
with the gut (Carabotti et al., 2015). 
The colonic microbiota can be thought of as a metabolic organ due to its essential functions 
including: providing energy from fermentation of indigestible carbohydrates and proteins; 
synthesis of vitamins B and K (Hill, 1997) and regulating mucosal physiology (Tlaskalová-
Hogenová et al., 2011); liver function (Björkholm et al. 2009); immune response (Round and 
Mazmanian, 2014); obesity and satiety (DiBaise et al., 2008) and gene expression (e.g. activation 
of g-protein coupled receptors that induce cell derived hormones that regulate gut motility 
(Samuel et al., 2008)). It also provides protection against infections from invading pathogens 
and chronic diseases such as some cancers, inflammatory conditions and heart disease by release 
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of metabolites and competition with pathogenic bacteria for space and nutrients (Fukuda et 
al., 2011; Aune et al.,2006).  
The composition of the colonic microbiota is usually stable but can fluctuate under some 
circumstances including acute diarrhoeal illnesses, antibiotic treatment, or by dietary 
interventions (Simon and Gorbach, 1984; Moore and Moore, 1995; Musso et al., 2010; 
Turnbaugh et al., 2009). Maintenance of a stable and diverse population of commensal bacterial 
groups contributes greatly towards improved colonisation resistance and protection against 
gastrointestinal disorders. Many studies have now shown that diet plays an important role in the 
composition of the gut microbiome (Gibson, 1999; Wu et al., 2011). 
The large intestine can contain more than 1011 bacterial cells/g of luminal content (Simon and 
Gorbach, 1984), and is thought to host between 400-500 different species of indigenous 
bacteria, (Moore et al., 1975) although this is difficult to determine as many species are 
impossible to culture outside of the colon and remain unknown. It has been estimated based on 
genetic analysis that the collective human gut microflora is composed of over 35000 bacterial 
species (Frank et al., 2007). Each person has a different combination of gut microbiota and 
these different combinations can contribute to health and disease. Figure 1.1. shows the 
distribution of microbiota in the human digestive tract. 
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Figure 1.1: The distributions of different bacteria in the gastro-intestinal tract of humans. 
Image from Riviere et al., 2016 citing Tap et al., 2009; Zoetendal et al., 2012; Delgado et al., 2013; 
Walker et al., 2014). 
 
4.4.2. Composition of colonic microbiota 
The composition of the colonic microbiota is usually stable and only changes drastically at the 
extremes of life or due to antibiotic application or illness. Although there are large individual 
differences in microbial composition the two dominant bacterial phyla in the gut are always 
Firmicutes (which contains over 200 genera, including Lactobacillus, Eubacterium, Faecalibacterium 
and Clostridium) and Bacteroidetes (Bacteroides and Prevotella,). The next most abundant are 
Actinobacteria (Bifidobacterium and Atopobium), and Proteobacteria (Proteus, Salmonella, Escherichia). 
Most colonic luminal bacteria are thought to belong to the genera: Bacteroides, Bifidobacterium, 
Streptococcus, Enterobacteriacae, Enterococcus, Clostridium, Lactobacillus and Ruminococcus. Clostridium, 
Lactobacillus, Enterococcus and Akkermansia are the predominant mucosal associated genera 
(Swidsinski et al., 2005). 
 The majority of the Firmicutes in the colon are split into two main groups, the Clostridium 
coccoides group (also known as Clostridium cluster XIVa) and the Clostridium leptum group (also 
referred to as Clostridium cluster IV) (Collins et al. 1994; Mariat et al. 2009). Both groups contain 
members of the genera Clostridium, Eubacterium and Ruminococcus. The Clostridium coccoides group 
4 
 
are a major group, representing almost 75% of the Firmicutes, including many butyrate 
producers like Eubacterium rectale (Kelly, Conway and Aminov, 2005).  
 
 
 
A 
B 
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Figure 1.2: Bacterial diversity A) Phylogenetic tree of major phylogenetic groups of intestinal 
bacteria (Blaut et al., 2002). B) Phylogenetic tree of human and mouse colonic bacteria 
obtained using 16S rRNA sequencing (Ley et al., 2005). 
 
Figure 1.2A shows the large diversity of colonic bacteria using a phylogenetic representation of 
groups of important known colonic bacteria. The species of resident colonic bacteria vary 
greatly between individuals (Simon and Gorbach, 1984; Moore and Moore, 1995).  Figure 1.2B 
shows the phylogenetic tree of a human compared to a mouse, there are large amounts of 
overlapping species but humans have many more Bacteroidetes bacteria, shown by the blue 
area, demonstrating that mouse models cannot be used as direct comparisons to human 
reactions. 
A study by Arumugam et al (2013) identified three distinct clusters of microbial populations 
(not specific to nation or continent), which were named enterotypes and suggested that gut 
microbiota are stratified. The enterotypes were hypothesised to be driven by groups of species 
that together contribute to the preferred community compositions and the three enterotypes 
are identifiable by the variation in the levels of one of three genera: Bacteroides (enterotype 1), 
Prevotella (enterotype 2) and Ruminococcus (enterotype 3). Dietary habits are considered one 
of the main factors contributing to the diversity of human gut microbiota and the maintenance 
of these enterotypes (Backhed et al., 2005), diet has a dominant role over other possible variables 
such as ethnicity, sanitation, hygiene, geography, and climate in determining the gut microbiota 
(De Fillipo et al., 2010). 
  
4.4.3. Fermentation 
Most bacteria in the colon are strict anaerobes, deriving energy from fermentation (Macfarlane 
et al., 1999). Dietary fibres (non-digestible carbohydrates) reaching the large intestine are 
converted to monosaccharides via fermentation by bacterial enzymes and metabolised to short 
chain fatty acids (SCFAs). Bacterial fermentation involves a wide variety of enzymes and 
biochemical pathways. This capacity is estimated to be encoded by 2-4 million microbial genes 
(Possemiers et al., 2011). Digestion of polysaccharides requires specific glycosyl hydrolase 
enzymes, some bacteria can produce a wide variety of these whilst others are more specialised. 
In 1991, Cummings and Macfarlane hypothesized that the breakdown of highly polymerized 
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materials in the gut is a co-operative activity, with enzymes from many different species 
participating in the process.  
 
 
4.4.4. Important colonic bacteria  
Bifidobacteria are an important class of saccharolytic Actinobacteria. They are at their highest 
proportion, in the colon, just after birth when they constitute about 90% colonic bacteria due 
to their ability to use fucosylated oligosaccharides in human milk (Yu et al., 2012) however, they 
decrease in number with the cessation of breastfeeding. In adults, they compose only about 5% 
of the total colonic bacteria, and even less in the elderly or those with Inflammatory Bowel 
Disease (IBD) which includes Crohn’s disease (CD) and ulcerative colitis (UC) or in individuals 
with irritable bowel syndrome (IBS), or after antibiotic use. Bifidobacteria provide B vitamins, 
antioxidants and polyphenols through fermentation and are involved in maturation of the 
immune system during early life, preservation of colonic barrier functions and protection from 
pathogens by reducing the luminal pH through the release of SCFA (mainly acetate) and 
blocking pathogen adhesion to the endothelium (Riviere et al., 2016). 
Lactobacillus is a Gram-positive facultative anaerobe and is part of the lactic acid bacterial group 
which produces lactate as the sole product of fermentation (Walter, 2008). The ability to ferment 
galactose is a major characteristic which can be used to differentiate Lactobacillus helveticus 
(galactose-positive) from Lactobacillus lactis and Lactobacillus bulgaricus (galactose-negative) (Turner 
and Martley, 1983).   Lactobacillus were theorised by Metchnikoff to “arrest intestinal putrefaction 
and postpone and ameliorate old age” (Metchnikoff, 1907), which kick-started work in to their 
use as probiotics (defined by the FAO/WHO as live microorganisms that when administered 
in adequate amounts confer a health benefit on the host). Lactobacilli comprise a small 
proportion of the colonic microbiota, rarely being cultured at population levels exceeding 
108 CFU per gram accounting for only 0.01% of the total cultivatable bacteria (Walter, 2008). 
Faecalibacterium prausnitzii is an important butyrate producing bacterium which belongs to the 
clostridial cluster IV (the most abundant gut bacterial group). Notably, faecalibacteria are 
present at low numbers in patients with IBD and display significant anti-inflammatory effects 
in mouse colitis models (Sokol et al., 2008). 
The most predominant anaerobic bacteria in the colon are Bacteroides species (around 25%), 
these bacteria colonize the gut in early life and maintain a complex and mostly beneficial 
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relationship with the host when maintained in the gut, however they can be pathogenic when 
transferred away from the gut.  B. fragilis is a potent pathogen and the most commonly isolated 
anaerobic pathogen despite accounting for only 0.5% colonic microbiota (Wexler, 2007). Several 
species of Bacteroides can utilize fucosylated oligosaccharides as carbon sources suggesting that 
their early colonization of the gut is aided by properties of human milk (Marcobal et al., 2011).  
Bacteroides are the principal polysaccharide degrading bacteria (Salyers and Leedle, 1983) and are 
able to grow on a wide variety of polysaccharides through their ability to produce a large variety 
of polysaccharide depolymerases and glycosidases (Salyers and Leedle, 1983; Macfarlane et al., 
1990).  
Clostridium histolyticum is a highly proteolytic cluster II bacterium that produces acetate as the 
major end product of metabolism (Collins et al., 1994). Members of the C. histolyticum group are 
recognized toxin-producers and may contribute towards gut dysfunction. Populations have 
been shown to be increased in children with autism, indicating a possible link (Parracho et al., 
2005). Some Bacteroides and Clostridium cause increased production of electron sink products such 
as succinate and lactate, which are used for methanogenesis instead of formation of SCFA at 
high growth rates, or during growth in the presence of excess substrate (Allison and Macfarlane, 
1989) resulting in fewer SCFA formed from the carbohydrate substrate. 
Desulfovibrionales (DSV) are a bacterial group in the Fusobacterium genus that metabolise the 
sulphate moiety of sulphated mucins and are important contributors to sulphide formation in 
the gut (Fite et al., 2004). DSVs oxidize lactate to acetate and carbon dioxide. The end product 
of sulphate reduction during anaerobic respiration is hydrogen sulphide (H2S) (Widdel, 1992) 
which is toxic to the colonic mucosa. Increased numbers of DSVs have been linked with acute 
ulcerative colitis (Rowan et al., 2010).  
 
Some beneficial bacteria can be ingested directly to improve health; these are known as 
probiotics. Probiotics are defined as ‘microbial organisms that remain viable and stable after 
culture, manipulation, and storage before consumption; survive gastric, biliary, and pancreatic 
digestion; are able to induce a host response once they enter the intestinal microbial ecosystem 
(by adhering to gut epithelium or other mechanisms); and yield a functional or clinical benefit 
to the host when consumed’ (Savvedra, 2007). Some beneficial bacteria can be used as 
probiotics, mainly the Lactobacillus and Bifidobacterium species including Lactobacillus acidophilus, 
Lactobacillus casei, Bifidobacterium bifidum and Bifidobacterium longum, and the yeast Saccharomyces 
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boulardii. These microorganisms are generally well-accepted and tolerated and rarely cause 
negative effects in humans (Goldin, 1998; Taibi and Comelli, 2014). 
 
 
4.4.5. Short Chain Fatty Acids  
SCFAs are volatile fatty acids consisting of a straight-chain, aliphatic tail of fewer than six carbon 
atoms and consist of mainly acetate, propionate and butyrate (95%) (Cummings, 1981) but also 
include formate and valerate. Lactate is also formed from fermentation, lactate is a 
monocarboxylic acid. SCFA are mostly produced from fermentation of carbohydrates but 
branched amino acids leucine, isoleucine and valine can be utilised creating branched SCFAs 
Isobutyrate and isovalerate. An average of 400 mmol/day (range of 150–600 mmol/day) of 
SCFAs is produced in the colon (Beck et al., 2014) and more than 95% are immediately absorbed 
by the colon, contributing towards about 10% of the energy requirements of the host 
(Cummings, 1981; Vogt and Wolever, 2003; McNeil, 1984).  They occur in a ratio of: butyrate 
[15 %], propionate [25 %], and acetate [60 %] (Beck et al., 2014). The concentration of total 
SCFAs in humans is reported to be ≈50–100 µM in peripheral blood and ≈300–450 µM in 
portal blood (Cummings et al., 1987). Table 1.1 shows the chemical formulas of SCFAs and 
lactic acid and Figure 1.3 shows the chemical pathways that generate them. 
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Table 1.1: Table of SCFAs and branched SCFAs showing structure and chemical formulas. 
 
 
 
The most abundant SCFAs, acetate, propionate and butyrate, have been shown to have multiple 
beneficial effects for the host, for example, providing dietary energy for the host and 
suppressing the growth of pathogens by decreasing the pH of the intestinal lumen (Blaut, 2002). 
These SCFAs were also found to have anti-inflammatory effects in rats (Vinolo, et al., 2011) 
Name  Formula 
Lactate  CH3CH(OH)CO2H 
Formate  HCOOH 
Acetate  CH3COOH 
Propionate  CH3CH2COOH 
Butyrate  CH3(CH2)2COOH 
Isobutyrate  C4H8O2 
Valerate  C5H10O2 
Isovalerate  C5H10O2 
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and influence intestinal motility in rats via G-protein coupled receptor activation, with acetate 
being the most effective, followed by propionate and butyrate (Dass et al, 2007).  
Acetate is utilised systemically by skeletal muscle and liver cells and can be used by adipocytes 
for lipogenesis. Acetate has been found to have a major role in the ability of bifidobacteria to 
inhibit toxicity from enteropathogens by inhibiting the transport of toxins from the gut lumen 
to the blood (Fukuda et al., 2011). 
Propionate may help to inhibit the synthesis of LDL cholesterol in animals and humans 
(Wolever et al., 1991) and propionate has also been linked with regulation of adipose tissue 
deposition in rats (Reshef et al, 1967) via an increase in circulating leptin levels (Xiong et al 
2004). 
Butyrate is the preferred energy substrate for the colonic epithelium and is preferentially 
transported by gut epithelial cells (Ritzhaupt et al., 1998). Rectally administered butyrate was 
also shown to relieve subjects from IBD symptoms (Scheppach, 1996).  Butyrate has been linked 
with protection from initiation of colon cancer by many different pathways including: 
promoting cell differentiation, cell-cycle arrest and apoptosis of transformed colonocytes and a 
reduction of transformation of primary to secondary bile acids by reducing luminal pH 
(Cummings, 1995, Williams et al., 2003). Primary bile acids are steroid carboxylic acids derived 
from cholesterol, synthesized in the liver and conjugated with taurine or glycine before secretion 
from the gall bladder into the intestine. Cholic acid and chenodeoxycholic acid are major 
primary bile acids synthesised in humans (Chiang, 2013).  Transformation to secondary bile 
acids occurs by partial dihydroxylation and the removal of glycine and taurine groups by colonic 
bacteria, allowing them to re-enter the circulation back to the liver for re-conjugation (Chiang, 
2013; Ajouz et al., 2014). Table 1.2 summarises the principal health benefits of the main SCFAs, 
acetate, propionate and butyrate. 
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Table 1.2: Health benefits of the most abundant SCFAs. (Hamer et al., 2008 ; Al-Lahham et al., 
2010; Havenaar, 2011 ; Macfarlane and Macfarlane, 2012 ; Chang et al., 2014 ; Louis et al., 2014; 
Tralongo et al., 2014 ; Chambers et al., 2017). 
SCFA Physiological effect 
Acetate Reaches the portal vein and is metabolised in various tissues  
Is a minor energy source for colonic epithelial cells 
Decreases the pH of the colon (decreasing bile salt availability and increasing 
colonic calcium, magnesium, zinc, and iron absorption, decreasing ammonia 
absorption and inhibiting growth of pathogens) 
Has anti-inflammatory properties. Acts on leukocytes, inhibiting release of 
inflammatory cytokines (TNF-α, IL-2, IL-6) 
Increases colonic blood flow and oxygen uptake 
Is an energy source for muscle and brain tissue 
Is used by cross feeding species as a co-substrate to produce butyrate 
Propionate Reaches the portal vein and is subsequently taken up by the liver 
Is a minor energy source for colonic epithelial cells 
Decreases the pH of the colon (decreasing bile salt availability, increasing 
colonic calcium, magnesium, zinc, and iron absorption, decreasing ammonia 
absorption and inhibiting growth of pathogens) 
Interacts with the immune system 
Has anti-inflammatory properties. Acts on leukocytes, inhibiting release of 
inflammatory cytokines (TNF-α, IL-2, IL-6) 
Promotes satiety by increasing colonic cell secretion of gut hormones peptide 
YY and glucagon like peptide-1 (GLP-1) that regulate satiety in the brain 
Reduces circulating cholesterol 
Decreases liver lipogenesis 
Improves insulin sensitivity  
Prevents proliferation and induces apoptosis of colorectal cancer cells 
 
Butyrate Is mainly taken up by colonic epithelium, small amounts reach portal vein and 
systemic circulation 
Is the preferred energy source for colonic epithelial cells 
Stimulates the proliferation of normal colonic epithelial cells 
Prevents proliferation and induces apoptosis of colorectal cancer cells 
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Affects gene expression of colonic epithelial cells 
Improves the gut barrier function by stimulation of the formation of mucin, 
anti-microbial peptides and tight junction proteins 
Interacts with the immune system 
Has anti-inflammatory properties. Acts on leukocytes, inhibiting release of 
inflammatory cytokines (TNF-α, IL-2, IL-6) 
Stimulates the absorption of water and sodium 
Reduces oxidative stress in the colon 
Promotes satiety by increasing colonic cell secretion of gut hormones peptide 
YY and glucagon like peptide-1 (GLP-1) that regulate satiety in the brain 
Decreases the pH of the colon (decreasing bile salt availability, increases 
mineral absorption, decreases ammonia absorption and inhibits growth of 
pathogens) 
  
 
 
Figure 1.3: Schematic representation of microbial metabolic pathways and cross-feeding 
mechanisms, contributing to SCFA formation in the human gut. Shaded geometric shapes 
summarize routes of formation for each of the three main SCFAs: acetate, propionate, butyrate. (Image 
adapted from Ríos-Covián et al., 2016) 
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4.4.6. Bacterial cross-feeding 
There is a large diversity in polysaccharide substrates that reach the colon, creating a vast array 
of ecological niches that are exploited by gut bacteria. Although some species can utilize 
different substrates, (e.g. substrates from the diet and host origin (Sonnenburg et al., 2005; Scott 
et al., 2006)), other species, are far more specialized. The ability to produce hydrolytic enzymes 
and transport systems determines the specificities of a bacterium’s feeding profile. Figure 1.3 
shows cross feeding mechanisms of metabolic pathways and Figure 1.4 shows examples of 
cross-feeding mechanisms between bifidobacteria and butyrate producing bacteria, utilizing 
different polysaccharides as carbon sources.  
Acetate, propionate and butyrate can be generated through cross feeding and different bacteria 
can utilize different pathways. For example, three different pathways are used by bacteria to 
produce propionate: the succinate pathway, where succinate is the substrate is present in some 
Firmicutes and some Bacteroidetes; the acrylate pathway, where lactate is utilised is present in a few 
members of the families Veillonellaceae and Lachnospiraceae (Flint et al., 2015) and the propanodiol 
pathway where deoxy-sugars are used. The succinate pathway is thought to be dominant 
(Salonen et al., 2014). 
A greater diversity of bacteria in the colon provides more opportunity for breakdown and fuller 
utilization of different dietary polysaccharides.  For example, the ability of bifidobacteria to 
break down arabinoxylan-oligosaccharides (AXOS) is strain dependant (Riviere et al., 2014) due 
to the heterogeneous nature of AXOS and AX, their complete hydrolysis requiring both 
debranching and depolymerizing enzymes. A study of AXOS consumption amongst members 
representing eleven different bifidobacterial species found different clusters who preferentially 
metabolise different AXOS, with some unable to utilise the xylan backbone but able to use 
arabinose, some able to utilise the xylan backbone only up to xylotetraose whilst not using the 
arabinose and some that can utilise both the xylan backbone and the arabinose sidechains, 
suggesting that AXOS metabolism is strain dependant and rather complex (Riviere et al., 2014). 
Most butyrate-producing bacteria belong to the Clostridium cluster XIVa (~80%) (Barcenilla et 
al., 2000) and use acetate to produce butyrate via the butyryl- CoA: acetate CoA pathway (Figure 
1.3), utilising butyryl- CoA: acetate CoA transferase enzyme which is present in the most 
abundant bacteria in the human colon, such as Faecalibacterium prausnitzii (~14%), Eubacterium 
rectale (~13%), and other bacterial groups such as Roseburia spp. (Riviere et al., 2015). Lactate is 
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formed from pyruvate through the action of lactate dehydrogenase in the homofermentative 
pathway (Figure 1.3) by many common gut bacteria including lactobacilli, bifidobacteria, 
enterococci, and streptococci and Eubacterium spp. (Barcenilla e al., 2000). However, under 
normal conditions, lactate is not present at high levels in mixed microbial communities such as 
faecal samples, possibly due to lactate utilization by different bacterial species. In normal 
individuals, faecal lactate is usually at a concentration of less than 5 mM but has been reported 
to accumulate in faeces from individuals who are suffering from ulcerative colitis, at 
concentrations up to 100 mM (Hove et al., 1994; Tsukahara et al., 2002).  
Cross-feeding by colonic bacteria has a huge impact on the microbial populations and resultant 
SCFA production as well as the efficient use of fermentable polysaccharides (Ríos-Covián et al., 
2016), and helps to explain the reported butyric effect of some polysaccharides like oligofructose 
(FOS), which are not known to be fermented by butyrate producing bacteria (shown in figure 
1.4- cross feeding 2). For example, some undefined bacterial species related to Eubacterium 
hallii were shown to use lactate to produce butyrate. The abundance of E. hallii in the gut 
suggests an important role in preventing lactate accumulation and butyrate production for these 
species (Duncan et al., 2004).  
 
 
Figure 1.4: Different types of cross-feeding that can take place between Bifidobacterium spp. 
and species of butyrate-producing colon bacteria in the human colon. Arrows indicate 
consumption of oligofructose, inulin, and AXOS (…..), production of carbohydrate breakdown 
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products and/or metabolic end-products (- - -), and cross-feeding interactions between the 
bifidobacterial and butyrate-producing strains (—). Image from Riviere et al. (2016). 
 
4.4.7. Protein fermentation 
Proteins that have not been digested in the upper digestive tract can also be fermented by 
colonic bacteria into branched fatty acids such as isobutyrate, isovalerate and other nitrogen and 
sulphur containing compounds. Because carbohydrate fermentation is more energetically 
favourable, there is depletion of fermentable carbohydrates in the distal regions of the colon, 
making proteins and amino acids a more dominant metabolic energy source for bacteria in this 
area of the gut (Macfarlane et al., 1992). Some end products of protein fermentation can be 
harmful to the host e.g. amines and ammonia, and a shift to protein fermentation has been 
linked with increases in diseases such as IBS and colonic cancers, which occur more often in 
the distal regions of the gut (Roberfroid et al., 2010).  
 
4.4.8. Gut dysfunction 
Inflammatory bowel disease is a result of a lack of immune tolerance to commensal gut 
microbiota. It is estimated to be present in around 0.8% people in Europe (Molodecky et al., 
2012) and most often presents as Crohn’s disease (CD) or ulcerative colitis (UC). Under normal 
conditions the mucosal layer in the gut covers the colonic epithelial cells and provides a first 
line of defence against microorganisms. Usually only specific types of bacteria can adhere to the 
mucus layer, but in sufferers of IBD, the mucus layer is damaged or discontinuous, becoming 
more permeable and allowing other microorganisms to reach the colonic epithelium. This 
results in immune recognition of antigens on the surfaces of the microorganisms and results in 
inflammation of the epithelium. 
CD presents as discontinuous inflammation which may extend deeply into the submucosal 
regions and can occur anywhere along the colon. In UC, inflammation involves only the 
superficial layers of the intestinal mucosa and is localised to regions of the gut most highly 
colonized by bacteria, beginning distally and moving proximally along the colon (Cho, 
2008). Irritable bowel syndrome (IBS)is recognized by chronic abdominal pain and discomfort 
associated with alterations in bowel habit and does not present with altered colonic physiology, 
but low-grade inflammation and immunological alterations believed to be associated with an 
activated adaptive immune response which is thought to be involved in the pathogenesis.  
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Unfavourable alteration of gut microbiota composition, known as dysbiosis, has been 
implicated in the pathogenesis of inflammatory bowel diseases (IBD), and other gastrointestinal 
disorders, including gastritis, peptic ulcer, IBS and even gastric and colon cancer (Swidinski et 
al., 2002; Frank et al., 2007; Sartor, 2008).  Low counts of F. prausnitzii have been correlated 
with CD (Sokol et al., 2009; Willing et al., 2009) and low   F. prausnitzii numbers and Roseburia 
spp. counts were seen in people with UC (Vermeiren et al.,2012). Both bacterial groups are 
butyrate producers and the enzyme responsible for butyrate production, butyryl-CoA: acetate 
CoA transferase, is also decreased in both the lumen and mucosa of those with UC. Butyrate 
has been linked with a reduction in inflammatory responses key to the pathogenesis of CD and 
UC (Segain et al., 2000; Scheppach et al., 1992). It is becoming clear that microbial alterations 
and resulting butyrate deficiency have a role in the pathogenesis of IBD but it is not known if 
this is cause or effect. 
 
1.2. Diet and health 
 
4.4.9. Dietary fibre 
Increasing morbidity from chronic diseases such as cardiovascular disease (CVD), type II 
diabetes and colonic cancers, is occurring not only in wealthy but also, disproportionately, in 
low and middle-income countries. The increase in non-communicable diseases such as those 
described above, have been linked with rapid urbanisation and changes to a more sedentary 
lifestyle, coupled with a move away from traditional high-fibre foods to increased consumption 
of processed foods including highly refined cereals with a lower intake of plant dietary fibre and 
whole grains cereals. 
Dietary fibre in food consists of plant cell walls which are not digested by human digestive 
enzymes and are instead partially or completely fermented by the microflora in the colon. 
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Dietary fibre has been historically difficult to define, with many different definitions in use 
around the world. The Codex Alimentarius Commission (CAC) has developed a definition that 
can be used universally.  
 
 
Table 1.3.  Description and sources of the main dietary fibre fractions captured by current 
definitions. Table edited from Buttriss and stokes (2008) original data from Gray (2006). 
“Dietary fibre means carbohydrate polymers with 10 or more monomeric units (Andersson 
et al., 2013), which are not hydrolysed by the endogenous enzymes in the small intestine of 
humans and belong to the following categories: 
1. Edible carbohydrate polymers naturally occurring in the food as consumed. 
2. Carbohydrate polymers, which have been obtained from food raw material by physical, 
enzymatic or chemical means and which have been shown to have a physiological effect of 
benefit to health as demonstrated by generally accepted scientific evidence to competent 
authorities, 
3. Synthetic carbohydrate polymers, which have been shown to have a physiological effect 
of benefit to health as demonstrated by generally accepted scientific evidence to competent 
authorities. 
Footnote 1 states, “when derived from a plant origin, dietary fibre may include fractions of 
lignin and/or other compounds associated with polysaccharides in the plant cell walls. These 
compounds also may be measured by certain analytical method(s) for dietary fibre. 
Footnote 2 states that, “Decision on whether to include carbohydrates of 3 to 9 monomeric 
units should be left up to national authorities.” 
Footnote 1 aligns with most definitions and recognizes ‘associated substances’ and lignin 
when part of, but not isolated from, the DF complex”. 
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Fibre component Description 
Cellulose Polysaccharides comprising up to 10 000 closely packed glucose units, arranged 
linearly, making cellulose very insoluble and resistant to digestion by human 
enzymes. Principal component of cell walls of most plants. Forms about 25% 
fibre in grains and fruit. 
Hemicelluloses Polysaccharides containing sugars other than glucose. Associated with cellulose in 
cell walls and present in both water soluble and insoluble forms. Main dietary 
sources are cereal grains. 
Pectins Polysaccharides comprising galacturonic acid and a variety of sugars; soluble in 
hot water and forms gels on cooling. Mostly found in fruit but also present in 
vegetables. 
Beta-glucans Glucose polymers that, unlike cellulose, have a branched structure enabling them 
to form viscous solutions. Major cell wall component in oats and barley. 
Resistant starch Starch and starch degradation products that are not absorbed in the small 
intestine. Four classes have been identified: physically inaccessible starch, RS1; 
native starch granules, RS2; retrograded starch, RS3; and chemically modified 
starch (Englyst & Cummings 1987). RS1 is present in legumes and grains, RS2 in 
unripe bananas, RS3 is produced during cooking, cooling and storage of foods. 
Other synthetic 
carbohydrate 
compounds 
Synthetic derivatives of cellulose (for example, methyl cellulose and 
hydroxypropylmethyl cellulose) are non-digestible and, unlike their parent 
(cellulose), are soluble. But they are hardly fermented by microflora. Polydextrose 
has an average degree of polymerisation of 12 and is synthesised from glucose 
and sorbitol. It is partially fermented in the colon (∼50% in humans) and has 
bulking and prebiotic properties. 
Gums and mucilages Gums are hydrocolloids derived from plant exudates. Mucilages are present in the 
cells of the outer layers of seeds of the plantain family, for example pysillium. 
Both are used as gelling agents, thickeners, stabilisers and emulsifying agents. 
Lignin Not a polysaccharide but chemically bound to hemicelluloses in plant cell walls. 
Other minor 
components 
Phytic acid (inositol hexaphosphate) is associated with fibre in some foods, 
especially cereal grains. May reduce mineral absorption in the small intestine as it 
binds strongly. Other compounds associated with fibre include tannins, cutins and 
phytosterols. 
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Dietary fibre includes a range of substances including polysaccharides, oligosaccharides, lignin 
and associated plant substances including the waxes cutin and suberin (indigestible fatty acid 
derivatives) which are bound to dietary fibre polysaccharides (noted in foot note 1), often 
forming cross links between other components and increasing resistance to digestion (DeVries, 
2003). The principal types of dietary fibre are the non-starch polysaccharides (NSP) which 
constitute the major proportion of dietary fibre, resistant starches, defined as “the starch and 
products of starch digestion that are not absorbed in the small intestine of healthy individuals” 
(Englyst and Cummings, 1982) and non-α-glucan oligosaccharides- short chain carbohydrates. 
Table 1.3 provides a description and main sources of DF according to current definitions. 
The National Diet and Nutrition Survey of the UK showed that cereal products contributed 
29/30% of the total daily energy intake of adult males/females, 22/21% of the intake of protein 
and 39/37% of the intake of non-starch polysaccharides (the major components of dietary fibre, 
DF) (NDNS, 2011). Some are almost completely fermented by gut bacteria, and others are less 
fermentable.  
The average fibre intake by UK adults falls far short of dietary recommendations, contributing 
to increasing health problems. The average intake is 12.8g/day for women and 14.8g/day for 
men. The recommended average intake for UK adults was 18g (NSP) per day (Department of 
health, 1991). This was increased in July 2015 by The Scientific Advisory Committee 
on Nutrition recommendation on carbohydrates, to a recommended 30g/ day for adults which 
is in line with the FAO/WHO opinion and more similar to recommendations for the rest of 
the world. 
 
4.4.10. Dietary fibre and health  
Dietary fibre is usually found in the diet as a mixture of different polysaccharides from different 
plant based sources. Those eating diets high in dietary fibre have been shown to have reduced 
risk of many chronic diseases such as cancers, cardiovascular diseases including coronary heart 
disease, obesity and type II diabetes. A meta-analysis by (Threapleton et al. 2013) showed an 
association with greater intake of dietary fibre (including cereal, fruit and vegetable fibre) and 
reduced cardiovascular disease and coronary heart disease, highlighting the case for increased 
intake of DF.  
20 
 
The more soluble and easily fermentable dietary fibres have been shown to reduce the effect of 
carbohydrates on increases in blood sugar (glycaemic index), reduce the amount of insulin 
required to reduce blood sugar (insulin sensitivity) and decrease cholesterol absorption 
(Hallfrisch and Behall, 2000; Marlet, 1997). Dietary fibre can improve general health by helping 
to regulate satiety and diluting the energy density of food. The addition of insoluble fibre to the 
diet helps to increase stool weight not only from fibre bulk but from increases in bacteria and 
water holding capacity (Harvey et al., 1973; Cummings, 1980). 
Fibre intake has also been linked to reductions in colorectal cancer risk (Aune et al., 2011; 
Trichopoulou et al., 2003). The European Prospective Investigation on Cancer study reported 
a 40% reduction in risk of colorectal cancer between the lowest (15 g/day) and the highest 
(35 g/day) intakes based on incidences of colon cancer (Trichopoulou et al., 2003). The 
protective effect was greatest for the proximal colon, and lowest for the distal regions. The 
mechanism of risk reduction from dietary fibre has been suggested to be due to: a reduction in 
exposure of the colonic mucosa to carcinogens by dilution from additional stool bulk (Reddy et 
al., 1989); reduction in contact time from decreased transit time (Harris and Ferguson, 1993); 
decreased binding of carcinogens (Ryden and Robertson, 1995a) and  reduction of colonic 
luminal pH by SCFAs produced from bacterial fermentation and modulation of cell 
proliferation by butyrate (Clausen, 1995). 
Studies on dietary fibre have often focussed on singular types of fibre e.g. resistant starch and 
inulin, (Englyst & Cummings 1987; Tarini and Wolever, 2010), however more relevant in vivo 
results are obtained from using real life scenarios such as a combination of different DF from 
whole grain intake (Schatzkin et al., 2007). 
 
1.3. Prebiotics 
Some DFs are classed as prebiotic or have prebiotic activity. Prebiotics have been defined as 
“non-digestible food ingredients that selectively stimulate growth or activity of gastro-intestinal 
microflora that confers benefits upon the host in terms of well-being and health” (Gibson and 
Roberfroid, 1995). This usually involves an increase of bifidobacteria and lactobacilli. A more 
recent definition of prebiotic activity is “a selectively fermented ingredient that allows specific 
changes, both in the composition and/or activity in the gastrointestinal microflora, that confer 
benefits upon host well-being and health” (Gibson et al., 2004). Not all dietary fibres are 
prebiotics, to qualify they must resist gastric digestion by acidity and mammalian enzymes and 
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gastrointestinal absorption. Recognized prebiotics consist mainly of glucose, galactose, xylose 
and fructose oligomers/polysaccharides and have monomers linked by β-configuration linkages 
which are not digestible by human digestive enzymes (e.g. Cellulose consists of glucose 
monomers linked via β-1-4 glycosidic linkages whereas starch consists of glucose monomers 
linked via α-1-4 glycosidic linkages). 
Differences in the structure or sizes of polysaccharides, such as changes in molecular mass 
(MM), type of bond between monomers or the presence of substitutions along a backbone of 
sugar units can cause significant changes in prebiotic properties (Kabel et al., 2002a; Kabel et 
al., 2002b; Holck et al., 2011).  
The proximal colon contains more saccharolytic bacteria and thus more sugars are fermented 
there. The more distil regions are where most dysfunctions arise and this is due to more 
proteolytic fermentation resulting in free amines (Macfarlane et al., 1992). Thus, it has been 
suggested that the presence of prebiotics in the distal region are likely to prove beneficial 
(Roberfroid, 2007). Most currently available prebiotics are derived from disaccharides and 
simple polysaccharides, for example fructo-oligosaccharides and galacto-oligosaccharides, with 
chain lengths (or degree of polymerization (DP) of 2-10 sugar residues. More complex structures 
may increase resistance to fermentation and allow a polysaccharide to persist further in to the 
distil colon.  
 
1.4. The wheat grain 
 
4.4.11. Structure of the wheat grain 
The mature wheat grain is composed of three major tissues, the endosperm (which is the major 
storage organ), the embryo, and the protective outer layers. The endosperm is made up of mainly 
starch, protein and cell wall polysaccharides and comprises two tissues. The major tissue is the 
starchy endosperm which is rich in starch (~80% w/w). However, the outer cells of this tissue 
have higher contents of protein (up to 40%) and are termed sub-aleurone cells. Surrounding the 
starchy endosperm is a single layer of cells with thick walls, high contents of protein and minerals 
and little or no starch. These are called the aleurone layer. On milling the starchy endosperm 
cells form the white flour fraction with the germ, aleurone and outer layers forming the bran 
fractions. 
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Proteins are the second most abundant storage compounds in the starchy endosperm, 
representing about 10-15% (w/w) (Toole et al., 2009), and are deposited in protein bodies which 
become compressed between the starch granules in the mature grain.  
Cell wall polysaccharides in the starchy endosperm account for only 2-3% dry weight, with the 
major components in wheat grain being arabinoxylan (AX) (about 70%) and (1→3,1→4)-β-D-
glucan (about 20%), with small amounts of cellulose ((1→1→4)-β-D-glucan) (about 2%) and 
glucomannan (about 7%) (Mares and Stone, 1973). Figure 1.5 is a schematic of a wheat grain, 
with the structures of the wheat grain and the constituents of each structure labelled.  
 
 
 
Figure 1.5: Schematic representation of transverse section through a wheat grain showing 
components. Image from Braun et al. 2003, (adapted) from Barron et al. (2007). The starchy 
endosperm is the largest tissue, containing mostly starch. 
 
White flour, made from the wheat starchy endosperm, is used to make most food products 
derived from wheat, including white bread. About 60% of flour produced in the UK is used in 
the manufacture of bread products, with the remaining 40% being used in a huge diversity of 
other food products including use as thickeners, batters and for brewing.  Bread is bought by 
99% of British households, and the equivalent of nearly 12 million loaves are sold each day 
(Zhong et al., 2000), median bread consumption per person is approximately 90 grams per day, 
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higher for men (113g) than for women (76g). Approximately 75% of the bread we eat is white 
and sandwiches are thought to account for 50% of overall bread consumption (Swan, 2004). 
Therefore, white bread is a useful vehicle with which to deliver dietary health benefits to a large 
proportion of the population. 
Arabinoxylans from the cell walls of the wheat grain have been reported to exhibit various 
biological activities, such as lowering serum cholesterol, having antioxidant activity; causing 
post-prandial glycaemic response reduction and anti-inflammatory and immune modulatory 
effects (e.g. enhancing natural killer cell activity). Additionally, they have been linked to an ability 
to reduce the risk of coronary heart disease and applications in weight management by increasing 
satiety (Ghoneum et al., 1998; Zhong et al., 2000; Lu et al., 2004; Stone and Morell, 2009).  
 
4.4.12. Arabinoxylan (AX) 
Hemicelluloses are branched polymers formed by combinations of various monosaccharides 
including, xylose, arabinose, galactose, mannose and fucose, with a linear backbone composed 
of monosaccharide subunits. In the 1920s a high viscosity hemicellulosic ‘pentosan’ 
polysaccharide, composed of xylose and arabinose (pentose sugars), was extracted from wheat 
flour by Hoffman and Gortner (1927). This was the first extraction of arabinoxylan (AX) from 
wheat flour. Subsequently AX polysaccharides were discovered in the outer layers of cereal 
grains such as wheat, maize, rye and their structures have since been extensively studied 
(Freeman and Gortner 1932; Fincher and Stone, 1986; Izydorczyk, and Biliaderis, 1995; 
Swennen et al., 2005; Toole et al., 2009).  
Wheat endosperm contains arabinoxylan in low but significant amounts, in soluble (0.7% w/w) 
and insoluble (1.2% w/w) forms.  
 
1.4.1.1. The structure of AX  
Arabinoxylan is the most abundant polysaccharide present in wheat grain, it consists of a chain 
of β-1,4-linked D-xylopyranosyl units which may be unsubstituted or mono-substituted with O-
2- or di-substituted with O-2- and O-3-α-L-arabinofuranose units (Gruppen et al., 1992) (Fig 
1.6). The structure of AX differs between tissues. The outer layers contain more highly 
substituted xylan chains which have more arabinose residues esterified to a phenolic acid called 
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ferulic acid, which is involved in cross-linking of polysaccharide chains., The starchy endosperm 
and aleurone have more mono- or disubstituted xylan chains and fewer ferulic acid substitutions. 
The AX structure is determined by several factors: the degree of polymerisation, the arabinose: 
xylose (A/X) ratio and the arabinose substitution pattern creating much heterogeneity and 
resulting in different physiochemical and biological properties. 
 
 
 
Figure 1.6: A) structure of AX with ferulic acid (FA) esterified to one arabinose monomer. B) 
structure of AX with FA esterified to one arabinose monomer cross linked with a second AX 
and FA. 
 
A 
B 
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In wheat endosperm about 25% of AX is water extractable (WE-AX) and soluble with a 
molecular mass between 200-300 kDa (Saulnier et al., 2007). WE-AXs have high heterogeneity 
but are characterised by their proportions of unsubstituted xylose residues; 60–65% mono-
substituted xylose residues (12–20%) and di-substituted xylose residues (15–30%) (Andersson 
et al., 1994; Cleemput et al., 1993; Delcour et al., 1999; Izydorczyk and Biliaderis, 1995).  AX 
that is not extractable with water is called ‘water-unextractable’ (WU-AX) or ‘alkali-extractable’ 
(AE-AX). The structure of AE-AX is very like WE-AX, but it has a larger average molecular 
mass (MM) and a slightly higher A/X ratio due to the higher proportion of arabinose side 
branches (Gruppen et al., 1991; Gruppen et al., 1992a; Gruppen et al., 1992b and Gruppen et 
al., 1993). 
The ratio of arabinose to xylose (A:X or average degree of arabinose substitution) in cereal AX 
ranges from 0.10 to over 1.0, depending on tissue and plant species. A value of around 0.6 is 
common for wheat WE-AX, although WE-AX sub-fractions from flour have been shown to 
have values ranging from 0.31-1.06 (Dervilly et al., 2000 and Dervilly-Pinel et al., 2001).  
The arabinose at the O-3 position of mono-substituted xylose residues can also be substituted 
with ferulic acid at the O-5 position, allowing the formation of cross-links by oxidation of 
ferulate present on adjacent AX chains (Bunzel et al., 2005) and creating ferulate dimers or tri-
ferulate residues which are stable to acid hydrolysis (Lafiandra et al., 2014). The ferulic acid 
substitutions can also cross link with lignin monomers to generate ferulate-arabinoxylan-lignin 
complexes, strengthening the cell wall (Fincher and Stone 1986).  
The A:X ratio influences solubility of AX as arabinose substitutions sterically inhibit aggregation 
of the (1,4)-β-D-xylan chains and lead to the formation of an extended, asymmetrical 
polysaccharide, thus, highly substituted AX is more soluble. For example, when a water-soluble 
arabinoxylan from wheat flour was treated with α-L-arabinofuranosidase, the resulting products 
had fewer arabinofuranosyl substituents and more readily aggregated into insoluble complexes 
(Marcotuli et al., 2016). 
 
 
4.4.13. Phenolic acids bound to AX 
Phenolic acids are a group of secondary metabolites which possess one aromatic ring bearing 
one or more hydroxyl groups, found in plants and are involved in defence against pathogens 
26 
 
and ultraviolet radiation (Poquet et al., 2008). They are present in cereals in three forms: as 
soluble free acids; soluble conjugates, esterified to sugars and other low molecular mass 
components and insoluble bound forms. Around 90% phenolic acids in wheat are bound 
(Saulnier et al., 2007).  
Phenolic acids can be divided into two groups and are derivatives of either hydroxycinnamic 
acid or hydroxybenzoic acid depending on their derivative acid (Figure 1.7). Hydroxybenzoic 
acid derivatives include p-hydroxybenzoic, protocatechuic, vanillic, syringic, and gallic acids. 
These acids are commonly present in insoluble bound forms and are typically components of 
more complex tannins and lignins. Hydroxycinnamic acid derivatives include p-coumaric, 
caffeic and ferulic acids. These acids are also present mainly in the bound forms, linked to cell 
wall structural components such as cellulose, lignin and AX through ester bonds (Li et al., 2008). 
 
 
Figure 1.7: Hydroxybenzoic acids and hydroxycinnamic acids are the two forms in which 
phenolic acids occur. Image edited from Manach et al. (2004). 
 
The most abundant phenolic compounds in cereals belong to the class of hydroxycinnamic 
acids and are mainly ferulic, diferulic, vanillic, p-coumaric, and syringic acids (Sosulski et al., 
1982).  Among the phenolic compounds found in wheat grain, ferulic acid is by far the most 
abundant and is strongly correlated with the antioxidant capacity of different wheat fractions 
(Mateo Anson et al., 2008). The trans isomer of FA accounts for about 90% of the phenolic 
acids found in wheat flour (Fulcher, 1982). 
Ferulic acid is concentrated in the outer parts of the grain. The aleurone layer and the pericarp 
of wheat grain contain 98% of the total ferulic acid. Figure 1.8 shows how ferulic acid is linked 
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to AX. One of the main food sources of ferulic acid is wheat bran (5 mg/g) (Kroon et al. 1997). 
Wheat bran is rich in ferulic acid; however, its bio-accessibility is very low because ferulic acid 
is covalently bound to the indigestible polysaccharides of the cell walls (Mateo Anson et al., 
2009).  
 
 
Although daily intake of phenolic acids varies geographically due to differences in diet, it is 
estimated that daily intake ranges between 20mg-1g (Luximon-Ramma et al., 2005). Although 
the dosage of phenolic acids required to protect against inflammatory diseases has not been 
determined it was shown that 50mg/kg/day ferulic acid protected diabetic rats by altering 
oxidative stress, expression of pro-inflammatory cytokines and apoptosis (Roy et al., 2013). 
However, the plasma concentration of any individual molecule rarely exceeds 1 µM after the 
consumption of 10–100 mg of a single compound (Hulthe and Fagerberg, 2002) due to the 
limiting step of bioavailability of phenolic acids including FA so differences in dietary intake 
may not affect bioavailability and therefore physiological effects. The in vivo activity of phenolic 
acids strongly depends on their absorption, further metabolism, and tissue distribution. Ferulic 
acid was efficiently transported as the free form through an in vitro model for the colonic 
epithelium consisting of cocultured Caco-2 and mucus-producing HT29-MTX cells. Transport 
was shown to be strongly linked to the hydrophobicity of the different phenolic acids tested, 
suggesting a transcellular rather than a paracellular transport (Poquet et al., 2008). 
Figure 1.8: Ferulic acid attached to AX. Ferulic acid is bound to the arabinoxylans via the acid group 
acetylating the primary hydroxyl at the C5 position of α-L-arabinofuranosyl residues (Hatfield et al., 1999). 
Image from Martins et al., 2011 
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Ferulic acid (FA) has been shown to be a potent anti-oxidant and this activity is more potent 
when the FA is conjugated (found as a ferulic acid β-glucuronide which contains FA and a sugar 
moiety- e.g. AX) (Ohta et al., 1997).  FA has been linked with prevention of various diseases 
associated with oxidative stress, such as cancers, cardiovascular diseases and inflammation by 
termination of oxidation reactions leading to formation of free radicals and cell damage 
(Castelluccio et al., 1995; Hudson et al., 2000). For example, oxidised LDL-cholesterol is a key 
antigen in the generation of atherosclerosis, but not regular LDL-cholesterol (Ohta et al., 1997). 
Oxidised LDL appears to be able to initiate and affect inflammatory mediators such as C-
reactive protein, interleukin (IL)-6, and tumour necrosis factor (TNF)-α (Hulthe and Fagerberg, 
2002). Polyphenols are the most abundant antioxidants in our diets. 
 
4.4.14. Bacterial hydrolysis of AX 
For microbiota to break down arabinoxylan during fermentation, many different bonds need to 
be hydrolysed, requiring different enzymes, and both the yield and the structure of the resulting 
AX are dependent on the substrate and the specificity of the enzymes used. Glycoside 
hydrolases (GHs) are enzymes that hydrolyse glycosidic bonds between two or more sugars and 
are produced by some gut bacteria. They are currently classified into 133 families based on their 
amino acid sequence similarities. The most important GH enzymes involved in AX degradation 
are the endo-β-(1,4)-xylanases (Henrissat 1991). These enzymes randomly cleave internal β-1,4-
linkages in the xylan backbone resulting in AX with a reduced MM and unsubstituted xylo-
oligosaccharides. There are two major families of xylanase, GH10 and GH11, which differ in 
structure and in catalytic properties (Biely et al., 1997). GH10 xylanases have a MM of about 
40kDa and acts preferentially on substituted xylan, whereas GH11 are about 20kDa and act 
preferentially on unsubstituted xylan (Vardakou et al. 2004, Vardakou et al. 2005). GH11 
xylanases will not catalyse hydrolysis in the presence of (1 → 2) and/or (1 → 3) linked arabinose 
substitutions on the xylose residues present in the (−1) and (+1) or (−2) subsite, whereas GH10 
enzymes appear to tolerate arabinose-decorated xylose residues in either the (−3), (−2), or (+1) 
subsites. (Beugrand et al., 2004). 
Arabinofuranosidases are required to cleave α-L-arabinofuranosyls that are linked to singly and 
doubly substituted xyloses and xylosidases hydrolyse 1-4 β-D-xylans from the non-reducing 
termini. Feruloyl esterases, also known as ferulic acid esterases, are the enzymes involved in the 
release of phenolic compounds, such as ferulic, p-coumaric, caffeic, and sinapic acids from 
polysaccharides (Benoit et al., 2008). A-L-Arabinofuranosidases (EC 3.2.1.55) catalyse the 
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hydrolysis of the bond between arabinose and the xylan backbone, thereby leaving behind a 
polysaccharide with longer stretches of unsubstituted xyloses, which can in turn be more easily 
degraded by xylanases (Figueroa-Espinoza et al. 2002). Ferulic acid esterases (EC 3.1.1.73) 
hydrolyse the ester linkage between ferulic acid and arabinose residues (Petit-Benvegnen et al. 
1998) (Figueroa-Espinoza et al. 2002), while β-D-xylosidases (EC 3.2.1.37) release terminal 
xylose residues from the non-reducing end (Tenkanen et al. 1996).  
The β-glucuronidase enzyme catalyses hydrolysis of β-D-glucaronic acid from polysaccharides 
and is associated with production of toxic metabolites (McBain and Macafarlane, 1998).  
Synergistic effects have been described between xylanases, α-L-arabinofuranosidases, and β-D-
xylosidases with respect to AX degradation into monomers which occurs in the gut (Sørensen 
et al. 2007). The presence of arabinose substitutions, ferulic acid side chains and diferulate cross 
linkages between ferulic acid side chains in arabinoxylan can significantly hinder the action of 
bacterial xylanase enzymes by physically inhibiting access to the β-1,4-linkages in the xylan 
backbone. Figure 1.9 illustrates where the various enzymes act to breakdown an AX 
polysaccharide.  
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Figure 1.9: Structure of xylan and the sites of its attack by xylanolytic enzymes. The backbone 
of the substrate is composed of 1,4- β-linked xylose residues. α-araf., α-arabinofuranose; pcou., p-
coumaric acid; fer., ferulic acid. (b) Hydrolysis of xylo-oligosaccharide by β-xylosidase. Adapted 
from Collins et al. (2005).  
 
1.4.1.2. The effect of AX in the colon 
The physiological effects of AX on gut microbiota and host health have been extensively studied 
and AX has been shown to provide health benefits when fermented (Englyst et al., 1987; 
Grootaert et al., 2007; Van Craeyveld et al., 2008; Hughes et al., 2007). The bifidogenic effect 
of AX has been demonstrated in a number of in vitro (Van Laere et al., 2000; Crittenden et al., 
2002) and in vivo studies (Neyrinck et al., 2011; Van Craeyveld et al., 2008) where introduction 
of AX with different cereal source/ dp/ substitution in to the diet of rats was shown to increase 
SCFA concentration, increase ceacal Bifidobacterium populations and reduce branched SCFA 
production (the result of protein fermentation). In vivo fermentation of AX by humans has been 
linked with increases in acetate, propionate and butyrate after consumption of AX enriched 
bread (Grasten et al., 2003). Fermentation of AX in vitro has also been shown to increase 
propionic acid production, which can decrease circulating LDL-cholesterol (Amrein et al., 2003; 
Grootaert et al., 2009). 
Fermentation of wheat endosperm AX results in the production of mainly acetate and 
propionate (Hopkins et al., 2003), although higher MM AX has been shown to increase 
concentrations of butyrate (Hughes et al., 2007).  
 
4.4.15. Beta-Glucan 
Cereal-derived β-glucans are unbranched hemicellulosic polymers (shown in Figure 1.10), 
similar to cellulose (β (1→4) glucan), but with β (1–3)-linked glucose residues every 3-4 units 
(Staudte et al., 1983). β-glucans have received much attention due to a beneficial effect as dietary 
fibre in cereals, for example in barley (Aman, 2006; Cleary and Brennan, 2006; Keenan et al., 
2007).  They are extended molecules comprising up to about 250,000 glucose units. 
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Figure 1.10: The structure of cereal beta-glucans. Cereal-derived β-glucans are unbranched (β 
(1→4) glucan), with β (1–3)-linked glucose residues every 3-4 units (Staudte et al., 1983). 
 
Cereal derived β-glucans have been recognised to have health benefits including the 
maintenance of normal serum LDL cholesterol concentrations (EFSA health claim ID 1236, 
1299), increase in satiety leading to a reduction in energy intake (EFSA health claim ID 851, 
852), reduction of post-prandial glycaemic responses (EFSA health claim ID 821, 824) and 
digestive function (EFSA health claim ID 850). A 4-week crossover trial found a diet enriched 
with barley foods was successful in reducing total and LDL-cholesterol in men, whilst a diet 
enriched in wheat products had no effect (McIntosh et al., 1991). 
Although most studies involving β-glucan have used oat sources, β-glucan is also found in barley 
and to a lesser degree in wheat. A study found β-glucan from oat and barley sources to have 
similar antiatherogenic effects on hamsters (Delaney et al., 2003). However, barley β-glucan is 
much less well researched than oat β-glucan. Structure appears to be important in regulation of 
physiological effect of β-glucans, fungal β-glucans with a β -(1, 3) chain with β -(1, 6) branching 
were found to be more effective than linear β -(1, 3) linear chain at immune modulation (Bohn 
and BeMiller, 1995). 
Various mechanisms have been suggested to explain the reduction of cholesterol resulting from 
the consumption of β-glucan: Prevention of bile salt reabsorption from the small intestine, 
leading to increased bile salt excretion; a reduced glycaemic response leading to lower insulin 
stimulation of hepatic cholesterol synthesis or via microbial fermentation in the gut, releasing 
SCFA including propionate, which has been linked with reductions in circulating LDL 
cholesterol concentrations in rats (Chen et al., 1984; Kishimoto et al., 1995) and humans 
(Wolever et al., 1991). Regarding the latter, other studies found that rat hepatic cells were far 
more sensitive to propionate hypocholesterolaemia than humans and human hepatic cells 
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required a far larger dose of propionate than would be biologically available (Lin et al., 1995). 
Hughes et al (2008) found an increase in propionate after using β-glucans in in vitro fermentation 
studies and attributed the increased production to increased numbers of Clostridium histolyticum. 
Some studies have linked β-glucans with prebiotic effects on single strains of Lactobacillus 
plantarum (Russo et al., 2012) but others have shown β-glucans to have little effect on mixed 
bacterial colonies (Hughes et al., 2008). It is not known if β-glucan can interact with other dietary 
fibres to create modulate prebiotic effects through cross feeding. 
 
4.4.16. Arabinogalactan-Peptide (AGP) 
AGPs are small, water extractable proteoglycans, containing glycans consisting of a (1→6)-β-D-
galactopyranosyl backbone substituted in the O-3-position with a single α-L-arabinofuranosyl 
or a single β-D-galactopyranosyl residue (which can also be substituted in the O-3-position with 
a single α-L-arabinofuranosyl residue) (Van den Bulck et al., 2005). The wheat AGP peptide 
core is encoded by the Gsp-1 gene and comprises 15 amino acids including three highly 
conserved hydroxyprolines (Hyp). Each peptide is O-glycosidically linked to a carbohydrate 
chain through the Hyp residue (Van den Bulck et al., 2005) (shown in Figure 1.11). Only one 
species of water-extractable AGP occurs in wheat flour, of which, 90% is reported to comprise 
the AG module, suggesting that this is the functional group and not the peptide (Tryfona et al., 
2010).
Figure 1.11: The structure of an AGP polysaccharide showing galactan backbone with 
arabinose side chains and amino acid residue. Modified from Tan et al. (2004). 
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Wheat endosperm AGP have been found in two different wheat cultivars with an arabinose to 
galactose (A/G) ratio of 0.66–0.73 (Loosveld et al., 1998) and reported apparent molecular mass 
ranging from 22-70 kDa (Fincher et al., 1974; Loosveld et al., 1998). The galactose content of 
the starchy endosperm non-starch polysaccharides is almost entirely derived from AGP and 
accounts for approximately 10% of the non-starch derived monosaccharides (Pellny et al., 
2012). Several studies have elucidated the structure and plant function of wheat AGP (Fincher 
and Stone, 1974; Fincher et al., 1974; Tryfona et al.,2010; Loosveld et al., 1998; Letarte et al., 
2006), but there have been no studies on the effect of AGP as a component of food. AGP has 
been estimated to be present in wheat flour at 0.27-0.38% flour dry weight and shown to 
influence bread making properties (Courtin and Delcour, 2002), but it is not known if AGP has 
prebiotic activity or any other physiological effects. 
A study on arabinogalactan-protein from white-skinned sweet potato, a polysaccharide with a 
similar structure to AGP but with (1→3)-β-d-galactopyranosyl linkages rather than (1→6)-β-d-
galactopyranosyl linkages found in AGP, showed it to cause a decrease in insulin resistance in 
mice by decreasing elevation of plasma glucose levels (Oki et al., 2011). This suggests that AGP 
could have beneficial effects which should be examined.  
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1.5. Aims 
The aim of this work is to determine how the structures of dietary fibre components and 
proportions of the various DF components found in wheat endosperm affect prebiotic activity. 
• To determine the prebiotic activity of the three most abundant dietary fibre components 
of wheat endosperm, arabinoxylan, β-glucan and arabinogalactan-peptide (chapter 3).  
• To determine whether DF components act synergistically and whether the ratio of 
polysaccharides affects prebiotic activity in vitro (chapter 3). 
• To determine if the structure of arabinoxylan influences prebiotic activity and whether 
differences in the degree of polymerization and arabinose substitution result in 
differences in bacterial fermentation (chapter 4).   
• To determine if simulated gastric digestion of isolated AX results in altered structure 
and effects prebiotic activity of arabinoxylan fractions of different molecular mass 
(chapter 5). 
 
These aims were addressed through the following research plans: 
• AGP was extracted from wheat flour and tested by in vitro fermentation to determine 
prebiotic activity. The in vitro fermentation of AGP was then compared to that of AGP 
and AX combined to determine any modulation of prebiotic activity.  
• B-glucan and AX were tested for prebiotic activity by in vitro fermentation and the 
relative levels of β-glucan and AX altered to explore effects on in vitro fermentation.  
• Commercial AX of different molecular masses were subjected to simulated gastric and 
duodenal digestion, prior to in vitro fermentation. The effect of simulated gastric 
digestion on polysaccharide structure was determined  
• AX was isolated from a transgenic wheat line with an altered arabinose substitution 
pattern. This was compared to AX from control lines to determine if specific 
modification of arabinose substitution had significant effects on prebiotic activity  
In all cases, prebiotic activity was determined by the enumeration of important bacterial groups 
using Flow- FISH and measurement of SCFA production.  
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2. Materials and Methods 
 
2.1. Carbohydrates 
Wheat arabinoxylan of low (Polysaccharide-Wheat Arabinoxylan- Low(P-WAXYL)), medium 
(P-WAXYM) and high (P-WAXYH) molecular mass and insoluble arabinoxylan (P-WAXYI), 
high viscosity barley β-glucan (P-BHBH) and FOS with dp 2-8 (P-FOS28) were purchased from 
Megazyme (Co. Wicklow, Ireland). 
Plant Material 
Plant material was grown prior to commencement of this thesis and therefore was not done 
personally. 
Triticum aestivum cv. Yumai-34 (a Chinese winter wheat), Transgenic wheat line TaXAT1 
(TaGT61_1) (hereafter referred to as GT61) was grown according to Sparks and Jones, (2009). 
Construct preparation and generation of transgenic material was done at Rothamsted Research 
as detailed in Anders et al. (2012). 
The azygous control wheat was grown at Rothamsted Research in temperature-controlled 
glasshouse rooms with 18°C to 20°C day and 14°C to 16°C night temperatures with a 16-h 
photoperiod provided by natural light supplemented with banks of Son-T 400 W sodium lamps 
(Osram, Ltd.) giving 400 to 1,000 µmol m−2 s−1 photosynthetically active radiation. 
White Flour 
Seed moisture was measured using NMR (Bruker Minispec, Billerica, Massachusetts, US) and 
adjusted to 16.5% by addition of sterile distilled water at a volume of 1mL per 100g grain per 
1% moisture increase before milling with Chopin CD1 mill (Calibre Control International 
Limited, Warrington, UK). First break and first reduction flours were combined to give white 
flour for analysis. 
 
 
 
2.2. Extraction of arabinogalactan-peptide (AGP) and WE-AX from white flour 
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The method was adapted from Loosveld et al, (1997) based on Fincher and stone, (1974), based 
on Preece and MacDougall (1958). 
Two hundred g flour was heated at 130 °C for 90 min to inactivate endogenous enzymes then 
20g (repeated ten times) was weighed into an extraction thimble (Whatman, 22mm x 80mm) 
then refluxed twice with 80% ethanol for 30mins using Soxhlet apparatus (shown in figure 2.1). 
The ethanol insoluble residue was kept and extracted with deionized water (1:5 w/v) for 60min 
at 40°C then centrifuged at 3000 x g for 15 minutes. The supernatant was retained and 0.4 mL 
(7000 units) of α-amylase (A7095, Sigma-Aldrich) solution added to hydrolyse residual starch, 
the solution was heated to 50°C for 24h and to deactivate the amylase heated to 100 °C for 30 
min. 
Amyloglucosidase (PRO E0057, Prozomix) (120 units) was added and the solution heated to 60 
°C for 12 h before centrifugation at 3000g for 15 mins. The supernatant was dialysed using 
Snakeskin dialysis tubing (3.5k molecular Weight cut off (MWCO) (Thermo Scientific) for 48h 
at 4°C with three changes of water.  Water extractable arabinoxylan (WE-AX) and 
arabinogalactan-peptide (AGP) were precipitated by stepwise addition of aliquots of ethanol 
(95%) to a final concentration of 80%. The solution was stirred for 30 min then incubated at 4 
°C overnight before centrifugation at 10,000 x g for 30 min at 4°C.  
Precipitates were dissolved in 300mL of deionized water for 60 min at room temperature with 
shaking and 95% ethanol was added to a final concentration of 65% (v/v) to separate WE-AX 
from AGP. AGP was recovered from the supernatants by vacuum rotary evaporation at 50 °C. 
Precipitated AX was lyophilised.  
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Figure 2.1: Soxhlet apparatus used to reflux WF.  
 
2.3. Analysis of AX structure using high performance-anion exchange 
chromatography with pulsed amphoteric detection (HP-AEC-PAD) - ‘enzymatic 
fingerprinting’  
 
The protocol was adapted from Ordaz-Ortiz et al. (2005). One hundred mg AX was suspended 
in 0.9mL MilliQ water (18.2M ohms) and 0.1mL enzyme solution containing 16U xylanase 
(PRO-E0062 Prozomix) to hydrolyse β-(14)-D-xylosidic linkages and/or 2U lichenase (PRO-
E0017 Prozomix) to hydrolyse β-(1—>4) and β-(1—>3) glycosidic linkages were added. The 
sample was incubated at 40°C for 16 hours under continuous rotation, then centrifuged for 5 
minutes at 16100 x g and 0.6mL of supernatant removed to a fresh tube and heated to 95°C for 
10 minutes in a water bath. The sample was then centrifuged at 16100 x g for 2 minutes and the 
supernatant filtered using a 0.45µm Millex-HV syringe driven filter using a Terumo 2mL syringe.  
The filtrate was diluted 1 in 20 in water (50ul sample plus 950ul water) mixed thoroughly and 
placed in a HPLC vial with internal standard (melibiose). Twenty µl of the diluted sample was 
injected onto a CarboPak PA1 (Thermo) anion exchange column on a Dionex ICS-3000 
(running at 250µL/min, in a constant 20mM NaOH environment with a sodium acetate gradient 
increasing from 0-27% between 0 and 40 minutes, then increasing from 27-80% between 41-46 
minutes before decreasing to 0% at 47 minutes).  
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2.4. Polysaccharide Analysis using Carbohydrate gel Electrophoresis (PACE) 
The polyacrylamide gel consisted of a 19.7 % (w/v) resolving gel (20.2mL water, 5mL Tris-Base 
Borate pH8.2, 24.6mL 40% (w/v) acrylamide, 20µL Tetramethylethylenediamine (Temed), 
200µL 10% (w/v) APS) and 10.5% (w/v) stacking gel (10.2mL water, 1.5mL Tris-Base Borate 
pH8.2, 4.2mL 40% (w/v) acrylamide, 12µL Temed, 60µL 10% (w/v) APS). 
ANTS labelling: 8- Aminonaphthalene-1,3,6-trisulfonic acid (ANTS) was used to fluorescently 
label the oligosaccharides released following digestion with specific endohydrolases xylanase 
GH11 (PRO-E0062 Prozomix) and β-1,3-1,4 glucanohydrolase lichenase (PRO-E0017 
Prozomix) as described in 2.3. Fifty µL of 1mg/mL AX digest was dried down by speed vac. 
Ten µL DMSO buffer (30µL Acetic acid, 170µL water, 200µL DMSO), 5µL ANTS (0.2M 
molecular probes, A350 in water: acetic acid 17:3) and 5µL 1M NaCNBH3 in DMSO were added 
to the dried AX digest. Samples were incubated at 37°C in a water bath for 16 hours, centrifuged 
for 30 seconds at 2,000 x g then dried under vacuum before being re-suspended in 100 µL of 
3M urea. ANTS labelled samples were loaded on to the polyacrylamide gel (3µL/lane). The gel 
was run at 200 mV for 30 minutes then 1,000 mV for 110 minutes, while cooled to 7-10°C. The 
PACE gel was then viewed in Gel-Doc IT TS2 310 imager using UV plate and GFP emission 
filter (513-557 nm). 
 
2.5. Monosaccharides analysis by high-performance anion exchange 
chromatography (HPAEC) 
Fifty µL of a solution of 1mg/mL AX was dried under vacuum to which was added 400 µL of 
2M trifluoracetic acid (TFA) and incubated at 120°C for 1 h in a heating block to hydrolyse 
samples. Hydrolysed samples were cooled on ice and dried in speed-vac at 30°C (overnight). 
500µL of water was added to remove any remaining TFA and the sample was dried again in the 
speed-vac. The sample was finally resuspended in 400 µL of MilliQ water. The hydrolysate was 
diluted further 1:1 with water (100 µL of each sample and 100ul of water was mixed and pipetted 
into glass vials with insert. Standard curves were constructed for fucose, rhamnose, arabinose, 
galactose, glucose, xylose and mannose using monosaccharide standards at concentrations of 2- 
100 µM prepared from stock solutions of 1mM. All samples and standards were run under the 
same conditions as described below. Twenty µL was injected onto a Carbopac PA20 column 
(running at 500µL/min, eluents water, 0.1M KOH, 1M NaOH. With a NaOH gradient of 
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10mM for 7 minutes, 10- 20mM for 8 minutes, 800mM for 25 minutes, 200mM for 0.5 minutes 
then returning to starting conditions of 10mM for 13.5 minutes to equilibrate the column) on a 
Dionex 5000 IC HPLC equipped with disposable gold electrode. 
 
2.6. HP-SEC-MALLS analysis of AX  
Ten mg of each commercial AX fraction were weighed into an Eppendorf tube with 1mL MilliQ 
water and heated to 60°C for one hour to dissolve. Samples were filtered through a 0.45µM 
filter and pipetted into a glass vial with insert. One hundred µL was injected onto an OHpak 
SB 802.5 HQ column on an Agilent 1260 infinity LC system, measuring UV, LS, dRI and dp. 
Samples were analysed using ASTRA software. The eluent was 0.1M NaNO3 with 0.02% NaN3 
with a flow rate of 0.5mL/min-1. Average MM (kDa) and intrinsic viscosity were measured 
(mL/g). 
 
2.7. MALDI-TOF-MS 
MALDI-ToF-MS method was adapted from Marsh et al., (2011) using a Micromass MALDI-
LR mass spectrometer (Waters, Manchester, U.K.) using a standard peptide mass fingerprinting 
method and mass acquisition between m/z 400 and 2400 (The laser firing rate was 5 Hz, 40 
random aims per spot, 10 shots per spectrum, 10 spectra per scan, 10 scans combined, 10% 
adaptive background subtracted, smoothed (SavitzkyGolay), and centroided to obtain the MS 
spectra). The MALDI-MS was tuned to 10000 fwhm and calibrated with a tryptic digest of 
ADH as detailed in 2.7.1.  
 
4.4.17. ADH digest for calibration  
An alcohol dehydrogenase (ADH) digest was prepared to calibrate MALDI-Tof mass 
spectrometer (to generate peptides of known mass). Four mg ammonium hydrogen carbonate 
was added to 1mL water (AMBIC buffer). 1mg ADH was dissolved in 300µL AMBIC buffer 
to make the ADH solution. One mg trypsin was dissolved in 500µL AMBIC buffer. Five µL of 
trypsin solution was added to the ADH solution and incubated at 37°C for 90 minutes to make 
tryptic peptides digest. Ten µL tryptic peptides digest was added to 990µL in 0.1% TFA (10µL 
TFA in 9990µL water) to produce 1pmol/µL tryptic peptides. 
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An α-cyano matrix of 2mg/mL α-cyano-4-hydroxycinnamic acid was made using 1mg/500µL 
of 49.5% ACN, 49.5% EtOH, 1% TFA). The α-cyano matrix was mixed with ADH digest in 
1:1 ratio to provide 500fmol/µl on target. One µL was spotted on to MALDI plate multiple 
times, other dilutions were also used, down to 50fmol/µl.  
4.4.18. Methylation  
Five NaOH pellets were ground into fine powder in a pre-warmed pestle. Three mL dimethyl 
sulphoxide (DMSO) was added. One mL of NaOH/DMSO slurry was added to 20mg 
lyophilised AGP sample with 0.5mL iodomethane and sample was capped and mixed using 
vortex for ten minutes. The reaction was quenched using dropwise addition of 1mL water and 
mixed immediately after each addition. Two mL CHCl3 was added, the sample was vortexed 
and left to settle in to two phases. The upper aqueous phase was removed and discarded and 
the lower layer was washed with water until the upper phase became clear. The lower CHCl3 
layer was dried with N2   20ul DHB matrix (10mg/mL Dihydroxybenzoic acid (DHB solution 
in 50% methanol) was added to each experimental sample.  
For samples, 20µL DHB solution were added to methylated samples and 1µL spotted on to 
MALDI target plate multiple times. Samples were air dried before running on MALDI, spectra 
were analysed using Mass Lynx software as described above (2.7). 
Experimental masses obtained from MALDI-ToF spectra, were matched to glycans using 
internet tools designed to find all possible compositions of glycan structures for their 
experimentally determined masses using GlycoMod (ExPaSy) 
(http://www.expasy.ch/tools/glycomod/), a table of these masses is shown in table 2.1. 
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Table 2.2: Molecular masses of most common monosaccharide residues and their methylated 
forms. 
 
 
 
2.8. Analysis of phenolic acid content  
 
4.4.19. Extraction of Phenolic acids 
Twenty mg samples were weighed (in triplicate) for each sample and suspended in 1mL 80% 
ethanol (v/v) and extracted twice, for free and conjugated phenolics followed by bound 
phenolics (giving a total of six extracts per total phenolic measurement). To extract free and 
free-conjugated phenolics, 5µL internal standard B (IS B) was added (IS B was a 20 x dilution 
of IS A: 1.5 mg.ml-1 3,5-dichloro-4-hydroxybenzoic acid in 80:20 (v/v) ethanol). The 20mg 
sample was mixed with 1mL 80% ethanol, vortexed, heated to 80°C for 10 minutes, sonicated 
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for 10 minutes and centrifuged at 5000 x g for 15 minutes. This was repeated twice and the 
supernatants combined and dried in a centrifugal evaporator. Four hundred µL 2M NaOH was 
added to the dried supernatant and kept in the dark for 4 hours (free and conjugated). For the 
extraction of bound phenolics 20µL IS A was added to the wet pellet (from the free and 
conjugated extraction) and 800µL of 2M NaOH added. Samples were left in the dark to 
hydrolyse for 16 hours. All extracts were acidified to pH 2 by addition of 125µL 12M HCL and 
pH tested with pH paper (Fisherbrand pH-fix). The phenolic acids were extracted three times 
with ethyl acetate (800, 700 then 600µL respectively) by phase partitioning. Samples were 
vortexed after each addition of ethyl acetate and centrifuged. The combined upper phases were 
dried by centrifugal evaporator. One hundred µL of 2%( v/v) acetic acid was added to each 
dried sample, and vortexed.  
 
4.4.20. HPLC analysis of phenolic acid extracts 
HPLC analysis of phenolic acid extracts from was carried out on a Shimadzu HPLC. 40µL of 
each sample was injected on to a Kinetex 5µm Pheny-Hexyl 100 A 150mm x 4.6 mm column 
and run for 18minutes. The eluent was acetonitrile (A) and 2% acetic acid (B) with the following 
stepped gradient: 0min 0% A, 100% B, 0.1-14min gradient to 70% A, 30% B, 14.1-18 min 100% 
A, 0% B. The flow rate was 1mL/ minute using a column temperature of 30°C and detection 
of 280/320 nm.  Standards of trans-ferulic acid (tFA) at 10, 25, 50, 75, 100, 125 and 150 m[µg] 
were run under the same conditions with internal standard to obtain a standard curve. Sample 
data were compared to the standard curve to calculate the amounts of pCa and tFA. 
 
2.9. In vitro gastric and duodenal digestion 
In vitro gastric and duodenal digestion was done using the protocol devised by Minekus et al. 
(2014). Five hundred mg of each commercial AX sample (low, medium, high molecular weight 
and insoluble arabinoxylan fractions from wheat flour (Megazyme Co. Wicklow, Ireland) were 
added to 5mL water and mixed using a magnetic stirrer. Five mL simulated salivary fluid (SSF) 
(described in table 2.1) and 375µL salivary amylase (A0521 Sigma-Aldrich) were added, vortexed 
for 2 mins, and 10 mL simulated gastric fluid (SGF) and Pepsin (P0525000 Sigma-Aldrich) 
equivalent to 4000U added. The pH was checked and adjusted to pH 3 by dropwise addition of 
6M HCl.  The digest was incubated on a shaker at 250 rpm at 37°C for two hours (simulated 
gastric digest) based on a gastric emptying time between water (1h) and solid meal (3-4h) 
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(Minekus et al., 2014).  Twenty mL simulated intestinal fluid (SIF), 40mg porcine pancreatin 
(P7545 Sigma-Aldrich) and 19.4mg bile salts were added and samples were incubated at 37°C 
on a shaker at 250 rpm for two hours (simulated duodenal digest) based on times provided by 
Versantvoort et al., (2005). Samples were snap frozen in liquid nitrogen and then freeze dried 
(Lyodry compact, Mechatech systems, Bristol, UK). 
 
Table 2.1: Preparation of stock solutions of simulated digestion fluids. Volumes are 
calculated for a final volume of 500mL.  
 
 
 
 
 
 
 
 
 
 
 
 
2.10. In vitro fermentation in static batch culture 
Batch culture vessels were autoclaved and 45mL medium was added. The medium contained 
per litre: 2 g of peptone water (Oxoid Ltd., Basingstoke, United Kingdom), 2 g of yeast extract 
(Oxoid), 0.1 g of NaCl, 0.04 g of K2HPO4, 0.01 g of MgSO4‚7H2O, 0.01 g of CaCl2‚ 6H2O, 
2 g of NaHCO3, 0.005 g of haemin (Sigma), 0.5 g of l-cysteine HCl (Sigma), 0.5 g of bile salts 
(Oxoid), 2 mL of Tween 80, 10 µL of vitamin K (Sigma).  
 SSF SGF SIF 
 pH 7 pH 3 pH 7 
Constituent Conc. in SSF Conc. in SGF Conc. in SIF 
 Mmol-1 Mmol-1 Mmol-1 
KCl 15.1 6.9 6.8 
KH2PO4 3.7 0.9 0.8 
NaHCO3 13.6 25 85 
NaCl - 47.2 38.4 
MgCl2(H2O)6 0.15 0.1 0.33 
(NH4)2CO3 0.06 0.5 - 
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Polysaccharide samples (AX/Pre-digested AX/AGP/β-glucan depending on experimental set 
up) were added to each to give a final concentration of 1% (w/v).  Each vessel was inoculated 
with 5 mL of faecal slurry, which was prepared by homogenizing fresh human faeces (10%, 
w/v) in phosphate-buffered saline (PBS; 8 g/L NaCl, 0.2 g/L KCl, 1.15 g/L Na2HPO4, and 
0.2 g/L KH2HPO4), pH 7.3 (Oxoid), with a manual homogenizer (Fisher, Loughborough, 
United Kingdom) (Three faecal donors were used per experiment, between 23-59 years of age 
and on a normal diet without any special dietary requirements and that had not taken antibiotics, 
or prebiotic or probiotic supplements in the previous three months). Vessels were kept 
anaerobic with N gas and incubated at 37°C with a water jacket for up to 48h. Three mL samples 
were removed at different time points for analysis. Samples of 750µL were pipetted into sterile 
Eppendorf tubes in duplicate and centrifuged at 12045 x g for 5 minutes (Eppendorf Minispin, 
Eppendorf, Germany). The supernatants were removed and stored at -20 °C for SCFA analysis 
(2.11). 
 
2.11. Quantification of SCFA using HPLC 
The supernatants (from 2.10) that had been stored at -20°C were thawed and filtered using 
0.2µM nitrocellulose filter and 20 µL was injected on to a Phenomenex Rezex ROA Organic 
Acid H+ (8%) HPLC column (Watford, UK) at 50°C on a Shimadzu HPLC with 0.0025 M 
H2SO4 eluent at a flow rate of 0.6 mL min-1. SCFA (lactate, formate, acetate, propionate and 
butyrate) were quantified using standard calibration curves from 5-50mM. 
 
2.12. Fluorescence in-situ hybridisation coupled with flow cytometer (Flow-FISH) 
The targeted bacterial groups were enumerated by FISH using 16S rRNA targeted 
oligonucleotide probes labelled with fluorescent dye. Bacteria that were counted were known to 
be present in human microflora and belonged to the following groups:  Bifidobacterium genus, 
Lactobaccillus/ Enterococcus group, Bacteroides- Prevotella group, Clostridium coccoides/ Eubacterium 
rectales groups, Roseburia, Atopobium cluster, Clostridium cluster IX, Fusobacterium prausnitzii, 
Desulfovibrionales, Clostridium-cluster I and II. 
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4.4.21. Fixation of samples for Flow-FISH 
750µL samples from batch culture fermentations were pipetted into sterile Eppendorf tubes in 
duplicate and centrifuged at 12045 x g for 5 minutes (Eppendorf Minispin, Eppendorf, 
Germany). The supernatants were removed and stored at -20 °C for SCFA analysis (2.11). The 
pellets were resuspended in 375µL 1M PBS and 1125µL 4% (w/v) paraformaldehyde solution 
(2g of paraformaldehyde, 30ml of ddH2O and 100µl of 1M NaOH added to a Duran bottle and 
incubated at 50°C in a water bath with constant stirring every 15 minutes until all the powder 
had dissolved. One hundred µl 1M HCl and 16.6ml 3M PBS was added to the bottles and the 
solutions made up to 50ml, followed by filter sterilisation through 0.22µm filter into a sterile 
container and stored at 4°C.) 
Samples were incubated at 4°C for four hours to fix, then spun as before and the supernatants 
discarded. The pellets were resuspended in 1mL 1M PBS and then centrifuged at 12045 x g for 
5 minutes. This step was repeated once more to remove residual paraformaldehyde. PBS was 
removed using a pipette and samples were resuspended in 300µL 1M PBS and 300µL EtOH 
and stored at -20°C.  
 
4.4.22. Addition of fluorescent probes and hybridisation 
Following thawing at room temperature each sample was vortexed and 100 µl was added to 500 
µl of 1M PBS in a 1.5mL Eppendorf tube. Samples were mixed via pipetting and then 
centrifuged for 3 min at 12045 x g (Eppendorf Minispin, Eppendorf, Germany). The 
supernatants were discarded and the pellets were resuspended in 100 µl of TE-FISH buffer 
(0.1M Tris-HCl, pH 8, 0.05M EDTA, pH 8) containing lysozyme (1mg/ml).  The samples were 
incubated in the dark for 10 min at room temperature, vortexed and centrifuged as before. The 
supernatants were discarded and the pellets washed with 500 µl of 1M PBS, mixed by pipetting, 
vortexed and centrifuged as before.  
The supernatants were discarded and the pellets were resuspended in 150 µl of hybridization 
buffer (per 1mL: 180µL 5M NaCl, 20 µL1M Tris/HCl (ph 8.0), 300µL formamide, 499µL 
distilled H2O 1µL 10 % sodium dodecyl sulphate), mixed by pipetting, vortexed and centrifuged 
as before. The supernatants were discarded and the pellets resuspended in 1ml of hybridization 
buffer, homogenized thoroughly by pipetting and 50 µl of each sample, in hybridisation buffer, 
was aliquoted into Eppendorf tubes.  
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Four µl of the appropriate probe (MWG Biotech, Ebersberg, Germany) was added to each 
Eppendorf tube. Probes are shown in Table 2.2.  Eub338 I-II-III is a universal bacterial probe, 
which binds with the all types of bacterial cells and was used as a positive control in addition to 
each sample probe to measure the total number of bacterial cells in each sample.  Non-Eub338, 
which does not bind to any bacterial cells, was used as a negative control. The sample probes 
used were Bif164 (Langendijk et al., 1995), Bac303 (Manz et al., 1669), Lab158 (Harmsen et al., 
1999), Ato291 (Harmsen et al., 2000), Prop853 (Walker et al., 2005), Erec482 (Franks et al., 
1998), Rrec584 (Walker et al., 2005), Fprau655 (Hold et al., 2003), Chis150 (Franks et al., 1998) 
all linked to fluorescent Alexa647) and mixed Eub338 I-II-III (linked to Alexa488). Four µl of 
Eub338 I-II-III was added to all samples. Samples were gently vortexed and incubated in a 
heating block for 16 hours at 35°C covered with aluminium foil.   
One hundred and fifty µl of hybridization buffer were added to each tube and vortexed gently. 
Samples were centrifuged for 3min at 12045 x g and the supernatants removed and discarded. 
The pellets were washed with 200 µl of washing buffer (per 1mL: 12.8 µL 5M Na Cl, 20 µL 1M 
Tris/HCl (pH 8.0), 10µL 0.5 M EDTA (pH 8.0), 956.2 µL ddH2O, 1 µL10 % sodium dodecyl 
sulphate), vortexed gently and incubated for 20 min at 37°C in a heating block.  After incubation, 
the samples were centrifuged as before and the supernatants discarded. Three hundred µL PBS 
was added to each sample tube. Samples were vortexed and screened using a flow cytometer 
(Accuri C6, BD Biosciences, USA) with Accuri CFlow software. Samples were run under the 
following conditions: 100,000 events, ungated sample, medium fluidics speed. Control samples 
Non EUB FL1, EUB FL1, Non-EUB FL4, EUB FL4 were run to determine autofluorescence 
and total bacteria. Individual bacterial group probes were calculated based on these values. 
Values were adjusted according to dilution factor by multiplication by the amount of sample 
taken to analyse/amount of PBS added to the sample (100*300).  
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Table 2.2. Oligonucleotide probes used during Flow-FISH analysis of batch culture 
samples. (50ng/ml) * These probes are used together in equimolar concentrations) 
Probe 
Name 
Sequence (5’ to 3’) 
Fluorescence 
Targeted 
Bacteria  
Non Eub ACTCCTACGGGAGGCAGC Alexa-488 None 
Eub338I* GCTGCCTCCCGTAGGAGT Alexa-488 All 
Eub338II* GCAGCCACCCGTAGGTGT Alexa-488 All 
Eub338III* GCTGCCACCCGTAGGTGT Alexa-488 All 
Non Eub ACTCCTACGGGAGGCAGC Alexa-647 None 
Eub338I GCTGCCTCCCGTAGGAGT Alexa-647 All 
Eub338II GCAGCCACCCGTAGGTGT Alexa-647 All 
Eub338III GCTGCCACCCGTAGGTGT Alexa-647 All 
Bif164 CATCCGGCATTACCACCC Alexa-647 Bifidobacterium 
Lab158 GGTATTAGCAYCTGTTTCCA 
Alexa-647 
Lactobacillus and 
Enterococcus 
Bac303 CCAATGTGGGGGACCTT Alexa-647 Bacteroides 
Erec482 GCTTCTTAGTCARGTACCG 
Alexa-647 
Eubacterium 
rectale/Clostridium 
coccoides cluster 
Rrec584 TCAGACTTGCCGYACCGC Alexa-647 Roseburia  
Ato291 GGTCGGTCTCTCAACCC Alexa-647 Atopobium 
Prop853 ATTGCGTTAACTCCGGCAC 
Alexa-647 
Clostridium cluster 
IX 
Fprau655 CGCCTACCTCTGCACTAC 
Alexa-647 
Faecalibacterium 
prausnitzii 
DSV687 TACGGATTTCACTCCT Alexa-647 Desulfovibrionales 
Chis150 TTATGCGGTATTAATCTYCCTTT 
Alexa-647 
Clostridium 
histolyticum 
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2.13. Statistical analysis 
Statistical analysis was undertaken by S.J. Powers (Rothamsted Research). One-way analysis of 
variance (ANOVA) and F-test were applied to determine differences between treatments. 
Differences were deemed significant when P<0.05. The Genstat (2015, 18th edition, © VSN 
International Ltd, Hemel Hempstead, UK) statistical package was used for all analysis. 
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3. Do Combinations of different Dietary Fibres from wheat flour 
affect Prebiotic Activity? 
 
3.1. Abstract 
The main components of the non-starch polysaccharide (NSP) fraction of wheat flour are AX, 
β-glucan and a water-extractable arabinogalactan-peptide (AGP). These components occur in 
in different amounts and ratios in different cereals. Therefore, it was hypothesised that these 
NSPs could act synergistically resulting in different prebiotic activities when fermented in vitro 
at different ratios. AGP was isolated from wheat flour and characterised, whereas AX and 
mixed-linked β-glucan used in this series of experiments were purchased from Megazyme. The 
three fractions were then tested singly and in combination in in vitro fermentation studies to 
assess their prebiotic activity when used individually and or in different combinations and ratios. 
SCFAs produced from in vitro fermentation were measured using HPLC; flow-FISH was used 
for bacterial enumeration. Increases in beneficial bacteria, bifidobacteria were observed with 
combinations of AGP and AX fractions after 8h. Acetic acid production increased after 24h but 
no other SCFA increased significantly compared to the negative control treatment (no 
polysaccharide). There were increases in the beneficial bacterial group Atopobium and decreases 
in the sulphate reducing bacterial group Desulfovibrionales when AGP and AX were combined 
compared to when used individually, demonstrating additive effects. When AX and β-glucan 
were combined at different ratios in in vitro fermentation the greatest increases in total SCFAs 
(20.29M at 0h to 72.93 mM at 24h), bifidobacteria (log10 7.33 to log109.15) and total bacteria 
(log10 8.8 to log109.8) were observed when AX and β-glucan were combined at a 3:1 ratio. 
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3.2. Introduction 
The major components of non-starch polysaccharide (NSP) of wheat flour are AX, β-glucan 
and water-extractable AGP, all are included in the CODEX Alimentarius Commission (CAC) 
definition of dietary fibre. Although there has been much research on the effects of AX and β-
glucan in isolation, the prebiotic activity of these components when used in combination has 
not been investigated. This should be investigated as it is unlikely that these DFs would be found 
separately in foods. As AX and β-glucan are present in cereals together with AGP and have 
been part of the human diet for thousands of years, it is possible that our gut microbiota have 
co-evolved with the presence of these fibres resulting in a greater ‘prebiotic effect’ for fibre 
mixtures than for single individual types of fibre. As these NSPs are present in different ratios 
in different foods, for example, in wheat the ratio of AX: -glucan is 3:1 whereas in barley the 
ratio is 1:3 (i.e. the reverse), different combinations could stimulate the growth of different 
bacteria and result in different SCFA production. AGP comprises about 0.4% of the dry weight 
of the wheat endosperm (Mares and Stone, 1973b) which is about equal to the amount of WE-
AX (Loosveld et al., 1997; Wilkinson et al., 2017). It is composed mainly of carbohydrate (92%) 
with a A: G ratio of 0.67 (Fincher and Stone, 1974) attached to a 15-amino acid peptide. The 
structure of wheat AGP has been determined (Tryfona et al., 2010) but nothing is known about 
whether it acts as a prebiotic.  
An experiment was therefore designed to determine whether there are synergistic effects of the 
major DF components and if so, which ratio of components might provide the greatest 
beneficial effect as determined by prebiotic activity. 
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3.3. Materials and Methods 
 
4.4.23. Polysaccharides  
AGP and AX were extracted from white flour isolated from white flour produced from wheat 
cv. Yumai-34 using the method described in 2.2.  
Commercially available AX and barley β-glucan preparations from Megazyme (Bray, co. 
Wicklow, Ireland) was used for this series of experiments, as the in vitro fermentation system 
used was with large-scale vessels requiring 500mg of each polysaccharide.  A medium MM AX 
fraction was selected for these experiments as it had previously been shown to have the greatest 
prebiotic activity of the four commercially available AX preparations. 
 
4.4.24. Characterisation of polysaccharides  
The polysaccharides were characterised prior to use, in terms of monosaccharide composition, 
structure and size.  
AGP was also characterized using MALDI-TOF-MS after per-methylation as detailed in 2.7. 
Monosaccharide, structural analysis and size determination was as detailed in 2.5 and 2.6. 
 
4.4.25. In vitro fermentation of AX and β-glucan 
In vitro fermentation was performed as described in 2.10. AX and β-glucan were added to 100mL 
vessels in the following amounts 1g AX alone; 666mg AX: 333mg β-glucan; 500mg AX: 500mg 
β-glucan; 333mg AX: 666mg β-glucan; 1g β-glucan alone. These were compared to FOS (1g) 
and a negative control, in triplicate, using faecal samples obtained from three healthy donors.  
Polysaccharide was added to basal media at 1% (w/v). Samples were inoculated with 10% faecal 
slurry, as before. Sub-samples were taken at 0h,4h, 8h and 24h.  
 
4.4.26. In vitro fermentation of AGP and AX 
Small scale in vitro fermentation was performed as described in 2.10. Smaller scale fermentation 
was used due to the small amounts of AGP and AX extorted from WF. AGP (100mg), AX 
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(100mg) or AGP+AX (50mg of each) were compared to FOS (100mg) and a negative control 
(no polysaccharide) in 10mL vessels in triplicate for each sample, using faecal samples obtained 
from three healthy donors. Polysaccharide was added to basal media at 1% (w/v). Samples were 
inoculated with 10% faecal slurry, and sub-samples were taken at 0h, 8h and 24h.  
 
4.4.27. Enumeration of bacteria by flow-FISH 
Bacteria were enumerated from samples taken at 0h, 8h and 24h using flow-FISH as detailed in 
2.12. 
 
4.4.28. SCFA analysis  
SCFA were quantified using HPLC as detailed in 2.11.  
 
4.4.29. Statistical analysis  
The Genstat (2015, 18th edition, © VSN International Ltd, Hemel Hempstead, UK) statistical 
package was used for all analysis. ANOVA data was supplied by SJ Powers (Statistical 
department, Rothamsted Research) and applied as detailed in 2.13. 
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3.4. Results and Discussion 
 
4.4.30. Polysaccharide characterisation 
Table 3.1 shows that all polysaccharides have a purity of 91% or above. Previous studies have 
used samples containing polysaccharides of 90% purity, therefore it can be concluded that 
>91% is sufficient purity for reliable results (Van Laere et al., 2000; Hughes et al., 2007).  
Commercially available AX was compared to commercially available β-glucan and extracted AX 
compared to extracted AGP to reduce extraneous variables by reducing variation from DF 
source. 
 
Table 3.1: Characterisation of AGP, AX and β-glucan: 1 data provided by Megazyme 
(Co. Wicklow, Ireland); 2 isolated from white flour and determined by monosaccharide 
determination), described in Figure 3.1. 
Polysaccharide Purity MM (kDa) 
Extracted AX2 91 %2 n/d 
Extracted AGP 96.73%2 n/d 
Commerical Βeta-glucan 94%1 4951 
Commercial AX1 95%1 323.9 
 
 
3.4.1.1. Monosaccharide analysis  
Figure 3.1 shows monosaccharide analysis of AGP and AX isolated for the study from wheat 
flour (Triticum aestivum cv. Yumai-34), samples were purified with isolated polysaccharide 
comprising >91% of the total monosaccharides present. Arabinose and galactose comprised 
96.73% (±0.18) of total sugars in AGP, with other monosaccharides detected, glucose and 
xylose comprising 2.36% for glucose and 1.74% for xylose. The A: G ratio for AGP was 0.48. 
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This is lower than the average ratio of 0.66–0.73 found by Loosveld et al. (1998) which could be 
related to the wheat cultivar. 
For isolated AX, the arabinose and xylose content was 91% (±0.05), with galactose 5% and 
glucose 4%. The A:X ratio for AX was 0.62. 
Figure 3.2 shows monosaccharide analysis of commercial β-glucan and commercial AX. No 
glucose or galactose were detected. 
 
 
Figure 1.1: Monosaccharide analysis of extracted AGP and AX using a Carbopac PA20 
column. (N=3) Error bars are SD. AGP is composed of mostly arabinose and galactose, with small 
amounts of glucose and xylose, whilst AX is composed mostly of arabinose and xylose with small 
amounts of glucose and galactose. 
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Figure 3.2: Monosaccharide analysis of commercial β-glucan and Medium MM AX 
using a Carbopac PA20 column. (N=3) Error bars are SD. Β-glucan is entirely composed 
of glucose whilst AX is composed only of arabinose and xylose.  
 
3.4.1.2. Analysis of AGP by MALDI-TOF-MS  
 
MALDI-TOF-MS was used to confirm the structure of the carbohydrate moiety of the AGP, 
based on the molecular masses of the oligosaccharides released by the exo-b-(1->3)-galactanase, 
as described in Tryfona et al (2011). Figure 3.3 shows the spectrum from 400-2400 m/z and 
Figure 3.4 shows magnification of the spectra from 400-1300 m/z. for greater clarity. 
Oligosaccharide composition is indicted by Hex (hexose residue) or Pent (pentose residue) and 
subscript indicates the number of residues present. The most dominant ion was ‘Pent4’, at 637 
m/z which is predicted to be four arabinose subunits (chapter 2.7 shows details of ion 
identification). 
Figures 3.3 and 3.4 show similar results to the spectra for AGP obtained from Triticum aestivum 
cv. Cadenza white flour found by Tryfona et al. (2010). Thus, the monosaccharide composition 
(Fig 3.1) and the mass spectra obtained for AGP confirmed the purity and identity of the AGP 
isolated and used in the in vitro fermentation experiments.  
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Figure 3.4: Zoomed in and labelled MALDI-ToF MS spectra showing ions from methylated 
olligosaccharides released by exo-B-(1->3) galactanase digestion of AGP isolated from 
Triticum aestivum cv. Yumai-34 white flour. 
Mass (m/z) 
Figure 3.3:  MALDI-ToF MS spectra showing ions of m/z diagnostic of methylated 
oligosaccharides released from AGP by exo-B-(1->3) galactanase digestion. AGP was isolated 
from Triticum aestivum cv. Yumai-34 white flour. Spectra shows 400-2400 m/z 
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4.4.31.  Analysis of in vitro fermentation of AGP and AX by changes in SCFA 
concentrations and composition of bacterial populations 
 
The concentration of SCFA and lactate after fermentation of AGP, AX and AGP+AX are 
shown in Table 3.2.  and the numbers of bacterial populations after fermentation of AGP, AX 
and AGP+AX are shown in Table 3.3. All substrates caused increases in SCFAs and beneficial 
bacterial groups concomitant with prebiotic activity. AX singularly has previously been shown 
to have prebiotic activity (Englyst et al., 1987; Grootaert et al., 2007; Van Craeyveld et al., 2008; 
Hughes et al., 2007) and data has been included from a separate experiment with a different 
negative control to observe whether AGP +AX in combination have greater prebiotic activity 
due to synergistic effects than AX or AGP singularly. 
All substrates AGP, AX and AGP+AX caused significant (p>0.95) increases of beneficial 
bacteria Bifidobacterium from 8-24h compared to the negative control. The AGP+AX sample 
gave increases similar to FOS (the positive control), whilst AGP alone gave still significant but 
smaller increases. The Bifidobacterium populations peaked at 8h for all samples and began to 
decrease after. This indicates that AGP and AX singly or in combination can be fermented 
quickly- at a similar rate to FOS. 
Bifidobacteria are known acetate producers (Fukuda et al., 2011; Bindels et al., 2015), so an 
increase in bifidobacteria may result in increased acetate production, which was observed after 
fermentation of all substrates, AGP, AX and AGP+AX together, with AGP and AGPP+AX 
showing larger increases, although all increases in acetate cannot be attributed to bifidobacteria 
as they are contribute a relatively small proportion of colonic bacteria. The faster increase in 
acetate shown in Table 3.2 for AGP than AGP+AX might suggest that AGP alone can be 
fermented faster by the bacterial populations present than AGP when mixed with AX. 
Presumably this could be because the two dissimilar structures would require a wider variety of 
hydrolytic enzymes to break them down or because the bacteria present were able to break 
down AGP faster than AX.  
Fermentation of AGP and AX together showed different responses to AGP alone. 
Fermentation of the two DFs AGP+AX together caused increased growth of Clostridium 
coccoides- Eubacterium rectale (p>0.95), plus significant (p>0.95) reductions in sulphate reducing 
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group Desulfovibrionales and proteolytic group Clostridium cluster I and II. These data show that 
AGP+AX appear to have greater prebiotic activity than AGP alone.  
The AGP+AX sample increased beneficial groups Clostridium coccoides/ Eubacterium rectale 
increased significantly (P>0.95) compared to the negative control at 8h from 23% to 37% 
bacteria. This increase was not sustained until 24h, demonstrating a short fermentation. This 
bacterial group was also increased with AX.  Eubacterium rectale is one of the most frequently 
recovered bacterial species from human faeces and is usually present in large numbers. It 
produces mixtures of SCFAs from fermentation including acetate, butyrate, lactate and formate 
but not propionate (Krumholz and Bryant, 1986) and so could also be responsible for large 
increases in acetate shown in Table 3.2. A significant (p>0.95) increase in Clostridium coccoides/ 
Eubacterium rectale compared to the negative control could exlplain the increase in formate 
observed after fermentation with AX. The were no significant (p>0.95) changes to formate 
concentrations in any other sample. 
The Atopobium group decreased with the AGP+AX substrate compared with the negative 
control, as did Desulfovibrionales and Clostridium cluster I and II. These groups are associated with 
pathogenic behaviour, Clostridium cluster I and II are associated with protein fermentation, and 
so reductions in these groups show AX+AGP have higher selectivity than AX alone or FOS 
(the positive control). Atopobium can be a butyrate producing group, reductions in this group 
may help to explain the lack of increase in butyrate in the AX+AGP sample.  
Significant differences (p>0.95) compared to the negative control, were seen in the 
concentration of acetic acid, which increased to a similar level as the positive control (FOS) for 
AGP and AGP+AX together after 24h, although increases were significant (p>0.95) after 8h 
fermentation of FOS but only after 24h fermentation of AGP+AX and AX, indicating a quicker 
fermentation of FOS than AX and AX+AGP.  
After 8h fermentation, average acetate concentration had increased significantly (p>0.95) to 
23.83 mM in the AGP samples, and to 21.12mM in the AX sample, but only 17. 05mM in the 
AGP plus AX sample which was not significant t (p>0.95), however by 24h this difference had 
disappeared. This might suggest that AGP or AX alone can be fermented faster by the bacterial 
populations present than AGP when mixed with AX. Presumably this could be because the two 
dissimilar structures would require a wider variety of hydrolytic enzymes to break them down 
or because the bacteria present were able to break down AGP faster. 
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There was a large decrease in lactate concentration in the AGP, AX and AGP+AX samples 
after 24h compared with the negative control. Lactate is formed from pyruvate through the 
action of lactate dehydrogenase in the homofermentative pathway by many common gut 
bacteria including Lactobacillus, Bifidobacterium, Enterococcus, and Streptococcus and Eubacterium spp. 
(Barcenilla e al., 2000).  An increase in bifidobacteria was shown (Table 3.3), which could explain 
the concomitant decrease in lactate observed, as the lactate is used by cross-feeding bacteria. 
Under healthy gut conditions lactate is usually found in low concentrations in faeces (<5mM) 
(Duncan et al., 2004) because bacterial breakdown of lactate markedly exceed production 
(Belenguer et al., 2011). Therefore, decreases in lactate over the course of the fermentation in 
both AX samples reflect healthy colonic conditions.  
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Table 3.2: SCFA and lactate concentration in batch cultures at 0, 4, 8 and 24 hours’ fermentation comparing no substrate, FOS, AGP and AGP+AX. 
Negative control is no added carbohydrate and positive control is FOS. One way AVONA was applied to the data to test the interaction between 
treatments. Standard error of the mean (SEM) is shown in brackets. Significant interaction between treatments and negative control are denoted * p= 
0.05 (F-test) and are shown in bold.  
 
Time Lactate (µM) Formate (µM) Acetate (µM) Propionate (µM) Butyrate (µM) Total (µM) 
Negative 
control 
0 2.28 (1.20) 2.79 (4.97) 3.13 (1.05) 3.52 (0.62) 2.86 (1.08) 21.61 (1.48) 
8 6.30 (1.79) 1.58 (5.21) 8.31(1.84) 5.10 (0.97) 1.57 (0.65) 27.12 (5.41) 
24 10.17 (2.42) 4.31 (5.06) 8.28 (2.04) 10.25 (5.19) 3.32 (1.24) 36.33 (8.49) 
FOS 
0 7.22 (3.51) 3.57 (4.88) 9.16 (1.09) 5.27 (1.80) 2.33 (0.28) 27.55 (8.28) 
8 12.61 (8.95) 9.91 (3.91) 30.57* (4.77) 11.27 (5.59) 3.09 (1.98) 67.45 (17.12) * 
24 10.16 (5.53) 7.46 (4.64) 33.35* (6.69) 13.03 (7.03) 8.36 (6.59) 72.36 (32.92) * 
AGP 
0 7.86 (5.12) 1.61 (5.59) 6.80 (3.25) 3.49 (1.52) 5.78 (1.67) 25.54 (5.97) 
8 5.75 (2.37) 6.24 (2.24) 23.83* (5.95) 12.33 (5.09) 2.81 (1.07) 50.96 (11.40) * 
24 3.48* (1.65) 5.33 (3.68) 39.34* (4.53) 8.60 (6.90) 5.20 (3.53) 61.95 (9.94) * 
AGP + AX 
0 10.01* (2.58) 10.95 (10.65) 6.95 (3.49) 5.48 (1.37) 3.53 (0.84) 36.92 (9.28) 
8 4.50 (1.98) 7.30 (3.80) 17.05 (8.52) 12.86 (5.25) 2.37 (1.94) 44.08 (15.81) 
24 2.38* (1.03) 10.52 (5.62) 38.91* (9.58) 15.61 (6.47) 2.95 (1.74) 67.42 (10.47) * 
Negative 
control for AX 
0 11.02 (3.68) 0.00 (0.00) 4.21 (1.22) 4.36 (1.10) 2.26 (0.47) 21.85 (3.15) 
8 5.66 (0.43) 0.62 (0.28) 9.05 (2.40) 8.77 (1.41) 2.14 (0.28) 26.24 (3.97) 
24 6.45 (0.16) 3.71 (0.93) 9.83 (2.72) 9.33 (1.84) 1.48 (0.19) 30.08 (1.97) 
AX 
0 
16.39 (3.37) 0.00 (0.00) 4.93 (1.01) 5.05 (0.60) 1.54 (0.20) 
27.91 (3.04) 
8 
10.19* (2.86) 6.63 *(2.30) 21.12* (4.46) 8.09 (0.48) 1.76 (1.76) 
47.79 (4.99) * 
24 
2.56* (1.31) 15.90*(4.17) 27.64* (4.85) 9.76 (2.77) 1.29 (0.12) 
57.15 (12.25) * 
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Table 3.3: Bacterial enumeration of in vitro batch culture fluid after fermentation with AGP or AGP plus AX. Negative control is no added 
carbohydrate and positive control is FOS. Values are mean log10 bacterial numbers/mL found using flow FISH. One-way AVONA was applied to the data 
to test (F-test) the main interaction between treatments. Values in brackets are SEM. Significant interaction between treatments and negative control are 
denoted * (p< 0.05) and shown in bold. 
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Negative 
0 7.96 (0.26) 6.80 (0.38) 7.14 (0.031) 8.53 (0.33) 6.78 (0.75) 7.20 (0.58) 7.35 (0.36) 8.28 (0.25) 7.85 (0.47) 6.86 (0.40) 8.97 (0.33) 
8 7.72 (0.11) 7.16 (0.12) 7.43 (0.22) 8.37 (0.25) 7.38 (0.02) 7.20 (0.10) 7.42 (0.27) 8.06 (0.24) 7.69 (0.30) 7.31 (0.17) 8.85 (0.22) 
24 7.68 (0.66) 7.25 (0.73) 7.36 (0.68) 8.00 (0.49) 7.46 (0.71) 7.51 (0.52) 7.53 (0.60) 7.49 (0.58) 7.38 (0.46) 7.12 (0.73) 8.62 (0.57) 
FOS 
0 7.88 (0.27) 7.01 (0.46) 7.57 (0.43) 8.23 (0.27) 7.41 (0.50) 7.01 (0.49) 7.45 (0.35) 8.22 (0.25) 7.75 (0.46) 7.11 (0.59) 8.87 (0.30) 
8 9.83* (0.15) 7.32 (0.60) 8.20* (0.40) 9.70* (0.17) 8.16 (0.70) 8.02 (0.46) 8.22 (0.38) 8.31 (0.41) 7.88 (0.55) 7.69 (0.48) 10.26* (0.09) 
24 8.95* (0.21) 7.13 (0.72) 7.43 (0.66) 8.73 (0.20) 7.29 (0.72) 7.17 (0.54) 7.72 (0.60) 7.89 (0.58) 7.61 (0.60) 7.16 (0.60) 9.36 (0.27) 
AGP 
0 7.96 (0.25) 7.02 (0.26) 7.23 (0.10) 8.59 (0.19) 7.66 (0.24) 7.27 (0.30) 7.41 (0.17) 8.19 (0.24) 8.04 (0.19) 7.16 (0.19) 9.00 (0.20) 
8 8.89* (0.45) 6.87 (0.51) 6.74 (0.70) 8.92 (0.36) 7.89 (0.22) 7.23 (0.14) 7.32 (0.30) 8.47 (0.16) 8.06 (0.08) 7.18 (0.35) 9.49 (0.31) 
24 8.70* (0.78) 6.57 (0.33) 6.98 (0.83) 8.66 (0.47) 6.77 (0.30) 6.57 (0.37) 7.20 (0.78) 7.34 (0.17) 6.49 (0.35) 5.54* (0.76) 9.14 (0.55) 
AGP+AX 
0 7.98 (0.18) 7.06 (0.36) 7.20 (0.46) 8.63 (0.29) 7.37 (0.46) 7.12 (0.46) 7.20 (0.41) 8.38 (0.19) 7.95 (0.36) 7.04 (0.40) 9.06 (0.26) 
8 9.35* (0.46) 7.22 (0.44) 7.74 (0.28) 9.36* (0.38) 7.61 (0.78) 7.00 (0.12) 7.63 (0.31) 8.59 (0.23) 8.00 (0.35) 6.94 (0.30) 9.89 (0.33) 
24 8.82* (0.28) 6.88 (0.76) 6.73 (0.67) 8.82 (0.19) 6.64 (0.75) 6.27* (0.28) 6.47 (0.53) 7.13 (0.30) 6.07* (0.45) 5.62* (0.43) 9.25 *(0.13) 
Negative 
for AX 
0 8.53 (0.33) 7.65 (0.13) 7.95 (0.12) 9.11 (0.04) 8.63 (0.11) 7.60 (0.16) 8.20 (0.09) 9.07 (0.04) 8.61 (0.06) 7.75 (0.15) 9.70 (0.03) 
8 8.58 (0.32) 7.90 (0.03) 8.55 (0.08) 9.01 (0.08) 8.25 (0.13) 7.70 (0.09) 8.70 (0.06) 8.90 (0.02) 8.54 (0.10) 8.20 (0.12) 9.67 (0.07) 
24 8.76 (0.30) 7.77 (0.18) 8.45 (0.13) 8.92 (0.07) 7.74 (0.20) 7.85 (0.10) 8.76 (0.08) 8.54 (0.06) 8.12 (0.12) 7.93 (0.12) 9.58 (0.10) 
AX 
0 8.52 (0.41) 9.84 (0.14) 8.11 (0.17) 9.13 (0.01) 8.65 (0.06) 7.88 (0.05) 8.28 (0.12) 8.89 (0.09) 8.58 (0.03) 8.00 (0.16) 9.67 (0.07) 
8 9.23* (0.19) 7.92 (0.20) 8.84 (0.23) 9.09 (0.38) 8.32 (0.52) 7.65 (0.37) 8.93 (0.24) 9.00 (0.19) 8.61 (0.19) 7.81 (0.40) 9.94 (0.24) 
24 9.84* (0.09) 7.67 (0.22) 8.55 (0.44) 9.57* (0.18) 8.42* (0.40) 8.45* (0.53) 8.63 (0.44) 9.06* (0.17) 8.26 (0.20) 8.11 (0.42) 10.29* (0.05) 
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4.4.32. In vitro fermentation of AX and β-glucan, analysis of changes in SCFA 
concentrations and composition of bacterial populations  
 
Table 3.4 shows the SCFA and lactate concentration of samples incubated with: AX alone, AX: 
β-glucan (3:1), AX: β-glucan (1:1), AX: β-glucan (1:3), β-glucan alone and FOS after 24 hours’ 
fermentation and Table 3.5 shows the bacterial populations. In this experiment, larger 100mL 
vessels were used, requiring 1g substrate, because the substrate was commercially bought and 
therefore readily available. 
Differences were observed between the prebiotic activities of AX and β-glucan fractions. 
Fermentation of AX, AX: β-glucan (3:1), AX: β-glucan (1:1) and FOS increased total SCFA 
concentration significantly (p>0.95) compared to the negative control. This increase was mainly 
due to production of acetate. Acetate and butyrate concentrations increased significantly for AX 
alone; AX: β-glucan (3:1) and AX: β-glucan (1:1) compared to the negative control. Neither 
acetate or butyrate were significantly increased compared to the negative control for AX: β-
glucan (1:3) or β-glucan alone, however no increases in bacterial groups were observed for these 
samples, supporting this finding. 
The data from Table 3.4 and Table 3.6 showing acetate concentration and the Bifidobacterium 
populations support each other as bifidobacteria are known producers of acetate (Fukuda et al., 
2011; Bindels et al., 2015) and the increases in acetate and bifidobacteria are observed with the 
same samples (AX, AX: β-glucan (3:1), AX: β-glucan (1:1) and FOS). The largest increase in 
bifidobacteria resulted from fermentation of AX: β-glucan in a ratio of 3:1. Only fermentation 
vessels containing AX at a concentration of least 50% showed an increase in bifidobacteria, 
showing a bifidogenic effect for AX but not β-glucan and supports previous studies where oat 
and barley β-glucans did not affect bifidobacteria numbers but AX did result in an increase in 
bifidobacteria (Hughes et al., 2007; Hughes et al., 2008; Kim and White, 2009). Thus, the results 
of the present study confirm that AX is the preferred substrate for bifidobacteria. The increases 
in bifidobacteria were as sustained for FOS as for AX, with all increases lasting from 8-24h.  
Table 3.5 shows the ratios of SCFA after 24 hours’ in vitro fermentation with the different ratios 
of polysaccharides. The highest proportion of propionate is seen with the β-glucan sample alone 
at 44.9%, just above the negative control at 37%. Butyrate remains low for all samples, peaking 
in the AX: β-glucan (1:3) sample at just 17.7%. Acetate is the highest contributor of total SCFA 
for all samples. The addition of larger amounts of AX appears to drive the concentration 
85 
 
towards greater acetate production, whereas greater β-glucan appears to favour propionate 
production. Two studies found fermentation of β-glucan to favour production of propionate 
and fermentation of AX to encourage acetate (Hughes et al., 2007; 2008). Table 3.6 shows a 
significant (p>0.95) increase in the Bacteroides- Prevotella group at 24h compared to the negative 
control after fermentation of β-glucan, which supports this theory as microbiota from the 
Bacteroides- Prevotella group are known producers of propionate (Macy and Probst, 1979). It is 
proposed that three colonic Bacteroides species: Bacteroides thetaiotaiomicron, Bacteroides distasonis and 
Bacteroides fragilis are responsible for the majority of β-D-(1-->3)-glucanase activity responsible 
for β-glucan hydrolysis (Salyers et al., 1977a). 
The greatest increases in bacterial numbers were seen for the AX: β-glucan in a (3:1) sample.  
Fermentation of AX alone showed the next highest increase while the smallest increase in 
bacterial numbers occurred when β-glucan alone was used.  In fact, the proportion of β-glucan 
in the in vitro fermentation was inversely correlated with the increase in total bacteria. This 
suggests that AX is more readily used as a substrate for growth by bacteria than β-glucan. As 
the ratio of AX: β-glucan is greater in wheat (3:1) than barley (1:3), this data agrees with a study 
which showed that a wheat based diet in pigs resulted in a greater increase in gut bacteria than 
a barley based diet (Garry et al., 2007). The increase in total bacteria with higher amounts of AX 
is more sustained than with FOS as it continues in these samples for 24h whereas fermentation 
of FOS increases total bacteria only up to 8h. 
Fermentation of β-glucan alone caused the largest increases in Lactobacillus compared to the 
negative control after 24h, implying that β-glucan was the preferred substrate for these bacteria. 
Crittenden et al. (2002) found that β-glucan was fermented by Bacteroides and Clostridium 
beijerinckii but not fermented by Lactobacillus, Bifidobacterium or Enterococci. In this study, there is 
no difference in the number of bifidobacteria after incubation with β-glucan, showing that 
bifidobacteria are not increasing due to fermentation of β-glucan, but the Lactobacillus/Enterococci 
group did increase. There are two possibilities for these results, the study by Crittenden et al. 
(2002) used single bacterial species which were cultured on agar, whereas this study used 
populations of bacteria obtained from faecal samples which likely included obligate anaerobic 
species which are not currently able to be cultured. Therefore, it may be that some species of 
Lactobacillus/Enterococci found in the colon can ferment β-glucan. It is also possible that other 
bacterial species were fermenting the β-glucan and Lactobacillus species were proliferating as the 
result of cross feeding, which would not have occurred in the single-culture experiments done 
previously. 
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Fermentation of AX alone and AX: β-glucan (1:1) caused a large increase in Roseburia after 24h 
which implies that AX is also the preferred substrate for this bacterial genus, however, the AX: 
β-glucan (3:1) sample would also be expected to increase Roseburia if this was the case, because 
it has a large proportion of AX, but this was not the case. This may be the result of competition 
of different bacteria.  
The Clostridium coccoides- Eubacterium rectale group were significantly different from the negative 
control at 8h and 24h with AX alone, and for AX: β-glucan (3:1) and at 24h for AX: β-glucan 
(1:1). These bacterial groups appear to strongly favour fermentation of AX.  
Thus, it appears that AX is readily used as a substrate for fermentation in these experiments, 
more so than β-glucan, and that the bifidobacteria, Roseburia and Clostridium coccoides- Eubacterium 
rectale group bacterial groups show preferential growth with AX as a substrate. This is reflected 
in the SCFA profiles produced by these bacteria, namely increases in acetate and butyrate. 
Figure 3.5. shows the change in bacterial populations after 24 hours’ fermentation of AX, AX: 
β-glucan (3:1), AX: β-glucan (1:1), AX: β-glucan (1:3), β-glucan and FOS. It shows that with no 
substrate (negative control) most bacterial groups decrease, which is to be expected. There are 
no significant (p>0.95) increases over the course of the fermentation. Fermentation of FOS 
causes selective increases in beneficial groups Bifidobacterium, Clostridium coccoides/Eubacterium 
rectales, and Atopobium, whilst decreasing pathogenic groups such as Clostridium histolyticum and 
Desulfovibrionales. Bifidobacteria have long been associated with prebiotic activity (as described 
in 1.1.2.), Eubacterium rectales is a butyrate producer and has been linked with improvements in 
host health (Barcenilla et al., 2000), although in this case there was a small but not significant 
(p>0.95) concomitant increase in butyrate. The AX: β-glucan sample with the best apparent 
prebiotic activity is AX: β-glucan (3:1) as it causes increase of beneficial groups Bifidobacterium 
and Clostridium coccoides/Eubacterium rectales, like FOS but also increases Lactobacillus. It does not 
cause increases in pathogenic groups Clostridium histolyticum and Desulfovibrionales which was seen 
in the other treatments containing AX at different ratios. 
After fermentation of AX: β-glucan (1:3) there was no beneficial and selective bacterial growth. 
Despite increases of Bacteroides spp. which are known to produce propionate (Macy and Probst, 
1979) after 24h fermentation of β-glucan alone, no differences were observed between that or 
any other sample and the negative control.  Propionate production peaked in this sample after 
24 hours so it is possible that longer fermentation may have provided a significant increase in 
propionate. 
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Table 3.4: SCFA and lactate concentration in batch cultures at 0, 4, 8 and 24 hours’ fermentation comparing no treatment, FOS and different ratios 
of AX and β-glucan. Negative control is no added carbohydrate and positive control is FOS. One-way ANVOA was applied to the data to test (F-test) 
the main effect of treatment. Values are µM. SEM is shown in italics.  Significant interaction between treatments and negative control are denoted * (p< 0.05) 
and shown in bold. 
 
 
 
 
Time Lactate (µM) Formate (µM) Acetate (µM) Propionate (µM) Butyrate (µM) Total (µM) 
No treatment 
0 0.93 (0.40) 4.55 (0.68) 4.01 (0.45) 6.56 (1.81) 2.22 (0.19) 18.27 (0.26) 
4 4.79 (1.41) 5.23 (0.44) 6.72 (0.95) 13.46 (6.90) 2.56 (0.53) 32.77 (1.10) 
8 3.57 (1.50) 6.63 (1.39) 7.58 (2.02) 14.26 (6.37) 2.96 (0.61) 34.99 (0.91) 
24 1.72 (0.50) 5.27 (1.33) 9.66 (2.77) 7.58 (1.59) 3.22 (0.84) 27.45 (0.35) 
FOS 
0 3.75 (2.53) 3.74 (1.05) 3.29 (0.83) 5.67 (1.33) 2.11 (0.38) 18.56 (0.32) 
4 6.17 (2.76) 5.06 (0.52) 7.86 (1.21) 8.67 (2.56) 3.70 (0.96) 31.56 (0.40) 
8 21.62 (6.52) 19.10 (6.42) 18.65* (6.27) 7.05 (1.46) 5.31 (1.25) 71.73* (1.11) 
24 7.43 (3.96) 12.41 (6.84) 28.16* (3.23) 6.20 (1.73) 5.86 (1.86) 60.06* (0.83) 
AX 
0 5.01 (4.03) 4.77 (1.34) 4.28 (0.31) 7.55 a (2.45) 2.28 (0.30) 23.89 (0.63) 
4 9.84 (4.93) 6.54 (1.08) 9.82 (1.35) 12.88 (5.52) 3.61 (0.63) 42.69 (0.93) 
8 6.28 (2.59) 10.79 (2.14) 18.61* (3.46) 8.66 (1.33) 3.39 (1.40) 47.73 (0.35) 
24 2.12 (0.62) 13.82 (7.13) 35.59* (7.80) 7.46 (1.73) 5.38 (2.06) 64.36* (1.33) 
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Time Lactate (µM) Formate (µM) Acetate (µM) Propionate (µM) Butyrate (µM) Total (µM) 
AX 3:1 B 
glucan 
0 1.96 (0.94) 5.27 (1.15) 4.34 (0.43) 7.27 (2.09) 2.06 (0.41) 20.89 a (0.27) 
4 10.41(4.73) 6.92 (1.55) 8.56(1.16) 11.53 (5.32) 2.70 (0.27) 40.12(0.27) 
8 11.43(5.63) 13.02(2.45) 24.94* (7.91) 9.13 (1.85) 3.10 (0.82) 61.52* (1.18) 
24 3.97 (0.94) 10.72 (4.92) 43.63* (6.16) 9.01 (2.73) 5.60 (1.61) 72.93* (0.88) 
AX 1:1 B 
glucan 
0 5.18 (5.25) 3.38 (1.16) 3.57 (0.92) 5.69 (1.75) 2.79 (0.61) 20.61(0.76) 
4 6.50 (4.62) 3.43 (1.23) 6.74 (2.31) 10.21(3.83) 3.26 (0.95) 30.15 (0.64) 
8 7.15 (5.85) 8.05 (3.98) 7.86 (2.99) 12.10(5.01) 3.53 (1.05) 38.69 (0.75) 
24 1.24 (0.60) 10.41 (7.31) 31.77* (11.15) 5.31 (1.62) 7.03 (2.37) 55.77* (1.79) 
AX 1:3 B 
glucan 
0 2.67 (1.24) 6.87 (2.18) 5.44 (1.21) 7.15 (2.31) 3.29 (1.28) 25.45 (0.22) 
4 5.47 (3.40) 5.51 (1.02) 7.16 (2.29) 12.15 (6.35) 1.86 (0.24) 32.16 (0.96) 
8 5.42 (3.41) 9.39 2.68) 7.25 (0.90) 14.29 (3.46) 2.91 (0.78) 39.25 (0.53) 
24 1.68 (0.48) 7.10 1.28) 15.96 (4.18) 4.88 (1.45) 4.48 (1.15) 34.11 (0.57) 
B glucan 
0 0.87 (0.41) 4.35 (0.82) 3.70 (0.43) 5.64 (1.36) 2.15 (0.44) 16.81 (0.16) 
4 2.78 (1.22) 3.28 (1.24) 4.09 (0.27) 3.80 (0.58) 1.29 (0.15) 15.25 (0.21) 
8 2.78 (1.02) 3.70 (1.02) 5.65 (0.80) 5.31 (1.06) 1.49 (0.33) 18.93 (0.12) 
24 2.72 (0.97) 5.36 (0.73) 9.77 (2.21) 9.69 (3.77) 2.09 (0.29) 29.63 (0.56) 
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Table 3.5: % SCFA produced in in vitro colonic fermentation vessels at 24 hours containing 
AX and β-glucan alone and combined in different ratios. FOS is the positive control, and no 
added polysaccharide (no treatment) is the negative control. 
 
SCFA (%) 
 
Acetate Propionate Butyrate 
No treatment 47.2 37.0 15.7 
FOS 70.0 15.4 14.6 
AX 73.5 15.4 11.1 
AX 3:1 β-glucan 74.9 15.5 9.6 
AX 1:1 β-glucan 72.0 12.0 15.9 
AX 1:3 β-glucan 63.0 19.3 17.7 
B glucan 45.3 44.9 9.7 
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Table 3.6 Bacterial enumeration (mean log10 bacterial numbers / mL) of samples taken from static batch cultures after 0, 4, 8 and 24 hours’ 
fermentation comparing no substrate, FOS and different ratios of AX and β-glucan Negative control is no added carbohydrate and positive control 
is FOS. Values are mean log10 bacterial numbers/mL found using flow FISH. One-way AVONA was applied to the data to test (F-test) the main interaction 
between treatments. Values in brackets are SEM. Significant interaction between treatments and negative control are denoted * (p< 0.05) and shown in bold. 
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Negative 
0 7.54 (0.32) 7.32 (0.10) 7.66 (0.14) 8.43 (0.20) 7.63 (0.09) 7.41 (0.06) 8.04 (0.02) 8.30 (0.13) 7.79 (0.20) 7.14 (0.34) 9.00 0.14) 
4 7.76 (0.39) 6.91 (0.12) 7.92 (0.11) 8.31 (0.10) 6.81 (0.16) 7.04 (0.26) 7.90 (0.19) 8.33 (0.10) 8.05 (0.10) 7.28 (0.11) 8.99 (0.10) 
8 7.27 (0.51) 6.83 (0.21) 7.49 (0.56) 8.00 (0.40) 6.95 (0.16) 7.14 (0.21) 7.60 (0.49) 7.89 (0.45) 7.57 (0.38) 7.03 (0.31) 8.63 (0.41) 
24 7.56 (0.37) 7.18 (0.02) 7.27 (0.35) 8.05 (0.29) 7.20 (0.06) 7.51 (0.14) 7.66 (0.14) 7.65 (0.26) 7.73 (0.12) 7.34 (0.10) 8.74 (0.17) 
FOS 
0 7.48 (0.16) 7.39 (0.09) 7.86 (0.08) 8.32 (0.04) 7.73 (0.05) 7.60 (0.08) 8.26 (0.06) 8.34 (0.05) 7.82 (0.01) 7.30 (0.20) 9.01 (0.02) 
 
8.12 (0.17) 7.48 (0.20) 7.85 (0.14) 8.30 (0.11) 7.39 (0.03) 8.06 (0.07) 8.26 (0.08) 8.51 (0.10) 8.25 (0.03) 7.63 (0.10) 9.15 (0.04) 
8 9.42* (0.27) 6.97 (0.11) 8.29 (0.26) 8.89 (0.03) 6.94 (0.29) 8.31 (0.35) 8.52 (0.25) 8.78 0.22) 8.47 (0.26) 7.95 (0.15) 9.80* (0.21) 
24 9.07* (0.23) 7.14 (0.13) 7.71 0.18) 8.66 (0.04) 6.68 (0.15) 7.91 (0.26) 7.47 (0.13) 6.84 (0.32) 7.68 (0.25) 7.13 (0.36) 9.37 (0.14) 
AX  
0 7.66 (0.23) 7.42 (0.06) 7.84 (0.17) 8.47 (0.19) 7.75 (0.17) 7.43 (0.09) 8.07 0.11) 8.28 (0.09) 7.91 (0.15) 7.20 (0.16) 9.02 (0.10) 
4 8.49 (0.37) 6.65 (0.03) 7.92 (0.04) 8.56 (0.15) 7.13 (0.36) 6.73 (0.35) 7.60 (0.42) 8.24 (0.04) 7.93 (0.02) 6.91* (0.18) 9.23 (0.11) 
8 8.86* (0.15) 6.60 (0.23) 7.62 (0.49) 8.95* (0.12) 7.70 0.52) 6.78 (0.19) 7.32 (0.61) 7.66 (0.70) 6.80 (0.59) 6.51* (0.01) 9.45* (0.09) 
24 8.63* (0.28) 8.04* (0.13) 8.50 (0.11) 9.44* (0.14) 8.59* (0.01) 7.93* (0.05) 8.50* (0.10) 7.94 (0.28) 8.12* (0.06) 8.01* (0.19) 9.77* (0.01) 
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AX 3:1 B glucan 
0 7.33 (0.33) 7.17 (0.11) 7.55 (0.19) 8.18 (0.14) 7.55 (0.15) 7.25 (0.04) 7.80 (0.02) 8.12 (0.11) 7.68 (0.23) 7.02 (0.27) 8.80 (0.12) 
4 8.27(0.41) 6.77 (0.26) 8.24 (0.25) 8.24 (0.22) 7.25 (0.08) 7.72 (0.27) 8.28 (0.08) 8.42 (0.04) 8.11 (0.02) 7.17 (0.14) 9.23 (0.13) 
8 8.98* (0.52) 7.16 (0.39) 8.56 (0.27) 8.90* (0.10) 7.77* (0.10) 8.06* (0.22) 8.55 (0.13) 8.68 (0.05) 8.25 (0.11) 7.50 (0.16) 9.76* (0.23) 
24 9.15* (0.35) 7.91* (0.27) 8.37* (0.17) 9.23* (0.19) 7.52 (0.50) 7.78 (0.65) 8.19 (0.38) 8.17 (0.17) 7.79 (0.46) 7.54 (0.43) 9.80* (0.16) 
AX 1:1 B glucan 
0 7.45 (0.33) 7.17 (0.08) 7.50 (0.09) 8.24 (0.19) 7.44 (0.07) 7.25 (0.04) 7.87 (0.04) 8.11 (0.12) 7.65 (0.20) 7.06 (0.27) 8.82 (0.12) 
4 8.29 (0.39) 6.78 (0.17) 7.89 (0.19) 8.44 (0.12) 7.27 (0.29) 7.36 (0.41) 8.13 (0.08) 8.23 (0.09) 7.92 (0.06) 7.09 (0.17) 9.18 (0.11) 
8 8.57* (0.49) 6.88 (0.23) 7.85 (0.15) 8.73 (0.21) 7.34 (0.50) 7.48 (0.45) 8.00 (0.09) 8.14 (0.18) 7.83 (0.21) 7.28 (0.24) 9.45* (0.20) 
24 8.95* (0.12) 8.05* (0.31) 8.40* (0.10) 9.02* (0.11) 8.35* (0.16) 8.27 (0.29) 8.35 (0.13) 8.35 (0.11) 8.31 (0.24) 7.92 (0.45) 9.66* (0.05) 
AX 1:3 B glucan 
0 7.47 (0.35) 7.24 (0.16) 7.62 (0.20) 8.20 (0.31) 7.45 (0.18) 7.24 (0.11) 7.92 (0.09) 8.06 (0.23) 7.74 (0.26) 7.18 (0.19) 8.82 (0.21) 
4 7.45 (0.26) 6.75 (0.20) 7.18 (0.28) 7.79 (0.15) 6.85 (0.15) 7.04 (0.22) 7.38 (0.19) 7.35 (0.15) 7.18 (0.11) 6.87 (0.09) 8.42 (0.09) 
8 7.82 (0.53) 6.88 (0.32) 7.60 (0.72) 7.83 (0.49) 7.06 (0.31) 7.30 (0.04) 7.88 (0.64) 7.98 (0.50) 7.89 (0.40) 7.43 (0.33) 8.84 (0.47) 
24 8.61 (0.43) 7.88* (0.08) 8.43 (0.60) 8.46 (0.36) 7.67 (0.20) 7.64 (0.25) 8.33 (0.53) 7.77 (0.56) 8.06 (0.38) 7.95 (0.18) 9.36 (0.38) 
B glucan  
0 7.21 (0.33) 6.93 (0.18) 7.33 (0.23) 8.04 (0.27) 7.29 (0.21) 7.05 (0.13) 7.65 (0.09) 7.89 (0.17) 7.46 (0.26) 6.99 (0.18) 8.59 (0.22) 
4 7.26 (0.36) 6.65 (0.22) 7.41 (0.54) 7.91 (0.35) 6.98 (0.40) 7.11 (0.41) 7.46 (0.39) 7.38 (0.37) 7.21 (0.26) 6.97 (0.29) 8.47 (0.35) 
8 7.54 (0.46) 7.07 (0.34) 7.78 (0.69) 8.01 (0.56) 7.38 (0.58) 7.36 (0.53) 7.72 (0.62) 7.42 (0.60) 7.56 (0.53) 7.41 (0.44) 8.73 (0.55) 
24 7.90 (0.24) 8.32* (0.30) 7.53 (0.41) 8.09 (0.36) 7.51 (0.39) 7.20 (0.52) 7.58 (0.35) 6.86 (0.74) 7.20 (0.54) 8.11* (0.04) 9.10 (0.25) 
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Figure 3.5: The change in mean log10 bacterial numbers / mL after 24h fermentation found 
using Flow-FISH on samples from batch fermentation comparing different ratios of AX and β-
glucan. Error bars are SEM. 
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3.5. Conclusions 
 
Wheat is widely consumed for human nutrition, and has been for thousands of years. 
Consequently, the ratio of the DF polysaccharides present in wheat may have influenced the 
activities and populations of human gut microbiota, in healthy individuals. The results reported 
here provide support for this hypothesis,  
Fermentation of AGP+AX showed somewhat increased prebiotic effectiveness by increasing 
the growth of beneficial bacterial groups Clostridium coccoides- Eubacterium rectale group and 
reducing proteolytic groups Desulfovibrionales and Clostridium cluster I and II compared to 
fermentation of AGP alone and AX alone. This supports the hypothesis that DF can act 
synergistically and this seems plausible as DFs are usually found in combinations. A greater array 
of substrates would provide a wider choice of fermentable oligosaccharides to support a more 
diverse bacterial population, creating a healthier and more resilient microbiome.  
In 3.4.2. it was hypothesised that AGP is faster to ferment than AGP+AX as acetate 
concentration increased at a faster rate with fermentation of AGP alone, however in 3.4.3. it 
was noted that there was no change in the time of peak numbers of different bacterial 
populations, which would be a result of faster fermentation. A further study may be required 
with time points in between 8 and 24 hours to determine if AGP is faster to ferment than 
AGP+AX. 
Beneficial bacteria were shown to preferentially ferment AX compared to β-glucan with the 
preferred ratio of AX: β-glucan being that present in wheat (3:1). This makes sense as we are 
exposed to high levels of AX in wheat as a staple food world-wide, while β-glucan (alone, or at 
ratios greater than AX) in the diet is rather rare. 
This study showed that Bifidobacterium species preferentially fermented AX rather than β-glucan, 
and Lactobacillus species preferentially fermented β-glucan. This is supported by a study by 
Crittenden et al (2002) who observed bifidobacteria fermented AX and not β-glucan.  
A summary of the conclusions is shown in table 3.7. 
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Table 3.7: Summary of prebiotic effects   
 
 
  
AGP+AX AX+ β-glucan 
• AGP has prebiotic activity, which is 
shown by increase in SCFA and 
modulation of bacterial compositions 
after fermentation 
•  AGP+AX causes increase in acetate 
at the same rate as AGP alone 
• Prebiotic activity of AGP and AX in 
conjunction is greater than AGP alone 
due to beneficial changes in bacterial 
populations. 
• AX and β-glucan have different 
prebiotic effects when fermented 
in different ratios  
• AX, AX: β-glucan (3:1), AX: β-
glucan (1:1) increased total SCFA 
concentration. 
• Bifidobacteria favour AX 
fermentation 
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4. In vitro gastric digestion of AX and transgenic AX with altered 
structure. Does arabinosylation substitution pattern influence 
prebiotic activity? 
 
 Abstract 
AX has previously been shown to have prebiotic activity, however, the relationship between 
AX structure and prebiotic activity has yet to be characterised. The importance of AX structure 
was investigated in two ways: using AX isolated from transgenic wheat with a specific reduction 
in O-3 linked arabinose and secondly, using a pre-incubation of AX fractions in a simulated 
gastric digest prior to in vitro colonic fermentation to explore any potential modification of AX 
structure in the stomach. AX isolated from homozygous TaXAT1 RNAi transgenic wheat flour 
showed lower prebiotic activity compared to AX isolated from the corresponding azygous 
control wheat flour. Total bacteria and bifidobacteria increased to a greater extent in cultures 
containing the control AX fraction compared to AX from the TaXAT1 transgenic flour.  Pre-
incubation of AX in a static in vitro gastric digest solution resulted in smaller AXOS and a lower 
A:X ratio. AX exposed to simulated gastric digestion resulted in slower fermentation compared 
to control samples; at 8h 15.68mM acetic acid was produced compared to 30.83mM for the 
untreated AX. As with the AX isolated from TaXAT1, differences observed in SCFA 
production were not maintained throughout the time course of fermentation, and by 24h there 
was no difference between treatments. Propionate production, in control samples was 22.93mM 
compared to 12.49mM in gastric-digest treated samples, at 8h. By 24h there was no significant 
difference between treatments. Total SCFA, butyrate and lactate concentrations were also 
greater for untreated AX samples. AX with a higher A: X ratio appeared to be fermented faster 
than AX with a lower A:X ratio and resulted in microbiota with a more favourable composition 
and produced more SCFAs. 
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 Introduction 
Previous research has shown that AX has prebiotic activity and that the size of the AX is of 
importance (Hughes et al., 2007). It has been hypothesised that the structure of AX may also 
be important and that this can be altered by low pH, such as that found in the stomach, it has 
been proposed that the acid present in the stomach causes hydrolysis of the arabinose to xylose 
bonds (Whistler and Corbett 1955; Zhang et al., 2003). The aim of the present study was to 
determine whether the structure of AX is an important factor in modulating prebiotic activity 
of AX. This was investigated this in two ways. Determination of whether AX structure is altered 
from passage through the acid environment of the stomach to the colon, and uniquely, by use 
of AX isolated from transgenic wheat flour with a known alteration in arabinosylation pattern. 
It has been reported that under gastric acidities up to 10% L-arabinose can be released from 
arabinoxylan of corn hull, larch wood and banana peel hemicellulose (Zhang et al.,2003). 
Therefore, it was hypothesized that a similar release of arabinose from arabinoxylan fractions 
isolated from wheat flour could occur. Commercially available AX samples from wheat flour 
were analysed biochemically, before and after in vitro gastric and duodenal digestion, before 
being incubated in in vitro colonic batch cultures to determine whether prior gastric and duodenal 
conditions would result in subsequent differences in prebiotic activity.  
AX in wheat is composed of β-1,4-linked-D-xylopyranose units forming a backbone with α-L-
arabinofuranose decorations at the O-2 or/and O-3 positions of xylose units.  Glycosyl 
transferase enzymes in the GT61 family are responsible for attaching arabinose to the xylose 
backbone. A study by Anders et al. (2012) showed that suppression of the gene TaXAT1 
resulted in a 70–80% decrease in the amount of α-(1,3) linked arabinofuranosyl in AX, altering 
the substitution pattern of AX and reducing the A: X ratio.  
A homozygous RNAi transgenic wheat line described by Anders et al., (2012), hereby referred 
to as RNAi GT61, produces AX with an altered substitution pattern caused by a reduction in 
O-3 linked arabinose substitutions. RNAi GT61 was therefore used, along with its azygous 
control line, for experiments designed to explore the importance of arabinose substitution on 
prebiotic activity. An altered substitution pattern and reduced A: X ratio, as is present in AX 
isolated from RNAi GT61 could affect the rate of AX fermentation. A similar reduction in 
arabinosylation might also occur to AX that had undergone prior simulated in vitro gastric 
digestion (before in vitro colonic fermentation), although in this case the loss of arabinose units 
may be more random than in the case of AX isolated from RNAi GT61.   
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Prebiotic activity was tested by comparing bacterial numbers and bacterial activity (in terms of 
SCFA production). Numbers of different bacterial groups were counted using Flow-FISH and 
the metabolites of fermentation, SCFAs, were measured using HPLC. 
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 Materials and methods 
 
 Arabinoxylan 
AX extracted from white flour from homozygous RNAi GT61 and an azygous control line were 
as described in 2.2.  
 A commercial AX preparation (P-WAXYM) (Megazyme, Bray, co. Wicklow, Ireland) was used 
for investigation of the effect of prior exposure of AX to gastric conditions before in vitro colonic 
fermentation. A Medium MM AX fraction was selected for these experiments as they had been 
shown to have the greatest prebiotic activity of the commercially available AX preparations 
(chapter 5). 
 
 AX characterisation 
AX isolated from white flour from homozygous RNAi GT61 and azygous control wheat lines 
were characterised using monosaccharide analysis as described in 2.5, PACE, as described in 2.4 
and HPAEC, for determination of effects on arabinose substitution patterns as described in 2.3. 
AX fractions before and after in vitro gastric/duodenal digestion were also analysed by HPAEC 
as described in 2.3 following specific endoxylase treatment, to determine effects of the simulated 
gastric/duodenal environment on AX structure. HPSEC-MALS, as described in 2.6 was used 
to determine whether there had been any change in size brought about by exposure to the 
simulated gastric conditions prior to in vitro colonic fermentation studies.  
 
 In vitro gastric digestion of AX 
In vitro gastric and duodenal digestions were carried out as described in 2.9. using the protocol 
devised by Minekus et al. (2014).  
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 In vitro fermentation of AX 
In vitro fermentation was performed as described in 2.10. AX isolated from white flour from 
RNAi GT61 and the control line were compared as were pre- digested (simulated 
gastric/duodenal digest) untreated AX (not previously exposed to simulated gastric/duodenal 
digestive environment). Both sets of samples were added to 10ml vessels containing basal media 
and positive control (FOS) and a negative control (no carbohydrate) were set up as previously 
described. In vitro colonic fermentation cultures were set up in triplicate, using faecal samples 
obtained from three healthy donors. AX was added to basal media at 1% (w/v). Samples were 
inoculated with 10% faecal slurry. Samples were taken at 0h, 8h and 24h.  
 
 Enumeration of bacteria by flow-FISH 
Bacteria were enumerated from samples taken at 0h, 8h and 24h as detailed in 2.12. As described 
in 2.12, bacteria that were counted were known to be present in human microflora and belonged 
to the following groups:  Bifidobacterium genus, Lactobaccillus/ Enterococcus group, Bacteroides- 
Prevotella group, Clostridium coccoides/ Eubacterium rectales groups, Roseburia, Atopobium cluster, 
Clostridium cluster IX, Fusobacterium prausnitzii, Desulfovibrionales, Clostridium-cluster I and II. 
 
 SCFA and lactate analysis 
SCFA and lactate were quantified by HPLC as detailed in 2.11. 
 
 Statistical analysis  
The Genstat (2015, 18th edition, © VSN International Ltd, Hemel Hempstead, UK) statistical 
package was used for all analysis. ANOVA data was supplied by SJ Powers (Statistical 
department, Rothamsted Research) and applied as detailed in 2.13. 
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 Results 
 
 AX characterisation 
4.1.1.1. Monosaccharide analysis of RNAi GT61 AX compared to 
azygous control AX 
Monosaccharide analysis of AX from RNAi GT61 AX was done to determine if the A:X ratio 
was reduced compared to the azygous control AX. Monosaccharide analysis showed a reduction 
in both arabinose and xylose residues (Figure 4.1), however there was a greater reduction in 
arabinose monosaccharides, providing a lower A:X ratio (Table 4.1). A lower A:X ratio 
confirmed the published data (Anders et al., 2012), indicating a reduction in arabinosylation in 
the RNAi GT61 AX. 
 
 
Figure 4.1: Monosaccharide analysis of RNAi GT61 AX and azygous control AX using a 
Carbopac PA20 column. N=3 Error bars show standard deviation.  
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Table 4.1: Arabinose to xylose ratio of AX fractions after monosaccharide analysis using a 
Carbopac PA20 column. Values are average m [µg/mg] where N=3, values in brackets are SD. 
Adjusted A:X ratio is according to Loosveld et al., (2010). 
 
 
Arabinose 
 
Xylose Galactose Glucose Adjusted 
A:X ratio  
RNAi 
GT61 AX 
267.1 (±17.44) 449.2 (±23.01) 26.8 (±1.28) 61.8 (±3.67) 0.52 
Azygous 
control 
AX 
371.8 (±4.27) 602.2 (±45.82) 53.4 (±5.75) 42.9 (±4.56) 0.54 
 
 
4.1.1.2. HPAEC of AX from RNAi GT61 and azygous control 
 
AX from RNAi GT61 was compared to the azygous control using HPAEC to provide a 
‘fingerprint’ of the AXOS fragments. AX vary in structure, including the distributions of 
unsubstituted, monosubstituted and disubstituted xylose residues and so after digestion with 
endoxylase to release AX oligosaccharides (AXOS), the AXOS peaks were assigned as described 
by Ordaz-Ortiz et al. (2004, 2005); Saulnier et al., 2009). An example of identified AX 
oligosaccharides from a standard wheat are shown in Figure 4.2. When using HPAEC the 
carbohydrates with a higher degree of substitution and polymerisation (DP) elute later due to 
increased interactions with the column.   
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Figure 4.2: Representative HPAEC chromatogram indicating identities of AXOS peaks 
following endoxylanase (GH11) digestion of low MM wheat AX obtained from Megazyme (Co. 
Bray, Ireland). 
Shown in Table 4.2, the knock down of the glycosyl transferase (GT 61) in the RNAi GT61 
wheat line results in a reduction in the total arabinosylation of AX but notably a reduction in O-
3 linked arabinose (XA3XX, XA3A3XX, XA3XA3XX, XA3XA2+3XX) compared to the control line, 
(as described by Anders et al., 2012) which is as expected as the GT61_1 enzyme is responsible 
for the addition of monosubstituted arabinofuranose on the O-3 position of the xylose 
backbone. The largest reduction in AXOS is in the O-3 linked AXOS (shown in Figure 4.3 in 
red). There are reductions in the mixed linked (O-2+3 linked) AXOS in purple and the 
unsubstituted AXOS in green are also reduced but not as much. 
Table 4.2 and Figure 4.3 below show the AXOS fractions obtained from HPAEC analysis of 
AX from the RNAi GT61 and the azygous control AX. It can be seen that in the RNAi GT61 
AX, all AXOS fragments apart from the mixed linkage XA3A2+3XX are reduced compared to 
the control line. This supports the monosaccharide data in Figure and Table 4.1, which showed 
a reduction in xylose and a larger reduction in arabinose and confirms that the structure of the 
isolated AX used in the in vitro fermentation studies is modified in arabinosylation pattern, as 
observed by Anders et al. (2012). 
 
 
Table 4.2: AXOS fractions of AX extracted from RNAi GT61 WF compared to AX from azygous 
control. Analysed by HPAEC using Carbopac PA20 column. Values are means where N=3, 
values in brackets are SD. Control AX has greater amounts of all AXOS fractions, but there are 
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greater differences between the O-3 linked AXOS fractions XA3XX, XA3A3XX, XA3XA3XX, 
XA3XA2+3XX. 
 
 
Figure 4.3 Analysis of xylan structure in endosperm samples from homozygous TaXAT1 RNAi 
transgenic wheat. Oligosaccharide abundance (HPAEC peak area) from RNAi GT61 AX samples 
relative to corresponding azygous control after xylanase digest (PRO-E0062). N=3. Columns for AX 
oligosaccharides are coloured according to substitution with Araf: unsubstituted (green), 
monosubstituted only (red), di-substituted only (blue), and mono- and di-substituted (purple). 
Abundances of (1,3) ;(1,4)-β-glucan oligosaccharides [Glucose3 (G3) and Glucose4 (G4)] as result 
of simultaneous lichenase digest show no overall change.  
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Xylose 4.68 (±0.09) 3.64 (±0.17) 
Xyl2 1.38 (±0.02) 0.80 (±0.01) 
XA3XX 2.90 (±0.02) 0.92 (±0.03) 
XA2+3XX 1.90 (±0.01) 1.65 (±0.03) 
XA3A3XX 1.13 (±0.03) 0.34 (±0.006) 
XA3XA3XX 0.18 (±0.02) 0.086 (±0.15) 
XA3A2+3XX 0.32 (±0.03) 0.32 (±0.02) 
XA3XA2+3XX 0.70 (±0.04) 0.31 (±0.03) 
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4.4.32.2. PACE of RNAi GT61 AX and azygous control 
The samples that were analysed by HPAEC were also labelled with ANTS and subjected to 
PACE (Fig 4.6) Band thickness denotes abundance of AXOS fraction and Figure 4.4 clearly 
shows that the AX isolated from the RNAi GT61 wheat line has less O-3 linked XA3XX, 
XA3A3XX and XA3XA3XX and less mixed linked XA2+3XX, XA3A2+3XX and XA3XA2+3XX 
than the azygous control AX which supports the data from HPAEC analysis in Figure 4.3 and 
table 4.2.  
 
 
 
 
 
 
 
 
 
 
 
4.4.33. Analysis of prebiotic activity of AX isolated from RNAi GT61 compared to 
control AX (isolated from azygous control) by quantification of SCFA and 
changes in bacterial populations 
 
Table 4.3 shows the SCFA and lactate concentrations generated in the in vitro colonic 
fermentation system and Table 4.4 shows the bacterial populations. Fermentation of RNAi 
GT61 AX with reductions in mono-substituted O-3 linked arabinose substitutions resulted in 
Figure 4.4: Image of PACE showing AX from RNAi GT61 (GT61, left) and an azygous control line 
(CTRL, right). AX samples were derivatised with ANTS and separated in a polyacrylamide gel by size, 
where smaller oligosaccharides travel further down the gel. A darker band represent a larger number 
of AXOS fractions. GT61 has less linked XA2+3XX, XA3A2+3XX and XA3XA2+3XX and less O-3 linked 
XA3XX, XA3A3XX and XA3XA3XX, than an azygous control AX but more X and XX. 
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changes to the microbial composition and SCFA concentrations in vitro in comparison with 
fermentation of azygous control AX. 
The largest contributor to total SCFA in both AX samples is acetate, which increases 
significantly (p>0.95) with fermentation of the azygous control AX compared to the negative 
control from 8h. The concentration of acetate from fermentation of AX isolated from RNAi 
GT61 did not increase significantly compared to the negative control at any of the time points 
measured, indicating a reduction in prebiotic activity from the altered structure. The 
concomitant increase in Bifidobacterium populations may be the reason for the increase in acetate 
seen with the azygous control. Bifidobacterium populations do not increase significantly compared 
to the negative control with fermentation of the RNAi GT61 AX and therefore may explain 
why there is no significant (p>0.95) increase in acetate concentrations. 
Only the Lactobacillus bacterial group was increased significantly (p>0.95) compared to the 
negative control with RNAi GT61 AX, whilst fermentation of the azygous control AX caused 
significant increases of total bacterial populations and increases in Bifidobacterium and Clostridium 
coccoides/ Eubacterium rectales groups. Fermentation of the AX isolated from the azygous control 
caused an increase in prebiotic associated bifidobacteria from 7.1% total bacteria at 0h to 35.5% 
after 24h, and whilst the other main prebiotic associated bacteria, Lactobacillus, populations 
dropped in all samples after 0h, fermentation of the RNAi GT61 AX caused a recovery of this 
from 7.5% at 8h to 23.9% at24h, significant (p>0.95) compared to the negative control and 
greater than that seen with FOS. Azygous control AX appears to select more for Bifidobacterium 
spp. whilst RNAi GT61 AX appears to select more for Lactobacillus spp. This is in contrast with 
Hughes et al. (2007) where commercial low MM AX was shown to increase Lactobacillus 
populations, however, in the Hughes study the AX was from a commercial source and 
differences in the AX structures may have caused differences in the prebiotic activity. 
Formic acid levels increased significantly compared to the negative control for both the RNAi 
GT61 and control AX samples after 8 hours (Table 4.3).  Formate production peaked with both 
AX samples at 24 hours. The concentration of formate from fermentation of FOS reaches much 
greater concentrations than is seen with either AX sample. Thus, FOS appears to be a more 
favoured substrate for production of formate than AX.  This was unexpected and in contrast to 
other data (chapter 3 and 5) however, the isolated AX used in these experiments was not from 
a commercial source and thus may account for these differences. Relatively little is known about 
the role of formate in the gut. Formate is an electron donor which, along with H2, reduces CO2 
to methane in methanogenesis and appears to be elevated in inflammatory conditions 
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(Vanderhaeghen, et al., 2015; Bereswill et al., 2011) therefore formate increases may not be 
beneficial to the host and increases in formate should not be considered as a prebiotic effect. 
Lactate levels begin high and decrease to almost zero after 24 hours’ fermentation with both 
AX samples. Lactate is often a transient metabolite and is utilised for other metabolic processes 
including the production of SCFA in cross-feeding mechanisms by some colonic bacteria. 
Duncan et al. (2004) state that lactate is normally detected only at low concentrations (<5 mM) 
in faeces from healthy individuals. It is not known which bacterial species are responsible for 
lactate utilisation, however, four bacterial species related to Eubacterium hallii have been 
implicated. The large number of Lactobacillus bacteria present at 0h for all samples. may explain 
the high initial levels of lactate. 
Propionate concentration increased in all vessels, regardless of carbohydrate presence or 
modification. No significant differences were observed between either AX substrate or FOS 
and the negative control. Lactate is a precursor for propionate production so it is likely that 
lactate levels decrease due to utilisation for the formation of propionate. 
Fermentation of FOS showed increased production of butyrate after 24 hours, compared to the 
negative control but this was not the case for either of the AX fractions tested, where there were 
no differences in butyrate production compared to the negative control. 
Both the SCFA and bacterial population data agree that the azygous control AX shows greater 
prebiotic effects thorough stimulation of beneficial bacterial group bifidobacteria and resultant 
increase in acetate production. 
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Table 4.3: SCFA and lactate concentration in batch cultures at 0, 4, 8 and 24 hours’ fermentation comparing no substrate, FOS, azygous control 
AX and RNAi GT61 AX. Negative control is no added carbohydrate and positive control is FOS. One-way ANVOA was applied to the data to test (F-
test) the main effect of treatment. SEM is shown in italics Significant interaction between treatments and negative control are denoted * (p< 0.05) and shown 
in bold. 
 
 
Time 
(h) 
Lactic 
acid 
(µM) 
 
Formic 
Acid 
(µM) 
 
Acetic 
Acid 
(µM) 
 
Propionic 
acid (µM) 
 
Butyric 
acid (µM) 
 
Total (µM) 
 
No 
treatment 
0 11.02 (3.68) 0.00 (0.00) 4.21 (1.22) 4.36 (1.11) 2.22 (0.50) 19.15 (3.15) 
8 5.66 (0.44) 0.62 (0.27) 9.05 (2.40) 8.77 (1.42) 1.53 (0.36) 19.07 (3.97) 
24 6.45 (0.16) 3.71 (0.93) 9.84 (2.71) 9.33 (1.85) 1.20 (0.22) 26.57 (1.97) 
FOS 
0 24.05 (3.26) 0.11 (0.06) 4.93 (3.71) 5.20 (1.23) 1.54 (0.19) 39.90 (7.54) 
8 48.50* (6.97) 21.10* (4.99) 31.81* (5.44) 4.57 (0.94) 2.96 (0.87) 131.01* (14.50) 
24 65.44* (12.91) 29.57* (4.55) 75.06* (10.78) 11.76 (6.01) 10.48* (3.29) 207.60* (35.54) 
RNAi 
GT61 AX 
0 14.85 (2.32) 0.00  (0.00) 3.47 (0.96) 2.31 (0.42) 1.50 (0.08) 21.71 (2.38) 
8 6.80 (1.22) 4.94* (1.17) 14.45 (8.32) 12.12 (3.49) 0.93 (0.40) 36.60 (12.54) 
24 3.12 (1.18) 9.83* (3.09) 23.81 (9.42) 12.89 (3.23) 1.27 (0.63) 46.45 (13.17) 
Azygous 
Control 
AX 
0 16.39 (3.37) 0.00  (0.00) 4.93 (1.01) 5.05 (0.60) 1.54 (0.20) 26.55 (3.04) 
8 10.19 (2.86) 6.63 * (2.30) 21.12* (4.46) 8.09 (0.48) 1.76 (0.11) 47.13* (4.99) 
24 2.56 (1.31) 15.90* (4.17) 27.64* (4.85) 9.76 (2.77) 1.29 (0.12) 51.07 (12.25) 
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Table 4.4: Bacterial enumeration (mean log10 bacterial numbers / mL) of samples taken from static batch cultures after 0, 4, 8 and 24 hours’ 
fermentation comparing no substrate, FOS, azygous control AX and RNAi GT61 AX. Negative control is no added carbohydrate and positive 
control is FOS. Values are mean log10 bacterial numbers/mL found using flow FISH. One-way AVONA was applied to the data to test (F-test) the main 
interaction between treatments. Values in brackets are SEM. Significant interaction between treatments and negative control are denoted * (p< 0.05) and 
shown in bold. 
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No treatment 
0 8.53 (0.33) 8.76 (0.13) 7.95 (0.12) 9.11 (0.04) 8.63 (0.11) 7.60 (0.16) 8.20 (0.09) 9.07 (0.04) 8.61 (0.06) 7.75 (0.15) 9.70 (0.03) 
8 8.58 (0.32) 7.65 (0.03) 8.55 (0.03) 9.01 (0.08) 8.25 (0.13) 7.70 (0.09) 8.70 (0.06) 8.90 (0.02) 8.54 (0.10) 8.20 (0.12) 9.67 (0.07) 
24 8.76 (0.3) 7.90 (0.18) 8.45 (0.13) 8.92 (0.07) 7.74 (0.20) 7.85 (0.10) 8.76 (0.08) 8.54 (0.06) 8.12 (0.12) 7.93 (0.12) 9.58 (0.10) 
FOS 
0 8.69 (0.61) 9.63 (0.19) 8.16 (0.21) 9.16 (0.14) 8.29 (0.24) 7.57 (012) 8.26 (0.18) 8.89 (0.04) 8.37 (0.14) 7.73 (0.22) 9.79 (0.26) 
8 9.98* (0.22) 7.85 (0.08) 8.82 (0.09) 9.39 (0.23) 8.37 (0.29) 7.95 (0.33) 8.86 (0.11) 9.11 (0.12) 8.44 (0.20) 8.27 (0.24) 10.30* (0.14) 
24 9.63 (0.29) 8.34* (0.18) 8.87 (0.11) 9.24 (0.31) 8.40 (0.42) 8.12 (0.28) 8.90 (0.16) 8.78 (0.21) 8.44 (0.31) 8.08 (0.20) 10.13* (0.16) 
RNAi GT61 
AX 
0 8.38 (0.46) 9.31 (0.29) 7.79 (0.20) 8.99 (0.10) 8.46 (0.04) 7.49 (0.20) 7.99 (0.15) 8.84 (0.0$) 8.48 (0.08) 7.83 (0.29) 9.58 (0.11) 
8 9.04 (0.17) 7.61 (0.20) 8.65 (0.09) 9.05 (0.10) 8.53 (0.14) 8.01 (0.22) 8.73 (0.16) 9.03 (0.13) 8.69 (0.17) 8.30 (0.20) 9.86 (0.01) 
24 9.31 (0.16) 8.58* (0.17) 9.038 (0.04) 8.99 (0.17) 8.36 (0.29) 7.76 (0.15) 8.94 (0.09) 8.9 1 (0.32) 8.20 (0.14) 7.79 (0.14) 9.90 (0.13) 
Azygous 
control AX 
0 8.52 (0.41) 9.84 (0.14) 8.11 (0.17) 9.13 (0.01) 8.65 (0.06) 7.88 (0.05) 8.28 (0.12) 8.89 (0.09) 8.58 (0.03) 8.00 (0.16) 9.67 (0.07) 
8 9.23* (0.19) 7.92 (0.20) 8.84 (0.23) 9.09 (0.38) 8.32 (0.52) 7.65 (0.37) 8.93 (0.24) 9.00 (0.19) 8.61 (0.19) 7.81 (0.40) 9.94 (0.24) 
24 9.84* (0.09) 7.67 (0.22) 8.55 (0.44) 9.57* (0.18) 8.42 (0.40) 8.45 (0.53) 8.63 (0.44) 9.06* (0.17) 8.26 (0.20) 8.11 (0.42) 10.29* (0.05) 
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4.5. Results of in vitro gastric and duodenal digest of AX 
In vitro digestion was used to test if non-specific changes in arabinosylation affect prebiotic 
activity. It was theorised that gastric digestion would reduce the A:X ratio, i.e., similar to the use 
of RNAi GT61 AX but with random removal of arabinose depending on the 3D structure of 
the AX polysaccharide and exposure of bonds to the low pH. RNAi GT61 AX has less 
arabinose specifically at the O-3 linked position, which may cause structural differences between 
the AX polysaccharides. It is hypothesized that AX exposed to the acid environment of a 
simulated gastric digestion would remove arabinose in a much more random fashion. 
 
4.5.1. Monosaccharide analysis of AX before and after in vitro gastric and duodenal 
digestion. 
Monosaccharide analysis of AX before and after in vitro gastric and duodenal digestion is shown 
in Figure 4.5. After in vitro digestion, there is a small but significant (p>0.95) decrease in 
arabinose in the AX sample, reducing the A:X ratio from 0.77 to 0.74. There is no reduction in 
xylose. Comparison of Figures 4.1 and 4.5 show that although in vitro digestion reduces the A:X 
ratio, however it remains much greater than that of RNAi GT61 AX 
  
Figure 4.5: Monosaccharide analysis of Medium MM AX before and after in vitro gastric and 
duodenal digestion. Analysis of monosaccharides using a Carbopac PA20 column. (N=3) Error 
bars show standard deviation. 
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4.5.2. HPAEC of AX before (pre) and after simulated gastric and duodenal digestion 
(post) 
HPAEC was used to determine changes in the structure of the AX by quantifying AXOS 
fragments before and after simulated gastric and duodenal digestion (Figure 4.6).  
 In vitro digestion of AX resulted in changes to the structure. Smaller AXOS fragments, xylose 
and xylobiose, increased by 9.7% and 4% respectively, whilst the larger more highly 
arabinosylated AXOS fragments, XA3XX, XA2+3XX, XA3A3XX and XA3XA3XX, 
decreased by 2.8%, 7.3%, 1.6% and 0.9% respectively. It is likely that the low pH in the gastric 
digestion caused de-arabinosylation of the larger AXOS fragment, as shown in Zhang et al. 
(2003), making the xylan backbone more accessible to the endoxylase used in HPAEC analysis. 
This is supported by the data is Figure 4.6, showing a decrease in arabinose after digestion. 
 
 
 
-10 -8 -6 -4 -2 0 2 4 6 8 10 12
AX
Change in AXOS fractions after in vitro digestion (nC* min)
XA3A3XX XA3XA3XX XA3A3XX XA2+3XX XA3XX Xyl3 Xyl2 Xylose
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Figure 4.6: Change in AXOS shown by HPAEC analysis of AX before and after in vitro gastric 
digestion. Oligosaccharide abundance (HPAEC peak area) of AX, digested with endoxylase 
(Xylanase PRO-E0062 Prozomix) prior to running on HPAEC. Different patterns of AXOS are shown 
(as % positive or negative change pre-and post-gastric digestion). Values shown are average where 
n=3.  
 
4.5.3. HP-SEC-MALS of AX before and after simulated digestion. 
 
AX was separated by size exclusion chromatography before and after the in vitro gastric and 
duodenal digestion, to determine if digestion affects the size or viscosity of the polysaccharides 
(shown in Table 4.5). There was a reduction in MM and intrinsic viscosity after in vitro digestion, 
indicating that the gastric and duodenal digestion conditions do alter AX, most likely via 
hydrolysis of arabinofuranose by the low pH encountered in the simulated gastric phase, as 
stated in 4.5.2.  
 
Table 4.5: SEC-MALS of AX before and after simulated gastric and duodenal digestion. MM 
and intrinsic viscosity values from Wyatt Astra software. One hundred µL was injected onto an OHpak 
SB 802.5 HQ column. The eluent was 0.1M NaNO3 with 0.02% NaN3 with a flow rate of 0.5mL/min-
1
.  
 MM (kDa) Intrinsic viscosity (mL/g) 
 Pre-digest Post digest Pre-digest Post digest 
AX 323.9 177 288.632 180.121 
 
 
4.5.4. Analysis of prebiotic activity of AX following in vitro gastric and duodenal 
digestion compared with untreated AX by quantification of SCFA and changes 
in bacterial populations 
 
Table 4.6 shows the short chain fatty acid concentrations generated by in vitro colonic 
fermentation of AX fractions and Table 4.7 shows the bacterial populations.  
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Table 4.6 shows that acetate increases significantly in both AX samples compared to the 
negative control (p>0.95), however the control AX (not exposed to prior gastric/duodenal 
digestion) showed a significant (p>0.95) increase at 8h whilst the gastrically digested AX took 
24h to show a significant difference. Almost twice as much acetic acid was produced from 
fermentation of untreated control AX at 8h, (29.76mM compared to 12.46mM) but by 24h the 
difference between the two AX fractions was no longer apparent. The rate of fermentation 
therefore appears to be greatest in the control AX sample and this may relate to the loss of 
arabinose observed in the gastric/duodenal-treated AX sample, resulting in more unsubstituted 
xylose residues making the pre-treated sample less soluble and therefore less fermentable as it 
has been hypothesised that decreased solubility results in decreased fermentability (Roland et 
al., 1995). The significant increase in acetate in all samples compare to the negative control may 
be related to an increase in Bifidobacterium spp., which are known producers of acetate. Increases 
were observed in Bifidobacterium species after 24 hours for both AX samples compared to the 
negative control, although there were no differences between the two AX samples (i.e. pre-
treatment with gastric/duodenal digest or no digestion).  
The slower rate of acetate increasing in concentration from fermentation of the gastrically 
digested AX compared the control AX may suggest that gastrically digested AX is slower to 
ferment, however, after 4h all bacterial populations showed an increased population with the in 
vitro digested AX as substrate compared to the untreated control AX (by 8h there was no longer 
any difference). It is possible that acetate was slower to accumulate due to increased utilization 
for bacterial cross feeding to generate other SCFAs as bacterial numbers were greater, 
particularly in two groups Roseburia and Faecalibacterium prausnitzii, of which, there were 
significant (p>0.95) increases compared to the negative control with respective increases of 26% 
and 9.5%, with fermentation of the in vitro digested AX.  These increases were not seen with 
untreated AX. These bacterial groups contain species which have been found to utilise acetate 
to produce butyrate (Duncan et al., 2002), which may explain why the increase in acetate is 
slower with the digested AX, however there is no concomitant increase in butyrate to support 
this theory.  
The concentration of formate was significantly lower for the in vitro digested AX after 24 hours, 
even compared with the negative control. This was not the case for the untreated control AX. 
Formate has not been linked with any health benefits in humans but is used in cross feeding to 
generate acetate so reductions in formate are potentially beneficial. Propionate production did 
not differ significantly from the negative control for either AX samples. As lactate is a precursor 
to propionate it is of note that the lactate concentration decreased from the start of fermentation 
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for both digested and untreated AX. Lactate did, however, increase after 24hour fermentation 
in the FOS (positive control) treatment, which was unexpected as lactate is not usually recorded 
at high concentrations (18.71 mM) in healthy colonic conditions.  The concentration of butyrate 
was not significantly different from the negative control for any sample, suggesting no effect of 
treatment on butyrate production, despite increases in butyrate producing bacterial groups with 
the in vitro digested AX.  
Both AX samples caused a similar, significant (p>0.95) increase in the beneficial Clostridium 
coccoides- Eubacterium rectale group after 24h supporting the theory that AX has prebiotic activity 
but showing that this bacterial group shows no distinction between the two samples. 
 
These data show that in vitro gastric and duodenal digestion seems to increase beneficial bacterial 
groups Roseburia and F. prau. Which is contrary to SCFA data, as butyrate increases significantly 
compared to the negative control with untreated AX but not digested AX. 
It could be concluded that structural changes including random de-arabinosylation of AX in vitro 
gastric and duodenal digestion affects prebiotic activity, possibly reducing speed of 
fermentation. The data from Table (4.3) and (4.4) show that RNAi GT61 AX (which has a loss 
of specific arabinose side chains) causes changes in prebiotic activity compared to its control as 
well. Although it is unclear whether a specific loss of O-3 linked arabinose side has a different 
effect than from random loss of arabinose side chains through acid hydrolysis, it has been shown 
that changes to arabinosylation appear to affect the prebiotic activity of AX.  
The RNAi GT61 AX and its azygous control were extracted from wheat flour at Rothamsted 
Research, rather than being commercially bought and had a A:X ratio of 0.52 and 0.54 
respectively. This is much lower than the A:X ratio found after in vitro digestion of medium MM 
AX of 0.73. A higher A:X ratio has been shown to decrease the degree of fermentability (Pollet 
et al., 2012), however, substitution was shown to be secondary to dp in rat studies where AX 
with A:X ratios of 0.69 and 0.27 affected the measured intestinal characteristics similarly (Van 
Craeyveld et al., 2008).  
Different bacteria have different preferences for XOS or AXOS (Pastell et al., 2009), for 
example Bifidobacterium adolescentis possesses AX arabinofuranohydrolase-D3, an enzyme for 
releasing arabinose residues from double substituted xylose (van den Broek et al., 2005; Van 
Laere, Beldman, & Voragen, 1997). This bacterium is an example of bacteria which may be 
more able to break down in vitro digested AX, than RNAi GT61 AX, due to the presence of 
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double substitutions which survived digestion (as the A:X ratio was reduced only from 0.84 to 
0.81 indicating that a lot of arabinose substitutions remain). 
Therefore, the reduced A:X ratio found after in vitro gastric and duodenal digestion may have 
aided prebiotic activity by improving the degree of fermentability and causing a greater increase 
in beneficial bacterial populations, or the increase in bacterial populations may have been due 
to other changes in the AX structure like the reduction in MM and therefore solubility. The 
latter is more likely because the lower A:X ratio in RNAi GT61 AX did not also cause an increase 
in bacterial populations, which would be expected if substitution was the cause of increased 
prebiotic activity. 
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Table 4.6: SCFA production from faecal bacteria (mM per 1mL batch culture fluid) after incubation with either no substrate, FOS, untreated AX or 
AX that had undergone simulated gastric and duodenal digestion. AX is commercially available medium MM AX (Megazyme, Bray, UK). One-way 
ANOVA and F-test were used to compare treatments to negative control for each bacterial group. Values are means with SEM shown in italics. Significant 
interaction between treatments and negative control are denoted * (p< 0.05) and shown in bold. 
 
 
 
 
Time 
(h) 
Lactic 
acid (µM) 
 
Formic 
Acid 
(µM) 
 
Acetic 
Acid 
(µM) 
 
Propionic 
acid (µM) 
 
Butyric 
acid 
(µM) 
 
Total 
(µM) 
 
No 
treatment 
0 25.53 (6.39) 2.70 (0.40) 2.08 (1.29) 4.14 (0.43) 4.06 (0.50) 38.51 (1.34) 
4 17.81 (9.24) 4.39 (1.87) 1.92 (1.57) 5.15 (1.30) 8.15 (1.83) 37.42 (1.76) 
8 4.78  (2.17) 5.19 (2.12) 4.80 (1.96) 2.43 (1.56) 5.58 (2.61) 22.78 (0.20) 
24 2.66 (0.85) 9.55 (4.20) 10.10 (4.16) 5.06 (4.15) 3.64 (1.50) 31.01 (0.85) 
FOS 
0 21.07 (8.25) 1.13 (0.92) 10.14 (9.38) 3.01 (1.09) 8.50 (1.84) 46.84 (2.31) 
4 19.92 (7.91) 6.06 (1.78) 9.20 (2.52) 7.27 (3.16) 6.55 (1.04) 49.00* (1.40) 
8 6.34 (2.98) 4.24 (1.84) 20.49* (3.18) 6.05 (2.97) 10.04 (4.52) 47.15* (0.49) 
24 18.71* (5.08) 0.00* (0.01) 20.18 (3.86) 15.86 (6.59) 4.09 (0.61) 58.84* (1.47) 
AX 
0 21.95 (6.21) 2.66 (1.10) 3.91 (3.20) 6.41 (1.78) 4.62 (0.60) 39.56 (1.16) 
4 8.83 (0.51) 3.87 (1.19) 8.40 (3.58) 7.01  (3.09) 10.03 (4.31) 38.13* (0.83) 
8 6.30 (3.23) 1.76 (1.44) 29.76* (9.47) 17.37 (12.33) 12.22* (1.37) 67.42* (2.60) 
24 5.87 (3.92) 2.98  (2.43) 36.07* (12.11) 12.53 (5.07) 10.44* (3.68) 67.86* (1.98) 
Gastric 
digest AX 
0 17.15 (3.56) 4.40 (2.68) 5.88 (3.40) 3.14 (0.28) 6.68 (1.63) 37.26 (0.70) 
4 9.90 (3.12) 3.73 (0.92) 3.70 (1.53) 1.90 (0.54) 4.40 (1.24) 23.63 (0.51) 
8 6.36 (3.13) 1.89 (0.83) 12.46 (4.31) 1.37 (2.44) 4.93 (2.15) 27.01 (0.66) 
24 5.86 (4.46) 1.01* (0.82) 35.57* (0.70) 15.95 (8.74) 4.26 (0.64) 62.65* (1.84) 
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Table 4.7: Bacterial enumeration (mean log10 bacterial numbers / mL) of samples taken from static batch cultures after 0, 4, 8 and 24 hours’ 
fermentation comparing no substrate, FOS, untreated AX or AX that had undergone simulated gastric and duodenal digestion. One-way ANOVA 
and F-test were used to compare treatments to negative control for each bacterial group. Values are means with SEM shown in brackets.  Significant 
interaction between treatments and negative control are denoted * (p< 0.05) and shown in bold. 
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Negative 
0 7.8 (0.16) 7.41 (0.19) 7.75 (0.24) 8.68 (0.22) 7.97 (0.23) 7.50 (0.52) 7.88 (0.27) 8.14 (0.16) 8.19 (0.31) 7.44 (0.22) 9.17 (0.21) 
4  7.7 (0.25) 7.32 (0.36) 7.81 (0.36) 8.37 (0.42) 7.29 (0.29) 7.50 (0.36) 7.99 (0.37) 8.67 (0.22) 8.06 (0.25) 7.70 (0.25) 9.20 (0.24) 
8 7.38 (0.45) 6.87 (0.26)  7.3(0.51) 8.23 (0.36) 6.80 (0.36) 7.27 (0.29) 7.49 (0.53) 8.08 (0.34) 7.76 (0.19) 7.04 (0.33) 8.85 (0.28) 
24 7.19 (0.60) 6.41 (0.33) 6.97 (0.55) 7.59 (0.76) 6.23 (0.33) 6.94 (0.59) 6.85 (0.62) 7.32 (0.75) 7.19 (0.58) 6.46 (0.41) 8.26 (0.62) 
FOS 
0 7.77 (0.25) 7.04 (0.40) 7.55 (0.40) 8.55 (0.24)  7.67 (0.51) 6.76 (0.41) 7.54 (0.41) 8.33 (0.19) 7.75 (0.32) 7.10 (0.40) 8.99 (0.26) 
4 8.32 (0.46) 6.76 (0.50)  7.73 (0.41) 8.37 (0.29) 7.21 (0.63) 7.44 (0.73) 7.85 (0.40) 8.17 (0.34) 7.06 (0.84) 6.95 (0.62) 9.03 (0.39) 
8 8.66*(0.61) 6.23 (0.96) 6.97 (0.15) 8.32 (0.32) 6.60 (0.54) 7.35 (0.59) 7.26 (0.56) 7.83 (0.29) 7.28 (0.57) 6.61 (0.77) 9.04 (0.47) 
24 9.02*(0.17) 5.87(0.67) 5.46 (0.45) 8.82 (0.19) 5.34 (0.33) 6.23 (0.39) 5.76 (0.33) 6.85 (0.37) 5.68 (0.15) 5.93 (0.82) 9.30 (0.16) 
Untreated AX 
0 7.21 (0.30) 7.47 (0.36) 7.22 (0.31) 8.18 (0.30) 7.62 (0.30) 6.61 (0.30) 7.32 (0.30) 7.85 (0.31) 7.49 (0.30) 6.96 (0.30) 8.65 (0.30) 
4 7.79 (0.70) 6.41 (0.64) 7.56 (0.65) 7.69 (0.50) 6.91 (0.92) 6.78 (0.71) 7.64 (0.65) 7.89 (0.53) 7.26 (0.67) 6.74 (0.62) 8.61 (0.61) 
8 8.54 (0.52) 6.7 (0.62) 6.29 (0.94) 8.17 (0.36) 6.79 (0.72) 6.95 (0.85) 7.35 (0.90) 7.78 (0.63) 7.30 (0.66) 6.44 (0.79) 8.99 (0.48) 
24 8.84*(0.23) 6.72 (0.66) 8.10 (0.86) 9.11* (0.16) 6.48 (0.67) 7.20 (0.71) 8.29 (0.47) 8.29 (0.28) 7.94 (0.56) 7.03 (0.67) 9.67* (0.21) 
Gastric 
Digest AX 
0 7.4 (0.12) 7.3 (0.25) 7.45 (0.09) 8.34 (0.14) 7.62 (0.08) 6.89 (0.0.7) 7.48 (0.10) 8.11 (0.15) 7.44 (0.13) 7.26 (0.06) 8.79 (0.12) 
4 8.28 (0.40) 6.94 (0.06) 7.68 (0.09) 8.42 (0.20) 7.36 (0.09) 7.54 (0.51) 7.64 (0.07) 8.37 (0.17) 7.96 (0.12) 7.29 (0.12) 9.13 (0.18) 
8 8.26 (0.36) 6.92 (0.50) 7.48 (0.24) 8.15 (0.45) 6.49 (0.98) 7.74 (0.09) 7.60 (0.26) 8.22 (0.30) 7.51 (0.32) 6.64 (0.49) 9.13 (0.19) 
24 8.58 (0.25) 7.2 (0.47) 8.04 (0.17) 9.10* (0.14) 8.14* (0.23) 7.81 (0.09) 8.04 (0.13) 9.08* (0.15) 8.12 (0.36) 7.22 (0.32) 9.65* (0.10) 
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4.6 . Conclusions 
 
It was thought that structure plays a large role in the prebiotic activity of AX. Hughes et al 
(2007) demonstrated an effect of AX molecular size on prebiotic activity and the current study 
indicates that the arabinosylation pattern may also play a role in determining the level of 
prebiotic activity. 
AX from transgenic wheat line RNAi GT61 had a lower A:X ratio resulting from reduced 
arabinose substitution specifically at the O-3 position, thereby reducing its solubility. 
Fermentation of this AX showed alterations and possible reduction to prebiotic properties 
compared to fermentation of AX from the control, azygous wheat line. 
This study showed that Bifidobacterium species fermented AX isolated from white flour of the 
RNAi GT61 line to a lesser extent than AX isolated from the control line. Supporting previous 
studies which showed that XOS were poor substrates for bifidobacteria when compared to 
other carbohydrates (Hopkins et al., 1998; Crittenden et al., 2002; van den Broek et al., 2005; 
Van Laere, Beldman, & Voragen, 1997). Therefore, bifidobacteria would proliferate less when 
fermenting a less substituted AX because of reliance on other gut microbiota with xylanase 
activity for the release of xylose sugars.  
It was shown that in vitro gastric and duodenal digestion also affected the structure of AX, 
reducing arabinose substitution in a more random pattern that the RNAi GT61 AX, reducing 
MM and solubility, which also appeared to affect the prebiotic activity of AX. Fingerprinting 
using HPAEC showed an increase in smaller AXOS fractions after simulated gastric and 
duodenal digestion and a decrease in larger AXOS fractions due to these structural changes.  
Fermentation of digested AX increased two different butyrate producing bacterial groups that 
are thought to be beneficial to colonic health (Riviere et al., 2016), Roseburia and F. prau, 
suggesting that gastric and duodenal digestion does influence subsequent bacterial fermentation 
and that AX exposed to simulated gastric and duodenal conditions was a better substrate for 
bacterial fermentation, however the level of the SCFA butyrate was increased only with 
untreated AX, indicating that there may be other factors involved in prebiotic activity. 
As the SCFA data has indicated that gastrically digested AX results in a lower A:X ratio and 
therefore, lower solubility and lower rate of fermentation. It may be possible that a longer 
fermentation period would be required for an increase in bacterial numbers to be observed.  
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It can be concluded that the structure of AX can be altered by gastric digestion, and this appears 
to influence the microbial composition in a positive way. Not only was arabinose lost but also 
the size of the AX chains appear to be reduced, and there a decrease in intrinsic viscosity was 
also observed.  Specific reduction in the arabinose substitution pattern of AX (demonstrated 
with RNAi GT61 AX) can also affect the prebiotic activity, however this reduced prebiotic 
activity. Structure therefore clearly plays a role in influencing bacterial populations. 
Arabinosylation shows importance in modulation of prebiotic effects, as observed from the 
different effects of non-specific removal of arabinose units (simulated gastric digest), which 
appears to increase prebiotic activity compared to specific removal of arabinose units at the 3 
position (RNAi GT61), which may reduce prebiotic activity. 
 
 
  
Table 4.8: Summary of effects of RNAi GT61 AX compared to azygous control AX and prior in 
vitro gastric and duodenal digestion 
Effect of GT61 AX Effect of gastric digestion on AX 
• Reduction in A: X ratio of AX from 
specific removal of arabinose 
• Reduction in concentration of 
acetate compared to azygous control 
AX 
• Decrease in total bacteria and 
bifidobacteria compared to non-
transgenic AX 
• Possible reduction in prebiotic 
activity 
 
• Random reduction in A: X ratio of 
AX 
• Reduction in MM and viscosity  
• Slower initial production of acetate 
• Decrease in formate concentration 
• Increase in Roseburia spp.  and F.prau 
bacteria compared to untreated AX 
• Possible increase in prebiotic activity 
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5. In vitro fermentation of commercial AX fractions of different 
Molecular Mass after in vitro gastric and duodenal digestion 
 
 Abstract 
Three soluble arabinoxylan (AX) fractions from wheat flour with average molecular mass (MM) 
of 56.9, 323.9 and 374.2 kDa and one insoluble AX fraction were purchased from Megazyme. 
These were subjected to in vitro gastric and duodenal digestion as described by Minekus et al., 
(2014) prior to addition to in vitro fermentation. The following changes in AX structure were 
observed in all samples after in vitro digestion: an increase in smaller AXOS, a decrease in MM 
and intrinsic viscosity and A:X ratio and a reduction in bound ferulic acid. Changes in 
microbiota were monitored using fluorescence in-situ hybridisation (FISH) to quantify bacteria 
and HPLC to quantify levels of short chain fatty acid (SCFA) and lactic acid. Differences in 
prebiotic activity were observed between AX samples of different MM after changes in structure 
caused by in vitro digestion. Significant increases in SFCA production compared to the negative 
control were observed in all AX samples. The AX fraction of 323.9 kDa gave the greatest 
increases in SCFA production, while the insoluble AX fraction showed the smallest increases in 
SCFA production. Changes in different bacterial populations were observed depending on the 
MM of the AX sample, however none were observed with the insoluble fraction. 
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 Introduction 
 
AX has previously been shown to have prebiotic properties (Vardakou et al., 2008, Grootaert 
et al., 2009, Neyrinck et al., 2011). A study by Hughes et al. (2007) indicated that commercial 
AX fractions of low MM were most effective in in vitro fermentation systems, producing the 
highest levels of SCFA and selectively stimulating the largest increase in beneficial colonic 
bacteria, bifidobacteria and lactobacilli. However, the study by Hughes et al, 2007 did not use 
AX fractions that had been exposed to in vitro gastric and duodenal digestion conditions prior 
to addition to the in vitro colonic fermentation system. It was shown that gastric digestion could 
generate AX with lower levels of arabinose substitution, and also increase overall prebiotic 
activity (as discussed in chapter 4), it was also hypothesised that exposure of AX to low gastric 
pH may release bound phenolic acids, including ferulic acid which links AX chains together at 
the O-5 position of the arabinose units (Zhang et al., 2003) and may also affect the rate at which 
the AX is fermented, hence affecting prebiotic activity. 
It is thought that low MM polysaccharides are more rapidly and more selectively fermented by 
the beneficial bacteria, bifidobacteria and lactobacilli, than higher MM polysaccharides. This 
may be because low molecular mass substrates have more non-reducing ends per unit mass, 
which favours a more rapid attack by the exo-acting enzymes produced by bacteria in the gut 
(Gibson, 2004). It is likely that in vitro digestion lowers MM, therefore making polysaccharides 
more fermentable. AX degradation by bifidobacteria involves the consumption of arabinose but 
not always the consumption of xylose that makes up the backbone. The majority of 
bifidobacteria can only utilize xylan of length up to xylotetraose (Riviere et al., 2014). This could 
explain why lower MM AX was previously shown to promote the growth of bifidobacteria 
(Hughes et al., 2007). For complete utilization of AX , it is likely that bifidobacteria require co-
operation with β-endoxylanase producing bacteria such as Roseburia and Bacteroides species.  
Therefore, as a continuation of the work described in chapter 4 on in vitro gastric digestion of 
AX, we therefore determined whether these digestive pre-treatments would affect the results of 
in vitro AX fermentation compared to the previous study published by Hughes et al. (2007). 
Commercially available AX fractions with different average MMs were subjected to in vitro 
gastric and duodenal digestion prior to addition to the in vitro colonic fermentation system. 
Polysaccharides were characterised before and after simulated gatric/duodenal digests to 
determine if any structural changes had occurred before in vitro fermentation.  
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 Materials and methods 
 
 Carbohydrates 
All AX samples and FOS were purchased from Megazyme (Bray,co. Wicklow, Ireland).  
 
 Characterisation of AX 
5.3.2.1.  Monosaccharide composition: 
Commercial AX fractions were characterised using monosaccharide analysis as described in 2.5. 
 
5.3.2.2. Structural analysis of carbohydrates 
AX fractions after in-vitro gastric/duodenal digestion were analysed by HPAEC and PACE 
following specific endoxylanase treatment, to determine effects of the simulated 
gastric/duodenal environment on AX structure. Methods are as described in 2.3 and 2.4 
respectively. 
 
 Analysis of phenolic acid content  
Analysis of phenolic acid content was done as described in 2.8.  
 
 In vitro gastric digestion of AX 
In vitro gastric and duodenal digestion was carried out on all AX samples prior to fermentation 
as described in 2.9.  
 
 In vitro fermentation of AX 
In vitro fermentation was performed as described in 2.10. AX (500mg) was compared to FOS 
(500mg) and a negative control in triplicate using faecal samples obtained from three healthy 
donors (n=3). Polysaccharide was added to basal media at 1% (w/v). Samples were inoculated 
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with 10% faecal slurry, as before. Samples were taken at 0h, 4, 6h, 24h and 48h. The additional 
time-point at 48h was added as it was hypothesized that the insoluble AX fraction might take 
longer to ferment.   
 
 Enumeration of bacteria by flow-FISH 
Bacteria were enumerated from samples taken at 0h, 8h and 24h using flow-FISH as detailed in 
2.12. 
 
 SCFA analysis  
SCFA and lactate were quantified using HPLC as detailed in 2.11.  
 
 Statistical analysis  
The Genstat (2015, 18th edition, © VSN International Ltd, Hemel Hempstead, UK) statistical 
package was used for all analysis. ANOVA data was supplied by SJ Powers (Statistical 
department, Rothamsted Research) and applied as detailed in 2.13. 
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 Results  
 Monosaccharide Analysis of commercial AX samples of different MM 
following in vitro digestion. 
Monosaccharide analysis of AX provides information about the average degree of arabinose 
substitution (A/X ratio) as well as the purity of the fractions. The A: X ratios of water-
extractable wheat endosperm AX varies, Maes and Delcour (2002) found a range from 0.31 to 
0.85.  
Monosaccharide analysis of different commercial MM AX fractions from wheat using HPAEC 
showed that similar proportions of arabinose and xylose were present in each of the three 
soluble fractions(w/w) with very similar and very high A:X ratios ranging between 0.81 and 0.84 
(Table 5.1) and a larger ratio of 0.93 for the insoluble AX. Figure 5.1 shows the A:X ratio before 
and after in vitro gastric and duodenal digestion. The A:X ratio for all samples decreased after 
digestion.  
Glucose and galactose are present in the high MM AX (5.6% and 0.58% of total 
monosaccharides) and the insoluble AX samples (1.96% and 1.35% of total monosaccharides) 
before digestion. These monosaccharides are reduced or removed after dialysis in the in vitro 
digestion, in the high MM AX to 1.92% and 0% for glucose and galactose respectively and 0% 
for both for the insoluble AX.  
The correction factor to account for arabinose not associated with xylose found by Loosveld et 
al. (1997) was not applied in this case as commercial AX has already been purified. 
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Table 5.1: Monosaccharide composition of commercial different MM AX pre-and post-in vitro 
gastric and duodenal digestion showing A:X ratio using a Carbopac PA20 column. Values are 
average m [µg/mg] where N=3 and standard deviation is shown in brackets. 
 
 Arabinose 
 
Xylose Galactose Glucose A:X 
ratio  
Low MM 
AX 
Pre 391.5 (±6.34) 465.0 (±3.7 0 0 0.84 
Post 359.1(±15.18) 463.9 (± 8.85) 0 0 0.77 
Med MM 
AX 
Pre 384.9 (±2.77) 458.8 (±12.25) 0 0 0.84 
Post 371.3 (±1.15) 456.8 (±0.67) 0 0 0.81 
High MM 
AX 
Pre 340.6 (±11.5) 422.6 (±12.25)  4.7 (±4.71) 46.7 (±1.39) 0.81 
Post 
340.4 (±6.76) 445.2 (±25.65) 
0 15.4 
(±14.55) 
0.76 
Insoluble 
AX 
Pre 390.2 (±1.04) 418.9 (±27.50) 11.4 (±6.42 16.4 (±7.15) 0.93 
Post 342.9 (±28.79)  419.25 (±26.61) 0 0 0.81 
 
 
Figure 5.1: A:X ratio of AX samples pre-and post-in vitro gastric and duodenal digestion. 
Monosaccharides were resolved using a CarboPac PA20 column.  
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 Structural analysis of AX by HPAEC before and after in vitro gastric and 
duodenal digestion 
 
Following endoxylase digestion and HPAEC the peak areas for the identified AXOS (as seen in 
Figure 5.2) were compared for the various AXOS constituents before and after in vitro gastric 
and duodenal digestion. Figure 5.3 shows the relative % change in different AXOS fractions 
after in vitro gastric and duodenal digestion. 
After in vitro gastric and duodenal digestion, there are a greater number of smaller AXOS 
fractions xylose and xylobiose (Xyl2) in all samples and more xylotriose in the low and high MM 
AX samples. Subsequently the larger AXOS (XA3XX, XA2+3XX, XA3A3XX) decrease in all 
samples after digestion. The amount of the largest AXOS (XA3XA2+3XX) reduces very slightly 
after digestion, much less than the XA3XX, XA2+3XX and XA3A3XX fractions, indicating that 
this AXOS is less affected by the digestion than other AXOS, possibly due to its high level of 
substitution.  
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Figure 5.2: Changes in AXOS patterns in commercial AX samples (Megazyme co. Wicklow, 
Ireland) of different MM after in vitro gastric and duodenal digestion. Oligosaccharide 
abundance (HPAEC peak area). All Samples have undergone endoxylase digestion (Xylanase PRO-
E0062 Prozomix) before analysis. Products of digestion were analysed by HPAEC. Values are 
average where (N=3).  
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Figure 5.3: AXOS fragments, expressed as percent of total AXOS ‘pre’ and ‘post’ in vitro 
gastric and duodenal digestion. Oligosaccharide abundance (HPAEC peak area) of AXOS. All 
Samples have undergone endoxylase digestion (Xylanase PRO-E0062 Prozomix) before analysis. 
Products of digestion were analysed by HPAEC. (N=3) Error bars are SD. AXOS fractions X, XX, 
XXX, XA3XX, XA2+3XX and XA3A3XX, XA2+3XX, XA3A3XX are shown depending on quantity. 
 
 
  Structural analysis of different MM AX samples before and after simulated 
gastric and duodenal digestion by HP-SEC-MALS 
 
Commercial AX samples were analysed by HP-SEC-MALS before and after in vitro gastric and 
duodenal digestion to find out whether the MM is affected by exposure to gastric/duodenal 
digestion conditions. 
Samples of low MM AX, medium MM AX and high MM AX were separated by size exclusion 
chromatography before and after the in vitro gastric and duodenal digestion, to determine if 
digestion affects the size or viscosity of the polysaccharides (shown in Table 5.2 and Figure 5.4). 
HP-SEC-MALS analysis showed these fractions to have average MM of 56.9kDa, 326.9kDa, 
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and 374.2kDa respectively prior to digestion and 46.3kDa, 177 kDa and 236kDa post digestion. 
AXs with larger dp are accepted as having greater cross-linking capacity and a resulting capability 
to entrap and hold water, which in turn increases viscosity (Izydorczyk and Biliaderis, 1992). 
This is observed in Table 5.2 where the larger the MM of the AX, the higher the intrinsic 
viscosity. The intrinsic viscosity of all fractions also decreases after in vitro digestion. HP-SEC-
MALS of insoluble AX was not possible under the aqueous conditions used.  
All AX fractions showed reductions in MM and intrinsic viscosity after in vitro digestion, 
indicating that the gastric and duodenal digestion conditions do alter the AX fractions. It has 
been suggested that a positive correlation existed between solubility and fermentability (Roland 
et al. 1995) therefore an increase in solubility as observed in Table 5.2 and Figure 5.4 may 
increase fermentability.  
There was a greater reduction in size of the high and medium MM AX compared to the low 
MM AX. This would fit with the hypothesis that the low pH environment acts to remove 
arabinose units, as observed in figs 5.2 and 5.3. The result of this may also be to release phenolic 
acids, that cross-link AX chains together via the arabinose unit. This was explored next (chapter 
5.4.4). 
Figure 5.4 shows the elution time of the AX samples, when using HP-SEC, larger solutes are 
eluted faster due to fewer interactions with the column. The high MM AX is eluted first, and 
the low MM AX is eluted last both before and after in vitro digestion. The elution time for the 
high MM AX appears to increase after in vitro digestion, due to its decrease in MM. There is no 
discernible difference in the elution time of the low MM AX which is likely because there was 
a smaller change in MM after in vitro digestion. 
Variation in the MM of the high and medium MM AX samples appears to decrease after in vitro 
digestion (shown in Figure 5.4 by the reduced gradient of the line representing MM over time), 
suggesting the AX polysaccharides became more uniform. 
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Table 5.2: HP-SEC-MALS of different MM AX samples before and after simulated gastric and 
duodenal digestion. MM and intrinsic viscosity were obtained by HP-SEC-MALS. One hundred µL 
was injected onto an OHpak SB 802.5 HQ column. The eluent was 0.1M NaNO3 with 0.02% NaN3 with 
a flow rate of 0.5mL/min-1. Insoluble AX could not be run under the aqueous conditions. Lines at the 
bottom of each image show the signal strength. 
 
 
 
 
MM (kDa) Intrinsic viscosity (mL/g) 
 
Pre-digest Post digest Pre-digest Post digest 
Low MM AX 56.9 (±0.1) 46.3 (±0.3) 116.9 94.8 
Medium MM 
AX 326.9 (±0.3) 177 (±0.3) 288.6 180.1 
High MM AX 374.2 (±0.3) 236.1 (±0.2) 352.6 240.3 
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Figure 5.4.: HP-SEC-MALS of average Molar Mass of different MM AX samples before (left) and after (right) in vitro gastric and duodenal digestion 
on an OHpak SB 802.5 HQ column. Low MM AX is labelled in green, Medium MM AX is labelled in pink and High MM AX is labelled in red.  Lines at the 
bottom of each image show the signal strength.
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 Phenolic acid Analysis of Different MM AX samples using HPLC 
 
Commercial soluble AX fractions with low, medium and high MM and an insoluble fraction 
were analysed for phenolic acid content as it was hypothesised that acid hydrolysis removed 
bound phenolic acids.  Comparison of phenolic acid content before and after in vitro digestion 
was analysed by HPLC (detailed in 2.8.2). 
The major phenolic acid in wheat endosperm is trans-ferulic (tFA) which accounts for about 
90% phenolic acids found in wheat flour) (Fulcher, 1982) and is present in free, conjugated and 
bound forms, the bound form being much more abundant that the free and conjugated (Sosulski 
et al., 1982). This was observed in the current study, tFA was the only phenolic acid present on 
commercial AX samples and is shown in Table 5.3. 
The low and high MM AX initially had low levels of free and conjugated tFA (26.35-35.69 
µg/mg) and lower levels of bound tFA (3.82-4.13 µg/mg). A much higher amount of tFA, 
including both bound and free and conjugated was present in the insoluble fraction. This is as 
expected as AX polymers can be cross-linked by their phenolic acid side chains, reducing their 
solubility (Saulnier et al., 2007). The high level of bound tFA would imply that the insoluble AX 
fraction is highly crosslinked. No tFA was detected on the medium MM AX but this is to be 
expected as the commercial soluble fractions had all been prepared from a high molecular mass 
stock preparation. The low MM AX was prepared from the high MM AX using partial enzyme 
digest and the medium MM AX prepared from the high MM AX using partial acid hydrolysis 
(Pitkanen et al., 2009) therefore phenolic acids would already have been removed by acid 
hydrolysis. 
Free and conjugated tFA remain at similar levels after in vitro digestion (post) for the low and 
high MM AX, whilst increasing for the insoluble AX, whilst bound tFA fell to zero in all 
samples, suggesting that bound tFA was released by the low pH during gastric digestion. The 
little change observed in the low and high MM AX are likely due to the small amount of bound 
tFA present initially.  
A decrease in bound phenolics due to a low pH in the stomach could contribute to the increase 
in fermentability of the AX. Bound phenolic acids cause cross linking of AX chains, increasing 
aggregation and this could also impede access of microbial digestive enzymes to the specific site 
required for enzyme action.  Removal of bound tFA would also cause greater bioavailability of 
tFA in the gut, which has been linked to health benefits.  A dose of 10mg/kg has been shown 
to reduce the risk of high-fat diet associated obesity in mouse models via modulation of 
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enzymatic, hormonal and inflammatory responses (De Melo et al., 2017). Thus it would seem 
that gastric digestion could improve the ability for AX to be fermented and increases potential 
absorption of tFA. 
 
Table 5.3: Ferulic acid analysis of commercial different MM AX samples before and after in 
vitro gastric and duodenal digestion. Values are average where N=3, values in brackets are SD. 
 
 
Free and conjugated tFA 
(µg/mg) 
Bound tFA (µg/mg) Total (µg/mg) 
 
pre post pre post Pre Post 
Low MM 
AX 
35.69 (±0.74) 37.03 (±5.02) 3.82 (±0.51) 0 39.51 
(±1.25) 
37.03 
(±5.02) 
Medium 
MM AX 
0 0 0 0 0 0 
High MM 
AX 
26.35 (±1.51) 22.95 (±5.57) 4.13 (±2.44) 0 
 
30.48 
(±3.95) 
22.95 
(±5.57) 
Insoluble 
AX 
212.21 
(±8.91) 
722.20 
(±38.18) 
469.66 
(±26.83) 
0 681.87 
(±35.74) 
722.20 
(±38.12) 
 
 
 
 HPLC quantification of SCFA production from in vitro fermentation of 
different MM AX fractions after in vitro gastric and duodenal digestion 
 
Short chain fatty acid concentrations are shown in Table 5.4, and Table 5.5 shows the bacterial 
populations after the in vitro digested AX samples were fermented by colonic bacteria in static 
batch cultures for 0, 4, 6, 24 and 48 hours. Flow-FISH probes were used based on the earlier 
study by Hughes et al. (2007) to which this study compares. A longer fermentation time of 48h 
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was included in this study because in previous experiments (chapters 3 and 4) the highest 
concentrations of SCFA was observed at the final time point of 24h, therefore it was uncertain 
if the SCFA concentration could increase further with increased time and hypothesised that 
some AX samples may take longer than 24h to ferment. 
 It is shown in Table 5.4 and 5.5 that fermentation of AX can continue until 48h as the number 
of total bacteria continued to increase until 48h for the low MM AX and the total SCFA 
concentration also peaked at 48h. Total bacterial numbers declined after 24h fermentation of 
medium MM, high MM and insoluble AX (and the positive control, FOS) samples. Total SCFA 
production peaked at 48h for the low and medium MM AX and the insoluble AX. Interestingly, 
the concentration of total SCFAs also peaks at 48h with fermentation of FOS, which is thought 
to be rapidly fermented due to its low dp (Stewart et al., 2008). However, this late peak in SCFA 
is due to increases in propionate and butyrate (rather than acetate) which are secondary SCFAs 
formed through utilization of other metabolites through cross-feeding. Acetate concentration 
decreases after 24h in FOS, high MM AX and insoluble AX, indicating that the acetate may be 
being used in cross feeding. The lack of increases in acetate concentration for these samples 
indicates that fermentation has ceased. The concentration of acetate continues to increase with 
the low and medium MM AXs indicating that these samples were still being fermented after 
24h.  
Persistence in the colon is an important issue for prebiotics. It was thought that a greater MM 
would favour prolonged fermentation in the colon. This was not observed in this study as the 
low MM AX appeared to be fermented for longer than the medium, high MM AX or the 
insoluble AX.  The low MM AX was thought to be fermented the fastest as it has the smallest 
dp and more non-reducing ends in the xylose backbone w/w than the larger fractions, which 
are more available for hydrolysis by bacterial enzymes. It is possible that the low MM AX was 
more fully fermented than the other AX samples, due to these structural attributes and therefore 
it was fermented for longer. 
The total number of bacteria decreased after 24h of fermentation of the insoluble AX, indicating 
that fermentation rate had reduced and that bacterial populations would continue to decrease 
with increased time. The insoluble AX therefore did not appear to show the ability to persist 
further in the colon and be fermented in more distal regions than the soluble AX samples. A 
higher A:X ratio has been shown to decrease the degree of fermentability (Pollet et al., 2012) so 
it is possible that the insoluble AX was not fully fermented due to its complex structure. The 
insoluble AX fraction showed a significant (p>0.95) increase in SFCA production compared to 
the negative control after 24h fermentation, but this occurred slower than with the medium and 
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high MM AX samples, indicating that the insolubility of the AX structure makes it more difficult 
for bacterial enzymes to access the AX structure to hydrolyse it. 
Bifidobacterium populations increased significantly (p>0.95) compared to the negative control 
after 24h fermentation of the low mm AX (this was sustained until 48h) and high MM AX after 
24h (not sustained until 48h).  It is thought that bifidobacteria prefer lower molecular mass 
AXOS fractions (Hughes et al., 2007; Ho et al., 2017), however in this study bifidobacteria 
appear to prefer the high MM AX, reaching 7.34 log10 bacteria/mL after 48 hours’ fermentation 
compared 6.63log10 bacteria/mL. when fermenting the low MM AX. This is reflected in the 
concentration of acetate (as Bifidobacterium species are known producers of acetate (Fukuda et 
al., 2011; Bindels et al., 2015)) at 48h, for the high MM AX acetate concentration is higher, at 
20.33 mM compared to 16.52mM for the low MM AX. The longer fermentation time could 
provide enough time for the higher MM AX to be degraded, however as early as the 6-hour 
time point the number of bifidobacteria is greater after fermenting the high MM AX than the 
low and medium MM AX. 
The low MM AX appeared to be fermented more slowly than the medium MM or the high MM 
AX as it took up to 48 hours to cause a significant change in bacterial populations. The High 
MM AX increased Bifidobacterium populations after 24h compared to 48 hours for the low MM 
AX. The medium MM AX increased Clostridium coccoides / Eubacterium rectales after 24 hours 
compared to 48 hours for the low MM AX. This was contrary to expectations. After gastric 
digestion, the low MM AX was shown to have an A:X ratio higher than the medium or high 
MM AX, this may inhibit fermentation by blocking access to catalytic enzymes. Another 
hypothesis is that the low MM AX was more fully fermented due to the greater number of non-
reducing ends per unit mass, which are more easily hydrolysed by the exo-acting enzymes 
produced by bacteria in the gut (Gibson, 2004). 
The Clostridium coccoides / Eubacterium rectales groups increased with the medium MM AX after 
24h (sustained until 48h) and the low MM AX after 48h. The AX did appear to result in selective 
fermentation by bacterial populations, for example, the Clostridium histolyticum subgroup, which 
can be pathogenic in humans, decreased for all AX samples.  
Acetate levels increased steadily and peaked at 48hours for all samples. Significant increases in 
acetate concentration compared to the negative control (p>0.95) were found for low MM AX 
from 24h-48h, for medium MM AX from 24h-48h, high MM AX for 6h-48h and insoluble AX 
at 48h. Increases were highest for acetate in the medium MM AX sample with increases of 3.03-
fold compared to the negative control after 24 hours, the low, high and insoluble AX samples 
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gave increases in acetate of 1.73, 2.5 and 2.05-fold respectively.  The increases in acetate 
occurred without significant increases in bifidobacteria in the medium MM AX but could be 
due to increased metabolism or from other bacterial groups, not measured by the FISH probes 
used in this study.  
Significant increases in butyrate (p<0.05) compared to the negative control were found for all 
AX samples. (The low MM AX from 4-48h, for medium MM AX from 4-48h, for high MM 
AX from 6-48h, insoluble AX from 6-48h and FOS at 48h). Butyric acid production was highest 
with the medium MM AX where there was a 10-fold increase. There were also increases in 
butyric acid of 5.29-fold for low MM AX, 6.52-fold for high MM AX and 7.52-fold for insoluble 
AX.  
AX appears to stimulate butyrate production more than FOS, which may result from bacterial 
groups not measured in this study (e.g. Roseburia spp.) as the butyrate producing group 
Clostridium coccoides/ Eubacterium rectales that were measured in this study were increased with 
fermentation of FOS as well as with low and medium MM AX. 
All AX samples showed reductions in numbers of C. histolyticum at 48h fermentation, although 
this was not statistically significant (p> 0.95).  C. histolyticum preferentially ferments proteins 
potentially producing enterotoxins which cause a range of pathologies, from food poisoning to 
gas gangrene (Collins et al., 1994; Paredes-Sabja and Sarker, 2009). In the previous study 
(Hughes et al., 2007) all AX samples caused increases in this bacterium so prior in vitro gastric 
and duodenal digestion could cause AX to no longer stimulate this bacterium. 
Although Bacteroides species are often numerically dominant in healthy adults, a selective increase 
in their colonic activity is not considered to be beneficial as they are often identified as the 
causative agent of diarrhoea. The Bacteroides group includes potentially pathogenic species such 
as Bacteroides fragilis (Macfarlane, Cummings and Allison, 1986) which produce high levels of the 
enzyme β-glucuronidase, that catalyses hydrolysis of β-D-glucaronic acid from polysaccharides 
and is associated with production of toxic metabolites (McBain and Macafarlane, 
1998). Bacteroides bacteria did not increase significantly with any AX samples or the positive 
control, showing the selectivity of the AX substrates regardless of structure. Again, in the 
previous study (Hughes et al., 2007), Bacteroides species increase with all AX samples, so the 
changes resulting from the gastric/ duodenal environment appear to have changed the 
selectivity of AX. 
No significant (p<0.05) differences from the negative control were observed for formic acid 
and only one increase in lactic acid with the medium MM AX after 4h. This reflects the results 
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found by Hughes et al. (2007) for lactate (lactate levels increase from 0h-4h in this study but 
after 4h they reduce to less than 5mM due to cross feeding). It was previously found that 
propionate levels had increased by 5h in all AX samples, whereas in this study, propionate only 
increased after 24h for the medium and high MM AX and the insoluble AX and 48h for the low 
MM AX. The structural changes caused by prior in vitro digestion appear to have affected the 
fermentation profile and resulted in slowed and reduced propionate production. Formate was 
not measured in the previous study and so cannot be compared. Formic acid is a transient 
metabolite which peaked at 6 hours in all samples apart from the insoluble AX, which peaked 
at 4 hours. 
It is unclear why AX caused a significant (p>0.95) increase in butyrate in this study this was not 
observed in our previous studies (Chapter 3 and 4) where the same medium MM AX substrate 
was used. The same faecal donors could not be used in all the fermentation studies and 
differences in diet and lifestyle could add confounding factors into these studies.  Individual 
differences in microbiota and reactions to fermentation of polysaccharides could be responsible 
for the large deviation between donors in this study. 
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Time Lactate (µM) Formate (µM) Acetate (µM) 
Propionate 
(µM) Butyrate (µM) 
Total 
(µM) 
 
Negative  
control 
0 5.10 (0.09)  1.73 (0.04) 6.91 (1.39) 4.12 (2.01) 2.18 (0.18) 20.32 (5.77)  
4 8.67 (2.33) 2.25 (0.39) 7.34 (1.61) 5.37 (3.53) 1.97 (0.22) 25.60 (6.99) 
6 5.9 (0.19) 3.33 (0.40) 6.57 (1.74) 2.07 (0.12) 1.88 (0.23) 19.76 (3.55) 
24 5.27 (0.35) 1.96 (0.19) 8.28 (1.04) 2.03 (0.14) 1.24 (0.23) 18.79 (1.74) 
48 4.45 (0.02) 1.73 (0.08) 5.99 (0.82) 2.05 (0.11) 0.89 (0.22) 15.11 (1.40) 
FOS  
(positive  
control) 
0 4.72 (0.06) 1.7 (0.04) 1.57 (0.14) 3.71 (1.81) 1.91 (0.34) 13.60 (3.59) 
 
4 7.05 (2.37) 3.17 (1.22) 10.62 (6.00) 2.39 (0.50) 2.11 (0.73) 25.36 (15.64) 
6 6.36 (1.67) 5.46 (1.17) 17.31* (8.38) 4.04 (1.92) 1.89 (0.91) 35.06 (22.31) 
24 5.34 (0.98) 2.48 (0.54) 25.88* (4.63) 7.49 (5.01) 1.99 (0.98) 43.84* (15.76) 
48 4.47 (0.06) 1.72 (0.07) 25.29* (6.62) 15.94* (4.52) 3.7* (1.89) 51.14* (21.87) 
Low MM AX 
0 5.94 (0.04) 2.13 (0.02) 11.63 (2.89) 2.06 (0.15) 2.55 (0.42) 24.30 (6.64) 
 
4 10.76 (0.08) 2.16 (0.21) 9.2 (1.26) 1.99 (0.08) 5.05* (0.44) 25.82 (8.89) 
6 6.46 (0.82) 3.72 (0.96) 10.44 (5.44) 4.25 (2.28) 6.27* (0.36) 26.14 (11.20) 
24 4.51 (0.80) 2.24 (0.44) 14.03* (4.02) 5.51 (3.43) 6.56* (0.49) 27.19 (20.95) 
48 4.65 (0.07) 1.88 (0.19) 16.52* (7.59) 6.08* (2.62) 3.73* (2.93) 30.86 (18.72) 
Medium  
MM AX 
0 5.15 (0.26) 1.92 (0.16) 4.69 (1.20) 3.57 (1.66) 2.69 (0.18) 18.02 (4.11)  
4 14.85 (1.94) 3.31 (0.58)  8.72 (1.85) 2.12 (0.10) 4.97* (0.3) 31.63 (12.64) 
6 6.22 (0.39) 5.00 (0.67) 13.73 (4.78) 2.97 (1.05) 8.98* (0.28) 29.91 (14.07) 
24 7.2 (0.06) 2.06 (0.31) 25.09* (2.72) 7.74* (1.60) 12.61* (0.22) 44.69* (7.68) 
48 5.39 (0.31) 2.03 (0.22) 27.55* (6.26) 11.3* (3.16) 5.9* (3.86) 48.83* (15.69) 
High MM AX 
0 5.25 (0.35) 1.7 (0.05) 6.5 (0.35) 3.86 (1.86) 2.55 (0.16) 19.86 (3.37)  
4 7.14 (4.62) 3.21 (0.35) 12.51 (0.85) 6.37 (4.24) 3.41 (0.64) 30.97 (7.20) 
6 5.87 (0.11) 4.96 (0.14) 17.44* (1.5) 2.16 (0.22) 7.2* (0.02) 31.97 (3.51) 
24 5.67 (2.13) 2.37 (0.35) 20.7* (0.87) 7.57* (2.34) 8.08*(0.82) 38.71* (1.56) 
48 4.78 (1.16) 1.64 (0.02) 20.33*(2.86) 8.4* (2.00) 2.33 (0.76) 37.49* (9.23) 
Insoluble AX 
0 5.03 (0.34) 1.85 (0.09) 6.54 (1.24) 3.22 (1.05) 2.4 (0.24) 19.04 (1.47)  
4 7.86 (0.65) 3.52 (0.56) 7.92 (0.56) 2.1 (0.04) 4.11 (0.48) 25.51 (4.47) 
6 4.71 (1.06) 3.28 (0.30) 11.12 (2.43) 3.87 (0.96) 3.89 (0.28) 25.21 (3.79) 
24 4.87 (1.42) 1.59 (0.00) 17.05* (2.99) 7.05* (1.59) 9.33* (0.29) 32.90* (5.16) 
48 4.46 (0.48) 1.62 (0.03) 16.71* (2.28) 7.89* (0.57) 9.49* (0.58) 34.84* (4.65) 
Table 5.4: SCFA and lactate concentration in batch cultures at 0, 4, 8 and 24 hours’ 
fermentation comparing no substrate, FOS, and AX with different molecular masses that had 
previously undergone in-vitro gastric and duodenal digestion. Negative control is no added 
carbohydrate and positive control is FOS. One way ANVOA was applied to the data to test (F-
test) the main effect of treatment. SEM is shown in italics.  Significant interaction between treatments 
and negative control are denoted * (p< 0.05). 
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 Table 5.5: Bacterial enumeration (mean log10 bacterial numbers / mL) of samples taken from static batch cultures after 0, 4, 8 and 24 hours’ 
fermentation comparing no substrate, FOS, and AX with different molecular masses that had previously undergone in vitro gastric and duodenal 
digestion, using flow FISH. SEM are shown in italics.  Negative control is no added carbohydrate and positive control is FOS. One way ANVOA was 
applied to the data to test (F-test) the main effect of treatment. SEM is shown in italics.  Significant interaction between treatments and negative control are 
denoted * (p< 0.05). 
 
Time 
(h) 
Bifidobacterium 
genus 
 
Lactobaccillus 
Enterococcus 
group 
 
Bacteroides- 
Prevotella 
group 
 
Clostridium 
coccoides / 
Eubacterium 
rectales 
groups 
 
Clostridium-
histolyticum 
sub group 
 
Total 
 
Negative  
control 
0 6.14 (0.51) 5.76 (0.58) 5.52 (0.47) 6.04 (0.45) 6.04 (0.45) 6.85 (0.47) 
4 6.14 (0.33) 5.70 (0.23) 5.45 (0.46) 6.01 (0.29) 4.41 (0.69) 6.99 (0.04) 
6 6.60 (0.31) 6.20 (0.12) 6.37 (0.18) 6.60 (0.30) 5.83 (0.26) 7.50 (0.08) 
24 5.90 (0.26) 5.56 (0.36) 5.60 (0.47) 5.85 (0.28) 5.67 (0.31) 6.73 (0.35) 
48 6.09 (0.34) 5.78 (0.22) 6.30 (0.41) 6.09 (0.36) 5.96 (0.27) 7.36 (0.63) 
FOS 
(positive 
control) 
0 6.26 (0.26) 5.86 (0.44) 5.81 (0.29) 6.44 (0.28) 6.44 (0.28) 7.35 (0.19) 
4 7.19 (0.73) 6.04 (0.46) 6.41 (0.44) 7.06 (0.64) 5.28 (0.13) 7.70 (0.66) 
6 6.98 (0.61) 5.82 (0.11) 6.67 (0.29) 6.80 (0.50) 5.98 (0.08) 7.82 (0.33) 
24 7.45* (0.12) 6.73 (0.39) 6.90 (0.64) 7.46* (0.28) 6.17 (0.90) 8.28*  (0.30) 
48 7.26* (0.34) 6.25 (0.57) 6.82 (0.60) 7.33* (0.27) 6.27 (0.72) 8.04 (0.32) 
Low MM 
AX 
0 6.25 (0.25) 5.48 (0.31) 5.92 (0.36) 6.44 (0.42) 6.44 (0.42) 7.28 (0.35) 
4 7.45 (0.59) 6.12 (0.68) 6.73 (0.67) 7.42 (0.71) 5.69 (0.66) 7.88 (0.53) 
6 6.65 (0.44) 5.74 (0.48) 6.26 (0.48) 5.98 (0.27) 5.74 90.37) 7.20 (0.39) 
24 6.79 (0.93) 6.17 (0.90) 6.48 (0.96) 6.61 (1.01) 6.16 (0.81) 6.86 (0.77) 
48 6.63* (0.64) 5.86 (0.44) 6.37 (0.57) 6.67*  (0.60) 6.04 (0.44) 7.15 (0.61) 
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Time 
(h) 
Bifidobacterium 
genus 
 
Lactobaccillus 
Enterococcus 
group 
 
Bacteroides- 
Prevotella 
group 
 
Clostridium 
coccoides / 
Eubacterium 
rectales 
groups 
 
Clostridium-
histolyticum 
sub group 
 
      Total 
 
Medium 
MM AX 
0 6.33 (0.18) 5.74 (0.25) 5.86 (0.31) 6.68 (0.33) 6.68 (0.33) 7.42 (0.31) 
4 6.64 (0.37) 5.54 (0.25) 6.06 (0.29) 6.73 (0.39) 5.37 (0.31) 7.27 (0.32) 
6 6.91 (0.30) 6.13 (0.30) 6.94 (0.25) 6.97 (0.26) 5.94 (0.34) 7.72 (0.12) 
24 6.80 (0.53) 5.65 (0.38) 7.62 (0.33) 6.69* (0.59) 5.79 (0.05) 8.26* (0.09) 
48 6.48 (0.71) 5.88 (0.68) 6.32 (0.80) 6.70* (0.75) 5.98 (0.67) 7.27 (0.74) 
High MM 
AX 
0 6.50 (0.20) 5.78 (0.48) 6.19 (0.23) 6.69 (0.35) 6.69 (0.35) 7.51 (0.29) 
4 7.14 (0.37) 5.62 (0.17) 6.58 (0.24) 6.87 (0.44) 5.51 (0.29) 7.53 (0.36) 
6 7.31 (0.36) 6.00 (0.14) 7.02 (0.22) 6.99 (0.24) 5.93 (0.07) 7.75 (0.29) 
24 6.94* (0.26) 5.79 (0.09) 6.96  (0.48) 6.82* (0.63) 6.11 (0.22) 7.74 (0.25) 
48 7.34* (0.47) 5.19 (0.14) 6.07 (0.17) 7.12* (0.41) 5.76 (0.06) 7.63 (0.43) 
Insoluble 
AX 
0 6.01 (0.330 5.47 (0.17) 5.75 (0.23) 6.07 (0.43) 6.07 (0.43) 6.86 (0.25) 
4 6.80 (0.32) 5.86 (0.41) 6.27 (0.38) 6.78 (0.46) 5.80 (0.42) 7.38 (0.39) 
6 6.71 (0.36) 6.10 (0.40) 6.62 (0.31) 6.81 (0.44) 6.01 (0.40) 7.45 (0.38) 
24 6.55 (0.37) 5.79 (0.06) 6.14 (0.03) 6.52 (0.47) 5.82 (0.09) 7.31 (0.29) 
48 5.92 (0.52) 4.49 (0.61) 4.93 (0.78) 5.81 (0.56) 4.45 (1.01) 6.27 (0.56) 
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 Conclusions 
 
After in vitro gastric and duodenal digestion, different MM AX samples were reduced in 
arabinosylation, this combined with the removal of all bound phenolic acids through hydrolysis 
reduced the MM and the intrinsic viscosity of each of the samples due to a reduction in diferulate 
bridges formed between AX chains. Though digestion affected the structure, making them more 
similar in MM, phenolic content and viscosity, there were still differences between the samples 
and these differences were still sufficient to cause differences in prebiotic activity between the 
AX samples. 
Bifidobacterium populations were increased by fermentation of low and high MM AX and 
Clostridium coccoides/ Eubacterium rectales group populations were increased by fermentation of low 
and medium MM AX.  However, the greatest levels of SCFA, namely acetate and butyrate were 
produced from fermentation of medium MM AX (at 24h) so it is difficult to conclude which 
fraction provided the greatest prebiotic activity. Total bacterial populations were significantly 
increased only by fermentation of the medium MM AX despite no statistically significant 
increase in the bacterial groups measured by FLOW FISH. This is likely due to increases in 
bacterial populations that were not measured in this study and would explain the increased 
production of SCFA. This is in contrast to the data from a previous study by Hughes et al. 
(2007), who found that the lowest MM AX had in the greatest prebiotic activity. However, it 
has been shown that in vitro gastric and duodenal digestion affects the structure of AX and 
therefore alters prebiotic activity. 
The insoluble AX sample took longest to ferment, as was expected. It did not start causing 
increases of SCFA until 24h fermentation whereas the other samples began after just 4h. As 
changes took so much longer to occur, it is possible that a longer time point still would have 
allowed changes in microbial composition to be observed. This is something that could be 
looked into in the future as insoluble AX would be expected to persist longer in the colon in 
vivo. 
The release of bound phenolic acids makes them more bioavailable, creating beneficial effects 
for the host. Therefore, tFA could be an important component of AX in terms of its ability to 
modulate prebiotic activity and a future study comparing the prebiotic effects of AX with and 
without ferulic acid would be of interest to elucidate if absence of ferulic acid resulting from the 
in vitro gastric and duodenal digestion is responsible for changes in prebiotic activity.   
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Table 5.6 shows conclusions from this study, with comparison to the previous study which was 
done without gastric and duodenal digestion prior to fermentation to see if prior exposure to a 
gastric environment affected the prebiotic activity of different MM AX fractions. The insoluble 
AX was omitted as it was not used in the previous study. 
 
Table 5.6 Conclusions compared with the previous study by Hughes et al. (2007) 
 
  
Low MM AX after in vitro 
digestion 
Medium MM AX after in 
vitro digestion 
High MM AX after in 
vitro digestion 
Increase in smaller AXOS and 
decrease in larger AXOS after 
in vitro digestion 
Reduction in viscosity  
Removal of bound ferulic acid 
 
Increase in acetate from 4-
48h, as observed in Hughes 
et al. (2007) 
Increase in butyrate from 4-
48h, as observed in Hughes 
et al. (2007) 
Increase in bifidobacteria after 
48h, observed sooner in 
Hughes et al. (2007) 
Increase in Clostridium 
coccoides/ Eubacterium rectales 
group after 48h, observed 
sooner in Hughes et al. 
(2007) 
Increase in smaller AXOS and 
decrease in larger AXOS after in 
vitro digestion 
Reduction in viscosity  
Removal of bound ferulic acid 
 
 
Increase in acetate from 4-48h, as 
observed in Hughes et al. 
(2007) 
Increase in butyrate from 4-48h, 
as observed in Hughes et al. 
(2007) 
Increase in total bacteria after 48h 
Increase in Clostridium 
coccoides/Eubacterium rectales group 
after 24h, observed sooner in 
Hughes et al. (2007) 
 
Increase in smaller AXOS and 
decrease in larger AXOS after 
in vitro digestion 
Reduction in viscosity  
Removal of bound ferulic acid 
 
Increase in acetate from 4-
24h, as observed in Hughes 
et al. (2007) 
Increase in butyrate from 4- 
48h, as observed in Hughes 
et al. (2007) 
Increase in bifidobacteria after 
24h, observed sooner in 
Hughes et al. (2007) 
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6. General Discussion 
 
6.1. General conclusions 
 
This thesis explored the relationship between wheat dietary fibre (DF) and prebiotic effects, 
focussing on how the structure of arabinoxylan (AX) and how different combinations of types 
of DF affect prebiotic activity. Wheat DFs are highly abundant and already used in food 
ingredients. Therefore, further knowledge as to their effects as prebiotics could be exploited to 
design changes in their composition which could be incorporated into food products to create 
healthier foods.  
Chapter three focussed on arabinogalactan-peptide (AGP), which comprises a complex glycan 
attached to a 15-residue peptide via O-glycosylation to hydroxyproline residues. The structure 
has been determined but no studies had been carried out on physiological effects of AGP as a 
food ingredient, therefore it had not been tested for prebiotic activity. In this study the prebiotic 
activity of AGP was compared with AX. AGP was shown to have prebiotic activity similar to 
that of AX and the prebiotic activities of both DFs were enhanced by providing AGP and AX 
together in in vitro experiments. This study showed that different types of DF could have the 
ability to enhance the effect of available prebiotics through synergy. 
Chapter three also determined the effects of combinations of dietary fibre components on 
prebiotic activity, focussing on AX and β-glucan. AX and β-glucan were fermented in different 
ratios to determine whether there was an enhanced effect of the two DFs on prebiotic activity. 
It was shown that a ratio of AX: β-glucan (3:1) had the greatest prebiotic activity, performing 
better than AX alone. This is the ratio that is found in wheat flour so it was postulated that 
colonic bacteria have adapted to this ratio of DF in staple foods made from wheat flour and 
hence are able to efficiently ferment these substrates when provided together. This study 
supported the idea that different types of DF could have the ability to enhance the effect of 
available prebiotics through synergy and so further research in to this could yield more effective 
prebiotic formulas.  
Chapter 4 focussed on structural changes to AX and how they affect prebiotic activity, using 
two approaches. Firstly, AX was isolated from a transgenic wheat line with altered expression 
of a glycosyl transferase enzyme responsible for addition of the O-3 linked arabinofuranose. The 
resultant AX had an altered A:X ratio and reduced arabinosylation. The rate and concentration 
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of SCFAs produced during fermentation, mainly acetate, were not as high as with the control 
AX, and the populations of total bacteria and Bifidobacterium were increased only in the control 
but not the RNAi GT61 AX. It was concluded that the RNAi GT61 AX had reduced prebiotic 
activity related to specific reduction in O-3 linked arabinose. It was shown in chapter 4 that the 
reduction of O-3 linked arabinose substitution caused by an altered GT enzyme in RNAi GT61 
AX can reduce prebiotic effects of AX. This is contrary to some studies which claim that a 
reduction in arabinose substitution has no effect on prebiotic activity (Van Craeyveld et al., 
2008) or even increased prebiotic activity (Pollett et al., 2012) however, the current study, 
uniquely, was able to use AX with a highly defined arabinosylation pattern, which may explain 
the contrasting results. 
The effect of structure on prebiotic activity was also studied using in vitro gastric and duodenal 
digestion, to simulate effects on AX structure prior to fermentation in the colon. It was shown 
that prior in vitro gastric and duodenal digestion causes a reduction in A:X ratio of AX, a total 
removal of bound ferulic acid and reductions in MM and intrinsic viscosity. The digested AX 
had a lower initial rate of acetate generation compared to the untreated control AX, however, 
the digested AX caused modulation of the bacterial communities which the untreated control 
AX did not. The digested AX caused increases in beneficial groups Bifidobacterium, F. prau and 
Roseburia, the latter two use acetate to produce butyrate and it was therefore concluded that the 
initial low acetate concentration observed with the pre-digested substrate was due to utilization 
for cross feeding to produce other SCFA. 
The random removal of arabinose units and reduction in arabinose substitution occurring 
during gastric digestion appears to enhance prebiotic activity. However, during the in vitro 
digestion, other aspects of AX structure were also affected as well as a reduction in 
arabinosylation, notably a reduction in dp and a removal of bound phenolic acids. These effects 
could also have contributed to the change in prebiotic activity, producing similar to the data 
obtained by Van Craeyveld et al. (2008), who postulated that changes in substitution were not 
as important as changes in dp.  
From the present study, it appears that the specific removal of O-3 linked arabinose can 
negatively affect prebiotic activity. However, the random removal of arabinose and changes in 
size do not. Further work is required to explore this further. The exposure of the AX isolated 
from the transgenic wheat line might be a first step determine the basis for this effect. 
Chapter 5 showed that although in vitro gastric and duodenal digestion of different MM AX 
samples resulted in greater similarity in structure, they still retained differences in prebiotic 
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activity. Fermentation of the low and medium MM AX resulted in the greatest increases in 
SCFA production and beneficial modulation of bacterial composition. The insoluble AX was 
very slow to ferment, probably due to its high degree of substitution and insolubility. Prior 
digestion modulated the prebiotic activity of the AX by increasing time taken to exert a prebiotic 
effect compared to a previous study (Hughes et al., 2007). 
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6.2. Future work 
Wheat flour DFs show potential to be prebiotics but further work is required to provide a 
greater understanding of their potential. As with all model systems, in vitro fermentation systems 
are not a fool-proof way of measuring prebiotic potential. Increases in a limited number of 
bacterial genera in faecal slurries in vitro cannot confirm a prebiotic effect because faecal slurries 
have been proven to be more representative of more distal regions of the colon, whilst more 
proximal reigns have a more saccharolytic profile (Macfarlane et al. 1992, 1998). The 
continuous, three-stage gut models, which replicate different the three regions of the colon, 
attempt to overcome this and further work should be carried out using first, continuous gut 
model and then human trials (Gibson et al., 2004). 
 
• A further fermentation study on insoluble AX is required to determine its persistence 
in the colon. A three-stage fermentation model is available at the University of Reading 
which replicates the three stages of the colon. Persistence of insoluble AX would be 
demonstrated by increases in beneficial bacteria and SCFA productions in the most 
distal section.  Greater persistence of AX into the distal regions should help to prevent 
the production of toxic metabolites from fermentation of proteins which occurs when 
carbohydrate sources are exhausted. 
 
• This work has focussed mainly on how the structure of AX affects prebiotic activity, 
however β-glucan is also a significant DF in wheat flour although more abundant (and 
soluble) in other cereals including oats and barley. However, as wheat is more common 
in the diet the amount of wheat β-glucan consumed is probably much greater than that 
of barley or oat β-glucan. A study comparing the structure and prebiotic effects of wheat 
β-glucan and barley β-glucan would determine if the source of DF is important. There 
is conflicting evidence in this field currently. 
 
• A study comparing AX with and without phenolic acids would demonstrate whether 
phenolic acids affect prebiotic activity. Based on a study by Grabber et al. (2008), who 
found that reductions in ferulate cross-linking of arabinoxylans to lignin enhanced the 
fermentation of hemicellulose. It can be hypothesised that increases in phenolic acids 
would increase fermentation times by creating cross-links in the arabinoxylan chains. 
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• Further studies should be carried out with wheat AGP to determine if it has prebiotic 
effects in vivo and at what dosage, including a dietary intervention study on humans. 
Development of methods to upscale AGP extraction would be required as the current 
method yields only ~200mg/200g WF.  
 
• Prior exposure of potential prebiotics including AGP to a simulated gastric/duodenal 
environment to obtain a more realistic idea of their prebiotic potential. 
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